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This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS 
are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by 
ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, 
and risk of transformation to acute myeloid leukemia (AML). Median age of patients 
with MDS is about 70 years. Various immune abnormalities occur in MDS patients, 
and the relationship between autoimmune disorders and MDS is described. Accurate 
prognostication and risk stratification for individual patients with MDS are important 
for clinical treatment decisions. Patients with MDS are classified into two broad 
prognostic categories: lower risk and higher risk. The approval of lenalidomide, 
azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of 
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Preface
Despite efforts in studies of the biology of myelodysplastic syndromes (MDS), a diagnosis of
MDS in individual patient relies mainly on morphological and cytogenetic examinations of the
bone marrow and blood. Genomic instability, gene mutations, deregulated gene expression, and
epigenetic changes play the key role in the pathogenesis of MDS. High-throughput genetic tech‐
nologies such as single nucleotide polymorphism and comparative genomic hybridization and
next-generation sequencing helped in performing mutation profiling but are preferentially used
in clinical trials and not in routine laboratories. These laboratories are limited by the cost-effective
care and interpretation barriers, and they do not currently use mutational profiling for diagnosis
of MDS. Many mutations are not specific for MDS, and they also occur in other myeloid malig‐
nancies. Besides somatic mutations, cytokine aberrations, immune dysregulation, alterations in
the bone marrow microenvironment (niche), abnormal RNA splicing, and changes in telomers
and signal pathways are involved in the MDS pathogenesis.
This book provides a concise review of advances in myelodysplastic syndromes and will be use‐
ful not only to the researchers and clinicians involved in this topic but also to medical students.
Introduction chapter is a brief review of current knowledge of MDS prognostication, pathogene‐
sis, and therapy. Chapter 2 discusses disorders mimicking MDS and difficulties in MDS diagno‐
sis. Chapter 3 analyzes the role of inflammation and immune suppression in the pathogenesis of
MDS. The application of immunosuppressive treatment may relieve the autoimmune manifesta‐
tions but also improves hematopoiesis. Chapter 4 focuses on the 5q- syndrome first described by
Van den Berghe et al. in 1974. Patients with 5q- syndrome have refractory anemia with del(5q) as
the sole karyotypic abnormality and medullary blast count of less than 5 %. The del(5q) occurs in
approximately 10–20 % of patients with de novo MDS. Pathogenesis of the 5q- syndrome has
been intensively studied in last years, and immunomodulatory or cereblon-binding drug lenali‐
domide is used for the treatment of transfusion-dependent anemia in these lower-risk del(5q)
MDS patients. MDS cases with del(5q) and additional karyotypic abnormalities and secondary
MDS cases with del(5q) have a poor prognosis in contrast to the good prognosis of the 5q- syn‐
drome. Chapters 5 and 6 review higher-risk MDS, monosomy 7, and chronic myelomonocytic leu‐
kemia, treated by hypomethylating agents (azacitidine and decitabine). Allogeneic stem cell
transplantation is the only treatment option with curative potential for higher-risk MDS patients
but is limited by age of patients. Resistance to chemotherapy is a serious obstacle to the successful
treatment. This important topic is discussed in an overview in Chapter 7.
Each chapter is written by scientists and clinicians with specific expertise in the field.
Ota Fuchs, PhD





Introductory Chapter: Myelodysplastic Syndromes
Ota Fuchs
Additional information is available at the end of the chapter
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Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem
cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent
karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML) [1–5].
MDS are rare in young people, and median age of patients with MDS is approximately 70 years
[6, 7]. Current management in MDS includes supportive care, drug therapy, and allogeneic
stem cell transplantation. MDS patients older than age 70 years are not good candidates for
allogeneic stem cell transplantation [8, 9]. The major complication of MDS patients after
allogeneic stem cell transplantation with reduced intensity conditioning is relapse of malignant
disease. Relapse can be predicted by monitoring of Wilms’ tumor 1 (WT1) gene expression by
real-time PCR and CD34+ donor chimerism analysis [10].
Single-nucleotide polymorphism array (SNP-A) analysis, standard metaphase cytogenetics,
and rapid progress in flow cytometric analysis, genes mutation analysis, and gene expression
profiling have identified key deregulated genes and signaling pathways important for accurate
prognostication and risk stratification for individual patients with MDS [11–18]. The initial
French–British–American (FAB) classification system of MDS was published in 1982 [19] and
was later refined to the International Prognostic Scoring System (IPSS) [20] and to World
Health Organization (WHO) Prognostic Scoring System (WPSS) [21, 22]. The new revised IPSS
(IPSS-R) integrated marrow cytogenetic subset, marrow blast percentage, and depth of
cytopenias (hemoglobin, platelet, and absolute neutrophil count) and was published in 2012
[23]. Validation of WPSS for MDS and comparison with IPSS-R has been recently described
[24]. Two other prognostic systems for MDS subgroups (M.D. Anderson lower risk MDS
prognostic scoring system; chronic myelomonocytic leukemia /CMML/ prognostic scoring
system) exist [18, 25].
In lower risk MDS, treatment focuses on amelioration of consequences of cytopenias and
transfusions and improving of quality of life. The first line of therapy of lower risk MDS with
normal chromosome 5 is treatment with erythropoiesis-stimulating agents (erythropoietin)
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
with or without of granulocyte colony-stimulating factor [26]. Transfusion-dependent lower
risk MDS patients with del(5q) are treated with immunomodulatory or cereblon-binding drug
lenalidomide [27]. Thrombocytopenia occurring sometimes in combination with anemia or
without anemia can be treated with romiplostin (thrombopoietin agonist) [27]. Neutropenia
is treated with growth factors (G-CSF and GM-CSF) [27]. Higher-risk MDS if untreated have
median survival only about 12 months. Two hypomethylating agents (azacitidine and
decitabine) inhibit DNA methyltransferases 3A and 3B and reverse the aberrant methylation
involved in MDS progression to AML. The development of novel therapeutic strategies in
MDS is dependent on recent advances in the molecular pathogenesis of MDS [6, 16, 28–39].
Various combination therapies in MDS are also intensively studied [27, 40, 41].
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Immune Dysregulation in Myelodysplastic Syndromes:
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Abstract
Myelodysplastic syndromes are clonal hematopoietic stem cell disorders, in which the
immune  system  plays  a  substantial  pathogenetic  role.  Patients  manifest  frequent
infections, mainly attributed to neutropenia, but sometimes opportunistic pathogens are
isolated  in  non-neutropenic  patients.  They  also  exhibit  autoimmune  diseases  or
syndromes with a background of immune activation and various “abnormalities” of T-
lymphocytes, B-lymphocytes, and NK cells. The most typical profile includes reduced
total T lymphocytes (mainly CD4+ helper T-cells, resulting in decrease or inversion of the
CD4/CD8 cell ratio) and impaired NK cell function. Many TH1 direction cytokines, and
particularly sIL-2R, IL-6, and TNF-α are usually found increased in the serum and bone
marrow, which have been strongly associated with advanced disease, anemia, and other
disease-related features. Clonal origin of lymphocytes has been confirmed only in few
cases. Mixed lymphocyte cultures and genomic assays have shown severely impaired
immunoregulatory abnormalities, probably induced by the hematopoietic cells. In a
minority of patients, immune activation is capable to prevent or delay clonal expan‐
sion, but these patients have more profound hematopoietic impairment. Immunosup‐
pressive treatment may not only relieve the autoimmune manifestations but also improve
hematopoiesis. However, this kind of treatment is not well tolerated, is associated with
severe infections, and in some cases may enhance AML evolution.
Keywords: myelodysplastic syndromes, pathogenesis, immune abnormalities, auto‐
immune diseases, immunosuppressive treatment
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Myelodysplastic  syndromes  (MDS)  are  diseases  emerging  from  somatic  mutations  of  a
pluripotent  hematopoietic  stem cell,  affecting  its  functional  capacity  for  maturation and
differentiation, but preserving it alive and capable to escape from apoptotic signals. The affected
cell creates a clone, gradually suppressing nonclonal cells, and finally dominating in the bone
marrow. Clonal cells are prone to additional genetic events, promoting survival advantage and
further impairing differentiation and maturation, thus generating a neoplastic phenotype, with
the evolution to acute myelogenous leukemia (AML). Since such genetic events occur serially,
but with a variable evolutionary potential, MDS represent probably the best in vivo model of
“step-by-step” progression from a premalignant state to a high-potential neoplasm, such as
AML. The multiparametric study of MDS can draw messages and conclusions, potentially
applicable for the pathogenesis and pathophysiology of all types of neoplasia.
One rather unexpected aspect of MDS pathophysiology is the strong involvement of the
immune system. Soon after the initial description of MDS, many “immune abnormalities” were
reported in the literature. The “easy” initial interpretation of the participation of the immune
system to the dysplastic clone was quickly changed, in favor of other explanations. But even
now, a clear interpretation and a definite treatment strategy for these “abnormalities” have
not been established. In this chapter, we describe the spectrum of “immune abnormalities” of
MDS and briefly discuss treatment approaches, targeting the immune system. Besides a
thorough literature review, we have used our personal experience, based on the study of more
than 1500 patients. Thus, this chapter includes also original data, presented at various
meetings, but not yet published as full papers, emerged from personal/institutional research
activities at the Department of Hematology of the University Hospital of Patras.
2. Infections unrelated to the severity of neutropenia among patients with
MDS
Infections of various etiologies are common among MDS patients and represent one of the
major presenting features, but also a leading cause of morbidity and mortality. Beside the
usually advanced patient age and comorbidity, the major predisposing factor in many
retrospective studies analyzing the frequency and severity of infections is the depth of
neutropenia. Functional neutrophil abnormalities have also been reported, such as impaired
locomotion and chemotaxis, reduced complement receptor-1 and -3 expressions, and reduced
enzymatic armamentarium, resulting in impaired respiratory burst and reduced bactericidal
and fungicidal capacity. These defects have been observed in all types of MDS but are more
frequent in the higher risk groups [1]. However, severe common and opportunistic infections
may be manifested in nonneutropenic patients. In these cases, besides the functional neutrophil
impairment, various acquired defects of the adaptive immunity, affecting immunocompetent
cell populations have been proposed as predisposing factors. Finally, transfusions, transfu‐
sion-induced iron overload, and the newer treatment modalities, such as lenalidomide and
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hypomethylating agents, may hamper immune functions and contribute to the development
of infections.
There are several published cases or small series of patients manifesting pyogenic collections/
abscesses, not only at common sites (perianal, splenic, liver), but also at rare and uncommon
(pararenal, intramuscular, paracolic, etc.), without the development of strong inflammatory
reaction [2, 3]. It has been suggested that mature granulocytes of MDS patients may not
produce effective inflammatory reaction to eliminate pathogens, and induce the formation of
granulomas or abscesses [1, 2]. MDS patients, even when nonneutropenic, may exhibit delayed
healing of infections and have increased intracellular neutrophil collagenase activity, irre‐
spective of WHO or IPSS subgroup [3].
Other patients manifest bacterial, viral, and fungal infections, from rare/opportunistic
pathogens, before any immunosuppressive or cytotoxic treatment, similar to those encoun‐
tered among patients with underlying congenital or acquired immunodeficiency. Among such
rare bacterial pathogens, coagulase-negative Staphylococci, rare Enterococci, Myc. avium-
intracellulare, Myc. Kansasii, Myc. Malmoense, Bacillus cereus, Corynebacterium and Phenylobacte‐
rium spp., Aeromonas hydrophila, Brevundimonas diminuta, Rhodococcus corynebacterioides, and
Bordetella hinzii are included. Among viral, fungal, and other pathogens, CMV and EBV
reactivation, HHV-6 infection, JCV-induced progressive multifocal leukoencephalopathy
(PML), Pneumocystis iirovecii, and Legionella pneumophila are included. Invasive fungal infec‐
tions are rather uncommon and may emerge during the myelosuppression, which follows
cytotoxic chemotherapy and/or allogeneic stem cell transplantation, in patients receiving
prophylactically or therapeutically strong combinations of antibacterial antibiotics. However,
many cases have been reported in the absence of these recognized predisposing factors.
Involved pathogens are both, yeasts, including C. albicans, Candida non-albicans spp., and
Cryptococcus neoformans and molds, such as Aspergillus and zygomycetes, and the usually
affected organs are the lungs, liver, spleen, and central nervous system (CNS), and more rarely
the skin, soft tissues, and other organs.
3. Association of autoimmune and immune-mediated diseases, with the
manifestation of MDS
3.1. Clinical syndromes of immune overactivity associated with myelodysplastic syndromes
3.1.1. Clearly autoimmune diseases
Only few years after the recognition of MDS as separate entities and the proposal of their first
classification system (FAB classification), it was obvious that they were associated with
increased frequency of various immune abnormalities, either abnormal laboratory findings,
such as organ- and non-organ-specific autoantibodies, or true clinical syndromes or diseases,
reflecting severely impaired adaptive immunity.
Among the autoimmune or immune-mediated clinical syndromes, described in association
with MDS, Coombs-positive immunohemolytic anemia (AIHA) [4], immune thrombocytope‐




nia (ITP) [5], Evans’ syndrome, autoimmune neutropenia, and pure red cell aplasia (usually
drug-related) are included. AIHA is somewhat more common, and is usually of warm type,
associated with mild to moderate chronic hemolysis [4]. It can be automatically presented or
triggered by red blood cell transfusions. Treatment is mainly based on corticosteroids, but
response rate is lower than in the idiopathic cases, and even when a “complete” response is
achieved, this cannot be objectively evaluated due to coexistence of the basic disease, which
has as a major manifestation anemia, although not clearly hemolytic. When corticosteroids are
ineffective or associated with unacceptable toxicity, cyclosporine-A, mofetil mycophenolate,
or pulses of vinca alkaloids may be used. In some instances immunosuppressive treatment
may be accompanied by trilineage response, improving also neutrophil and platelet counts.
Immune thrombocytopenia particularly of chronic type, when manifested in elderly patients
may mimic true MDS, particularly when there is additional underlying comorbidity and
patients also have anemia of chronic disease. In such instances, the differential diagnosis is
difficult and this is clearly an overlapping area of hematological disorders [6]. More compli‐
cating is the fact that these two different entities may share some common pathogenetic
features, concerning premature megakaryocyte cell death [7]. However, true immune throm‐
bocytopenia with high titers of antiplatelet autoantibodies may be the presenting feature [6,
8] or may complicate the course of a previously diagnosed MDS [9]. In some instances, ITP
may precede and MDS may follow some months or years, even after the achievement of
complete response of the ITP. Thrombocytopenia has been related to higher amount of
glycocalicin and platelet-associated IgG, higher MPV, more advanced disease, and worse
prognosis in patients with MDS. The occurrence of ITP has been more frequently reported in
chronic myelomonocytic leukemia (CMML) and the del-5q syndrome, whereas relatively
severe thrombocytopenia, with mild-moderate or absence of anemia and neutropenia has been
reported among patients with isolated del-20q [10]. Retrospective evaluation of 123 patients
with CMML revealed the presence of auto-/hyperimmune disorders in 19.5% of them,
compared to 3–4% incidence in the general population [11]. CMML has been considered the
MDS, most frequently associated with “paraneoplastic” manifestations. Finally, high frequen‐
cy of hypocomplementemia, often associated with severe cytopenia, particularly in patients
with lower risk MDS has been reported, suggesting the possible contribution of autoimmune
mechanisms in its pathogenesis [12].
3.1.2. Common clinical syndromes with a dominantly immune pathogenesis
Dominant position among the immune hyperactivity/autoimmunity syndromes possess the
various systemic vasculitides, such as febrile neutrophilic dermatosis (Sweet’s syndrome) [13],
other leucocytoclastic vasculitides, and necrotizing panniculitis, most commonly localized in
the skin and accompanied by rashes or resulting in extended skin ulcerations. Large vessel
arteritis (Takayasu’s disease), aortitis, and other organ-specific vasculitides, such as Wegener’s
granulomatosis, have been reported. Additional cutaneous manifestations associated with the
occult or prominent presence of an MDS include granulomatous eruptions, pyoderma
gangrenosum, erythema nodosum, erythema elevatum diutinum, bullous pemphigoid,
cutaneous lupus, Behçet’s disease, dermatomyositis, and Raynaud’s syndrome.
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Hematological (Other) Cutaneous syndromes
Immunohemolytic anemia Erythema nodosum
Immune thrombocytopenia Pyoderma gangrenosum
Evans’ syndrome Erythema elevatum diutinum
Chronic cold agglutinin disease Bullous pemphigoid
Autoimmune neutropenia Cutaneous lupus
Pure red cell aplasia Granulomatous eruptions
Raynaud phenomenon
Connective tissue type
Systemic lupus erythematosus Other syndromes
Classical seropositive rheumatoid arthritis Fever of unknown origin (disease related)
Seronegative rheumatoid arthritis Sarcoidosis – sarcoidotic-type granulomata
Sjögren’s syndrome Iridocyclitis – uveitis
Mixed connective tissue disease Sterile osteomyelitis
Polymyalgia rheumatica Hashimoto’s thyroiditis
Seronegative migratory synovitis Addison disease
Remitting symmetrical synovitis with pitting edema Behcet disease
Eosinophilic fasciitis Pericarditis
Relapsing polychondritis Pleural effusions
Polymyosistis Chronic autoimmune hepatitis
Dematomyosistis Inflammatory bowel disease
Ulcerative colitis
Vasculitic type Autoimmune pancreatitis
Sweet’s syndrome Pulmonary alveolar proteinosis
Leucocytoclastic vasculitis Bronchiolitis obliterans organizing pneumonia
Periarteritis nodosa Nephrotic syndrome
Wegener granulomatosis Segmental glomerulosclerosis
Large vessel arteritis (Takayasu disease) Peripheral demyelinating polyneuropathy
Aortitis Expressive aphasia
Necrotizing panniculitis
Table 1. Clinical syndromes of auto-/hyperimmune basis associated with myelodysplasia.
Fever of unknown origin in the absence of any known underlying condition has been described
in association with MDS and may be accompanied by mild lymphadenopathy and sarcoidic-
type noncaseating granulomata, high serum ferritin, and polyclonal hyper-γ-globulinemia.




Various rheumatic manifestations may also be associated with an MDS and some patients are
diagnosed following an initial presentation of a typical rheumatic disease. Remitting
seronegative symmetrical synovitis with pitting edema has been reported as an initial
presentation of MDS, with subsequent manifestation of relapsing polychondritis. Besides the
more frequent than expected classical rheumatoid arthritis and systemic lupus erythematosus,
seronegative migratory synovitis, various seropositive and seronegative polyarthritic
syndromes, polymyositis, polymyalgia rheumatica, eosinophilic fasciitis, Sjögren’s syndrome,
and mixed connective tissue disease have also been reported.
Less common syndromes are noninfectious serosal effusions, usually pleural, but sometimes
also pericarditis, chronic autoimmune hepatitis, Hashimoto’s thyroiditis, Addison’s disease,
inflammatory bowel disease, glomerulonephritis and nephrotic syndrome, focal and segmen‐
tal glomerulosclerosis, chronic autoimmune pancreatitis, ulcerative colitis, and various
syndromes reflecting immune-based inflammatory processes of the CNS, such as seizures,
expressive aphasia and paresis, and peripheral demyelinating polyneuropathy [14]. Finally,
noninfectious pulmonary infiltrates, sometimes typical for alveolar proteinosis and bronchio‐
litis obliterans organizing pneumonia (BOOP), in the absence of previous allogeneic trans‐
plantation have also been reported. Table 1 summarizes the various auto-/hyperimmune
syndromes, sometimes called “paraneoplastic,” associated with MDS.
3.1.3. Relapsing polychondritis
Of particular interest is the syndrome of relapsing polychondritis, which, besides the presen‐
tation as an idiopathic autoimmune syndrome, has almost exclusively been reported in
association with MDS and very rarely with other diseases. Thus, among newly diagnosed
polychondritis, without any evidence for a hematological disorder, BM examination may
reveal the presence of an as yet undiagnosed MDS [15]. Polychondritis is manifested as painful
inflammation of the cartilaginous areas of the body, such as the external ear, the basal area of
the nose and the nasal septum, the synovial cartilage, and the tracheal and bronchial cartila‐
ginous rings. Symptomatic period may persist for many days or some weeks, followed by
resolution, but symptoms reappear after weeks or months. The cartilage is finally destroyed,
resulting in anatomical malformation and functional disturbances. The syndrome may be
associated with fever, renal, cardiovascular, or ocular manifestations, as well as by symptoms,
related to organ-specific dysfunction, not clearly containing cartilaginous tissue [16]. Patho‐
genesis is clearly immune-based and may reflect immunological reaction against some marrow
stromal elements, which also exist in the cartilaginous tissue. Prompt intervention with
corticosteroids accelerates resolution of the inflammatory reaction and may reduce tissue
destruction and malformations.
3.1.4. Overview of patient series and epidemiological data on autoimmune manifestations
Autoimmune diseases have been reported on average in 10–30% of MDS patients, in all age
groups and disease subtypes sometimes more frequently among females and in patients with
higher risk MDS or CMML [9, 17]. In some early studies, the frequency of true autoimmune
diseases among series of MDS patients was not found increased compared to non-MDS
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subjects of similar age. Moreover, the detection of various autoantibodies, directed against
erythrocytic, neutrophilic, and platelet components, in the serum of MDS patients has been
disputed, whether it really represents an immune abnormality, and has been attributed to the
advanced patient age to thorough searching processes or to alloimmunization from the
frequent transfusions. It has been suggested, although not proved, that similar results could
be obtained from multiply transfused non-MDS patients of advanced age [18]. In another
study, patients exhibiting immune abnormalities were younger and had mainly therapy-
related MDS with complex chromosomal aberrations [9]. Among the reported cases with
available cytogenetics, trisomy 8 cases are rather overrepresented, but in the majority of
described series of patients no clear preponderance of any demographic, cytogenetic, or
histological feature was found [19]. In some studies, the frequency of autoimmune diseases is
higher, but there is the possibility of misinterpretation of dysplastic bone marrow changes
attributed to the advanced patient age or to the underlying autoimmune disease as indicative
of primary MDS [17]. In a large French multicenter retrospective analysis of 123 MDS patients,
exhibiting systemic inflammatory and autoimmune diseases (SIADs), vasculitic syndromes
were more frequently encountered among CMML, and a comparison of this group with 665
patients without such manifestations revealed that patients exhibiting SIADs were younger,
male, without RARS, with higher risk disease, and a poor karyotype, but without survival
difference [20].
Autoimmune manifestations may not be a single clinical syndrome, but a clustering of two or
more autoimmune or immune-based conditions may occur in the same patient. Autoantibod‐
ies most frequently found are either organ-specific or non-organ-specific, such as rheumatoid
factor, antinuclear antibodies, antineutrophil cytoplasmic (cANCA), or antineutrophil
perinuclear antibodies (pANCA), the last two been associated with various vasculitides.
Interferon regulatory factor-1 (IRF-1) mRNA expression was found 10-folds increased in MDS
patients with autoimmune manifestations, in sharp difference to those without, and to normal
controls. It was therefore suggested that absence of IRF-1 expression may be a protective
mechanism preventing autoimmunity in MDS [21]. However, from the prognostic point of
view although patients with autoimmune manifestations have similar overall survival
compared to patients without those with higher IRF-1 expression have longer survival [22].
There is no agreement whether autoimmune manifestations influence prognosis. This is
because the severity of autoimmune diseases and conditions, supervened by a MDS, may be
substantially diverse and prevent their evaluation as an additional prognostic factor. The
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improved survival, although in some studies it may accelerate evolution to AML. Furthermore,
achievement of remission and return to the MDS stage may induce relapse of the autoimmune
condition and in general the manifestation of autoimmunity follows the dysplastic phase and
disappear during evolution to AML [24].
In the largest retrospective epidemiologic and prognostic analysis of about 1400 patients, 28%
exhibited hyper/autoimmune manifestations and the most prominent was hypothyroidism
associated with Hashimoto’s thyroiditis (12% of the total population or 44% of the autoimmune
syndromes), followed by immune thrombocytopenia (12%), rheumatoid arthritis (10%), and
psoriasis (7%). Autoimmune conditions were more frequent among females with lower risk
disease, and less transfusion dependent. The probability for AML transformation was lower
and the median survival significantly higher for patients with autoimmune diseases (60 versus
45 months), and in multivariate analysis, adjusted for age and IPSS, the manifestation of an
autoimmune syndrome was an independent favorable prognostic factor [23].
4. Numerical abnormalities of lymphocytes in patients with MDS
4.1. T-lymphocyte abnormalities
Many investigational studies have focused on various parameters of adaptive immunity in
MDS. In the majority of patients, peripheral blood lymphopenia, mainly CD4+ cell lympho‐
penia, and to a lesser degree or at all, CD8+ cell reduction, frequently resulting in reduction or
inversion of the CD4/CD8 cell ratio has been recognized. These findings have not been
associated with specific FAB subtypes or any other clinical or laboratory feature [10, 20]. Many
studies have confirmed the previous findings, particularly in patients with RAEB, and
demonstrated severe functional T-cell impairment in terms of sluggish reaction to mitogenic
stimuli and increased radiosensitivity, reflecting impaired DNA repair, implying that these
defects might impact on patient hematopoiesis [25].
An initial approach for the interpretation of the numerical imbalance of T-cell subsets was that
they might be attributed to multiple red blood cell transfusions, since in some early studies a
correlation of the severity of T-lymphocyte abnormalities with transfusion intensity was
reported [26]. However, it soon became clear that T-lymphocyte imbalance was present already
at baseline, before any medical intervention, and therefore this finding might most probably
be a disease feature. T cells of MDS patients synthesize lower amounts of the TH1 direction
cytokines interleukin-2 (IL-2) and interferon-gamma (IFN-γ), following mitogenic stimulation,
respond inadequately to IL-2 and cooperate inefficiently with B lymphocytes in the induction
of immunoglobulin production [24–28]. Studies of NK cell function have always reported
reduced cytotoxic and cytolytic activity against cellular targets, as well as impaired both
complement-dependent (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)
[27]; however, in many other more recent studies, no abnormality in NK cells has been
identified. We have investigated several immune function parameters at baseline on the same
population of 81 patients with various MDS subtypes and we have shown that patients with
RAEB had more profound CD3+ and CD4+ lymphopenia, and significantly lower and
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sometimes inverted CD4/CD8 cell ratio. We have also shown that CD3+ and CD8+ cell
lymphopenia were associated with more frequent infections, higher AML evolution rate, and
shorter overall survival [28]. A Japanese group confirmed decreased CD8+ cells in RA patients
and inverted bone marrow CD4/CD8 cell ratio, with increased activated CD8+CD11α+ cells in
all patients. RAEB patients had decreased marrow total T cells and all MDS patients had
decreased marrow CD4+CD45RA+ naïve- and increased CD4+CD45RO+ memory T-helper
cells, probably indicating impaired immune surveillance permitting the undisturbed evolution
of the dysplastic clone. The prognostic significance of the numerical T-cell abnormalities on
the above-mentioned issues was confirmed by other groups [19, 29]. Evaluation of lymphocyte
subsets in bone marrow biopsies with specific immunostaining has not demonstrated any
quantitative or qualitative T- and NK-cell abnormality, but only revealed increased B lym‐
phocytes in patients with higher risk disease and it has been suggested that identification of
>3% B lymphocytes in the marrow biopsy is an adverse prognostic feature [30].




RA 8/12 66.7 11.9/3.00 18.2 ± 2.7 0.160
RARS 4/10 40.0 8.6/2.40 12.1 ± 1.9 0.003
RAEB 10/16 62.5 11.2/2.43 16.1 ± 2.2 0.029
RAEBt 2 / 8 25.0 6.3/2.25 10.7 ± 1.5 0.002
CMML 5 / 8 62.5 8.8/2.87 14.8 ± 0.7 0.022
Total 29/54 53.7 9.8/2.59 14.8 ± 1.0 0.0003
Controls 16/18 88.9 17.4/4.11 25.8 ± 2.4
Notes: Results of the skin reaction to the Multitest CMI test, consisting of 7 common antigens (Tetanus, Diphtheria,
Tuberculin, Candida, Trichophyton, Streptococcus, Proteus): patients with MDS as one group exhibited significantly
reduced composite score, compared to healthy controls, matched for age and gender. Significant differences were
found for all FAB MDS categories, with the exception of RA (unpublished data).Bold letters indicate statistically
significant differences.
Table 2. Results of the skin reaction to Multitest CMI® in patients with MDS
Patients with MDS-RA and with aplastic anemia exhibit Th1 and Tc1 polarization of their
immune activation [31]. Later this was confirmed also for patients with refractory cytopenia
with multilineage dysplasia (RCMD) and was correlated with very high serum and marrow
IFN-γ and tumor necrosis factor-α (TNF-α) levels, and high degree of apoptosis. Higher Th1/
Th2 and Tc1/Tc2 ratios have been observed in patients with lower risk IPSS and normal
karyotype, but not in aneuploid karyotypes. Th1 polarization may not be a uniform finding
in MDS patients, but concerns only a subgroup of RCMD with prominent CD8+ lymphopenia
[32].




Activated T lymphocytes do not belong to the dysplastic/leukemic clone and express HLA-
DR, CD25, CD45RO, and CD57, but not CD28 and CD62L. This antigenic profile is independent
of disease subtype, prognostic classification, kind of cytogenetic abnormality, or any other
feature [33]. Interestingly, both patients with lower risk MDS and those with aplastic anemia
have increased T-lymphocyte counts and B lymphocytopenia compared to patients with high-
risk MDS and to controls, but lower risk MDS patients exhibit stronger and uniform Th1/Tc1
polarization than those with aplastic anemia [34]. Moreover, bone marrow NK T-cell infiltrates
express the activated effector T-cell phenotype CD8+CD57+CD28−CD62L− and the NK C-
lectin-family receptors NKG2D and CD244. These infiltrates represent oligoclonal expansions
of autoreactive T cells, as this can be demonstrated by TCR clonality assays and are more
prominently identified in the bone marrow than in the peripheral blood [35].
MDS patients also exhibit impairment of delayed cutaneous T-cell hypersensitivity, as this can
be demonstrated with various skin patch tests, challenging reaction to common antigens. Most
importantly, they may lose immunologic memory against potentially important antigens, such
as tuberculin and clostr. tetani anatoxin, the clinical consequence of which is unclear [36].
Table 2 resumes the results from our study of skin reactions to the multitest CMI® in 54
patients with MDS compared to 20 controls (unpublished data).
Further understanding of the immune dysregulation of MDS was achieved through investi‐
gation of the regulatory T cells (T-regs). T-regs are a specific subset of helper T cells, inducing
immune tolerance and moderating the intensity of immune reactions. Many autoimmune and
neoplastic diseases are associated with T-reg impairment, favoring uncontrolled immune
activation and attenuation of immune surveillance against tumor growth. An increase of
polyclonal/nonclonal T cells in higher risk MDS, and a significant correlation of T-reg number,
with the percentage of marrow blasts, the IPSS and progression to AML has been reported [37].
T-regs, characterized as CD4+ CD25high+FOXP3+ or CD4+CD25high+CD127low cells, were found
increased in lower risk MDS but they were not correlated with any known disease feature or
lab finding [38]. Investigation of the T-reg kinetics, function, and trafficking has revealed that
in early MDS, peripheral blood and marrow T-regs are normal in number but dysfunctional,
exhibiting lower CXCR4 expression and impaired marrow homing. In contrast, at late MDS
or at leukemic transformation, T-regs increase and become functional and migrating. Effective
treatment partially restores the number, but disease relapse is again associated with T-reg
expansion. Thus, T-regs may share a pathophysiological role in MDS, since impaired sup‐
pressor function results in autoimmune phenomena, whereas in more advanced stages, their
expansion favors clonal development and leukemic transformation [39]. It has been suggested
that absolute number of a T-reg subpopulation, the “effector regulatory T cells,” characterized
as CD4+FOXP3+CD25+CD127lowCD45RA−CD27− cells, could be used as a prognostic factor in
lower risk MDS predicting severity of anemia, AML transformation, and overall survival [40].
Other interesting T-cell subsets are the IL-17 producing helper T cells, the so-called Th17 cells
and the Th22 cells. Th17 cells were found substantially increased in patients with lower risk
MDS and their number was inversely correlated with that of T-regs. T-regs, although sup‐
pressive for other T-cell populations, do not affect Th17 cell number. Thus, the Th17/T-reg cell
ratio has been found very high in lower risk disease and has been proposed as a marker of
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“effective” immunosuppression, high degree of apoptosis, and higher risk for autoimmunity,
as well as an indicator for application of immunosuppressive treatment [41]. In contrast, helper
T cells producing IL-22 (Th22 cells), involved in the pathogenesis of inflammatory reaction
and autoimmunity, were found increased in patients with advanced MDS and their number
was correlated with the mRNA levels of proinflammatory cytokines [42].
Finally, peripheral blood Tγδ lymphocytes, possessing a TCR with rearranged gamma/delta
chains, and particularly Vγ9Vδ2 T cells, the major Tγδ-cell subset, which represent an important
subpopulation for antitumor activity, were found reduced in patients with MDS and the
reduction was greater in patients exhibiting autoimmune manifestations. Although Tγδ cells
were not clonal, they reacted poorly to IL-2, and bromohalohydrin, a specific mitogen for these
cells, induced mitogenic responses in only 60% of the MDS studied, unrelated to any specific
disease feature. However, when activated, they exerted normal antileukemic effects against
leukemic blasts. Therefore, the impaired number and function of this T-cell subpopulation may
play a role in clonal expansion and disease progression of MDS [43].
4.2. B-lymphocyte abnormalities
Although B lymphocytes in MDS patients do not demonstrate the spectrum of abnormalities
detected in T cells, since their production and function is governed by T cells, their aberration
actually reflects the functional integrity of T cells. Information for B lymphocytes is fewer and
often conflicted. In many studies, decreased proportion and peripheral blood absolute B
lymphocytopenia, frequently accompanied by hypogammaglobulinemia and recurrent
infections has been reported [27, 44]. These findings are mostly confined to patients with lower
risk disease and are associated with T-lymphocyte imbalance and reduced numbers of bone
marrow B cells and B-cell precursors.
Analysis of the marrow CD34+ cell differentiation toward B lymphocytes in patients with low-
risk MDS has revealed low expression of B-lineage differentiation genes and reduced produc‐
tion of B-cell precursors, a finding proposed to be used as a hallmark of low-risk disease [45].
An additional factor contributing to B lymphocytopenia is that bone marrow B-, but not T
lymphocytes, exhibit increased apoptosis, similar to that observed in nonlymphoid cells.
Increased B-cell apoptosis could not be considered a clonal “property,” since it was found
neither in leukemic nor in normal marrows [44]. This was also confirmed on trephine biopsies
of patients with high-risk MDS only, and the percentage of B lymphocytes was inversely
correlated with prognosis [30]. Bone marrow flow cytometry analysis has shown increased
proportion of CD34+CD45low B-cell precursors in patients with RA and RARS, and lower values
in those with RAEB, whereas in AML B-cell precursors were not found at all, probably
reflecting differentiation incapability of the CD34+ cells. Indeed, an inverse correlation of
CD34+CD45low+ B cells with marrow blasts and a positive one with hemoglobin was found.
Abnormal expression pattern of B-cell differentiation antigens, with hypoexpression of
CD79α and TdT has also been reported, implying a possible role of the MDS marrow micro‐
environment in the maturation process of B lymphocytes [46].
Regarding the origin of B- and T lymphocytes, available data are again conflicting. In the
majority of clonal studies, neither T- nor B lymphocytes or NK cells were found to originate




from the dysplastic clone. Some studies have shown clonal origin of the B lymphocytes in a
proportion of MDS patients, and in a Japanese study, the majority of patients with RA and
those with immunological abnormalities exhibited clonal B lymphocytes [47]. Clonal origin
was also found in 5% of the CD20+/CD22+ B cells of patients with trisomy 8. By using interphase
FISH on sorted marrow cells, 13% of the CD5+CD19+ lymphocytes were clonal, implying that
a part of the B lymphocytes in some patients may be clonal and that these cells may contribute
to the manifestation of immune abnormalities [48].
B lymphocytes of MDS patients express low number of HLA-DR molecules (HLA class-II
antigens) and are either deficient of EBV receptors or they carry abnormal Fcγ and C3d
receptors, which cannot be used by EBV viral particles to enter and activate B cells. B-lym‐
phocyte cultures produce increased amounts of IL-6 and IL-10, following mitogenic stimula‐
tion. IL-6 is overproduced even without mitogenic stimuli. Finally, B lymphocytes of patients
manifesting immune abnormalities have lower number of cell surface Fas ligand receptors, a
finding possibly indicating their resistance to apoptosis.
Not surprisingly several quantitative serum γ-globulin and immunoglobulin abnormalities
have been described in MDS patients, such as polyclonal hyper-γ-globulinemia, monoclonal
M-spikes, or hypo-γ-globulinemia. Monoclonal components have been found significantly
higher than in normal age-matched population [49]. It has been suggested that dysplastic
monocytes might exert unspecific immune stimulation on B- and T lymphocytes through
increased IL-1 production favoring the development of monoclonal B-cell populations and
producing M-spikes.
Investigating the significance of serum protein electrophoresis in 158 patients, we noticed a
normal pattern in 36% (mainly in RA and RARS) and only in 8% of CMML. A normal baseline
pattern was associated with longer survival, independently of the IPSS and FAB classification.
An acute phase reaction (alpha2-globulins >10 g/l) was seen in 17% at baseline, developed in
additional 24% in the course of the disease, but in 80% of the patients transformed to AML and
was associated with shorter survival. Hypo-γ-globulinemia was found in 6%, mainly RARS,
was not related to frequent infections, and in RAEB it was associated with decreased marrow
cellularity, deeper cytopenias, and longer survival. Polyclonal hyper-γ-globulinemia was
found in 41% of patients (particularly RAEB-t, CMML) and monoclonal proteins in 16 cases
(10%) more commonly in CMML and 2.5 times more frequently than in a control population
of similar age. An additional 18% of the patients exhibited discrete M-components among
polyclonal spectrum of γ-globulins. This finding has not yet been described and its significance
is unclear [50].
4.3. NK cell abnormalities
Patients with MDS exhibit severe functional NK-cell impairment, but sometimes also numer‐
ical abnormalities. Cytotoxic NK-T cells, phenotypically characterized as CD3+CD8+CD16+,
are usually normal or decreased but IFN-γ production is normal or increased. NK cells,
characterized as CD3−CD8−CD11b+HNK1+ CD56+CD57+ cells, have been found normal,
rarely decreased, but sometimes even increased [51]. The NK activity of MDS patients is almost
always decreased compared to healthy controls [27, 51], although immunophenotypically NK
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cells are indistinguishable. In general, CD8+ T-cell function and the defective NK activity in
MDS have been strongly and inversely correlated with bone marrow blast cell percentage,
marrow cellularity, and serum sIL-2R levels [51]. Alloantigen- or mitogen-induced cell-
mediated cytotoxicity [27] as well as IFN-α and IL-2 production following NK cell activation
is also impaired and the preincubation of NK cells with IFN-α may partially increase NK
activity [52]. There are conflicting data regarding the origin of NK cells. By using FISH on
FACS-sorted cells of patients with monosomy 7, monosomic signs in CD3−CD56+ cells were
detected in 3 out of 4 [53]. In another study, between 20 and 50% but not all the NK cells were
clonal, demonstrating a kind of “chimerism” by clonal and nonclonal NK cells in the majority
of patients.
Many groups investigated whether IFN-α treatment could induce blast/clonal cell clearance,
through augmentation of the NK activity. In one study on 38 patients with RAEB, following
3-month treatment with IFN-α, NK activity and NK cell number and function was increased,
but these alterations were not associated with any meaningful clinical response. NK cells
exhibited normal tumor cell binding capacity, but inability of releasing cytotoxic factors,
possibly suggesting intrinsic functional defects [52]. Another group did not confirm any
quantitative defect and found normal expression of the activating receptors NKp46, NKp30,
and NKG2D, but a depressed cytolytic activity. Incubation with IL-2 upregulated the NKp46
expression, but did not enhance NK-cell cytotoxicity but induced higher rate of apoptosis [53].
A strong correlation of the NK activity with higher IPSS, abnormal karyotype, excess of blasts
and marrow hypercellularity, and downregulation of the NKG2D receptor has also been
reported [54]. The Nordic MDS study Group showed that decreased expression of DNAM1
and NKG2D receptors on marrow NK cells was inversely correlated with blast percentage and
suggested that DNAM1 plays a pivotal role in NK-mediated cell killing [55].
IL-12, alone or combined with IL-2, induces variable and unpredictable response to NK cells.
Some patients (mainly with RA) exhibit a response closer to normal, while others respond
poorly. The combination of IL-2 and IL-12 increases IFN-γ and TNF-α production in a
synergistic way. IL-12 alone is not so stimulatory, and the combination of IL-2+IL-12 generates
stimulation, similar to that obtained by IL-2 alone. Indeed, priming of peripheral blood
mononuclear cells (PBMC) with IL-12 increased their cytotoxicity against autologous leukemic
blasts to almost normal levels and significantly reduced WT1 mRNA expression, used as a
marker of residual leukemic burden, except in patients with overt, high-bulk AML. Thus, ex
vivo priming of cytotoxic NK-T and NK cells could be used as a tool, targeting residual disease,
following systemic chemotherapy [56].
In a study from Düsseldorf, the authors recognized a small subgroup of high-risk patients,
with almost absent peripheral blood NK cells, but intact populations of NK T cells. A larger
subgroup with normal number but poor function of NK cells was characterized by reduced
intracellular granzyme-B and perforin levels. This subgroup restored almost completely NK-
cell function, following mitogen or cytokine stimulation. NK cells were mainly immature but
exhibited normal mature/activated (CD56bright+CD107+) immunophenotype and a restricted
repertoire of KIR receptors. It is therefore suggested that the dysfunctional NK cells lead to
inefficient/insufficient immune surveillance and clonal expansion [57]. The Pittsburgh Group




reported different marrow frequencies of NK and NK T cells in MDS and AML. In MDS they
did not find numerical impairment of the NK-cell population, but a significant decrease in
mature CD56dimCD16+CD57bright cells, which had great prognostic significance for survival [58].
Other groups have reported increased intracellular granzyme-B levels in the NK cells of MDS
patients [59].
5. Serum cytokine profiles
The immune-activated status of MDS patients lead to overproduction and elevated serum
levels of many cytokines. We were the first group to report elevated serum soluble interleu‐
kin-2 receptors (sIL-2R) and tumor necrosis factor-α levels in 42 MDS patients confirming an
abnormal immune stimulatory status. Although the difference in TNF-α levels between early
and advanced MDS was not significant, patients with advanced MDS had significantly higher
serum sIL-2R levels compared to those with early MDS [60]. In vivo treatment with rhGM-CSF
or high-dose IL-3 further increases sIL-2R levels, which are associated with higher marrow
cellularity and blast cell percentage, faster AML evolution, and shorter survival. These findings
possibly reflect quantitative and qualitative abnormalities of the CD8+ and NK-cell subsets,
resulting in ineffective T-B cell communication and impaired NK-cell function, since sIL-2R
antagonizes the cellular receptor in IL-2 uptake, restricting T-cell activation [61]. sIL-2R levels
are negatively correlated with T- and NK-cell counts and positively with adverse events
occurring in the course of lower risk patients for whom sIL-2R levels are an independent
adverse prognostic factor.
Serum IL-6 levels were found elevated in the majority of MDS patients and serum GM-CSF
levels in less than half of them, although these cytokines were undetectable in normal subjects.
Higher IL-6 concentrations were found in patients with advanced subtypes, were inversely
correlated with the severity of the anemia and positively with peripheral blood and bone
marrow blast cell percentages, and may increase further following chemotherapy. IL-6, IL-7,
MCSF, TGFβ, and IL-1β are constitutively produced by marrow stromal cells of patients with
MDS and AML, but not from stromal cells of normal subjects, and IL-6 gene transcription could
be induced by exogenous addition of IL-1β confirming a cytokine network dysregulation [62].
Serum IL-8 levels were also found elevated, but they dropped under chemotherapy or during
remission.
A Dutch group measured serum levels of seven cytokines in 75 MDS patients and found
detectable levels of G-CSF in the majority of them, and increased IL-3 and IL-6 levels in a
minority of patients but not in controls [63]. Serum TNF-α levels have been correlated with
the severity of anemia, poor performance status, leucocytosis and monocytosis, higher β2-
microglobulin and lower albumin levels, liver and renal impairment, and shorter survival [62–
64]. TNF-α levels <10 pg/ml have been associated with achievement of higher remission rate
and longer PFS Progression Free and overall survival, whereas lower TNF-α and IL-1β levels
could predict response to treatment with erythropoietin [64]. Thus, TNF-α represents the most
important circulating and measurable cytokine, from the pathogenetic and the prognostic
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point of view. In general, serum levels of type-1 cytokines (IL-1β, IL-7, IL-8, IL-12, RANTES,
and IFN-γ) [64, 65] are found elevated in lower risk MDS, whereas inhibitory factors (IL-10,
sIL-2R) are elevated in higher risk disease.
The group of Mayo Clinic evaluated plasma levels of 30 different cytokines in 78 patients, and
showed that although levels of 19 cytokines differed significantly from controls, in multivariate
analysis, only levels of IL-6, IL-7, and CXCL10 had independent prognostic value for survival.
Indeed, patients with normal levels of all these three cytokines had a median survival of 76
months compared to only 25 months for patients with elevated levels of at least one of them.
For IL-6 levels in particular, a strong association with inferior leukemia-free survival, inde‐
pendent from other prognostic factors, was found [66].
Finally, a Spanish group, among other findings, demonstrated an inverse correlation of the
CD3+, CD4+, and CD8+ populations with age, as well as an inverse correlation of serum IL-10
levels with the number of CD8+ cells, disease progression, and overall survival [67]. In another
study, investigating the association of IL-10 gene polymorphisms with the development and
the features of MDS, the highly IL-10-expressing genotype -592 CC was associated with more
severe anemia and poorer survival compared to non-IL10-expressing genotypes, thus con‐
firming a significant prognostic role for IL-10 [68].
6. Functional immunoregulatory abnormalities of T lymphocytes
6.1. Mixed lymphocyte reactions (MLRs): basic information
A basic property of the immunocompetent cells is the recognition of the “self” and the
orchestration of an immune response against the “nonself” or the “altered self,” and when self-
recognition is impaired, an autoimmune disorder emerges. An initial interpretation for the
frequent autoimmune disorders and other immune abnormalities of MDS patients was that
they might probably reflect clonal origin of B- and T lymphocytes. Later, however, it was
demonstrated that, in the majority of cases, B- and T lymphocytes are nonclonal, but T-
lymphocyte abnormalities may influence disease course. Various T-lymphocyte subsets exert
complex immunoregulatory activities on other T-cell populations, B lymphocytes, and
monocytes. Mixed lymphocyte cultures are performed with the coculture of a pure T-cell
population (responder cells), upon which a kinetically inactive, but cell-surface intact, non-T
cell population (stimulant cells) affects, thus generating a mixed lymphocyte reaction. MLRs
represent dynamic in vitro models for the study of various cellular interactions and of the
immunoregulatory mechanisms developed between different immunocompetent cell popu‐
lations. When the stimulant and the responder cell population stem from the same subject, the
model is called autologous MLR (AMLR), whereas when the stimulant population stems from
another subject the model is called allogeneic MLR (Allo-MLR). AMLR and Allo-MLR constitute
practical tools for the investigation of various diseases and conditions with an underlying
immune-based pathogenesis or pathophysiology.
The proliferative reaction (MLR) is mediated through recognition of structural antigenic
domains of the cell surface of non-T cells, and particularly HLA class-II antigens. The stimu‐




lating capacity of the non-T-cell population is abrogated when cell membrane structure is
destroyed, either following mechanical stress or treatment with proteolytic enzymes. More‐
over, the stimulatory capacity is not a soluble factor and non-T- or B-lymphocyte supernatants
do not retain any stimulatory activity on T lymphocytes [69], whereas preincubation of the
non-T-cell population with anti-HLA-DR monoclonal antibodies completely abrogates the
AMLR and substantially depresses the Allo-MLR. The stimulatory potential of other mem‐
brane determinants on the MLRs was identified in a similar way. Such molecules are HLA
class I (HLA-A, -B, and -C) for the Allo-MLR, CD3-Ti complex for any type of MLR, and
probably additional minor antigenic determinants of the MHC. Stimulating capacity of the
non-T-cell population is dependent on the various mononuclear cell constituents included. B
lymphocytes are stronger stimulants than NK cells and null lymphocytes. Activated B
lymphocytes, surface IgM(+) B lymphocytes, and B lymphoblasts are better stimulants than
resting- and IgM(−) B lymphocytes, and this property is independent of their content in EBV-
DNA or the origin from a mitogen-enriched culture. The role of monocytes is contradictory,
since inactive monocytes enhance autologous reactivity, whereas the admixture of monocytes
in the responder T-cell population results in severe impairment of both AMLR and Allo-MLR.
MLRs share the characteristic features of an orchestrated immune reaction showing immuno‐
logic memory and specificity. When T lymphocytes, previously exposed to autologous non-T
cells and obtained the seventh day of culture, are re-exposed to the same non-T-cell population,
they demonstrate their peak proliferation earlier, on the third day of culture (secondary
AMLR), thanks to previously engrafted immunologic memory. The same has been confirmed
for the Allo-MLR, because when in the secondary culture the allogenic stimuli are different,
then different responder T-cell population is activated and the reaction shows the kinetic of
the primary MLR. There are different autoreactive and alloreactive T-cell populations. The
number of alloreactive T cells is 5–40 times higher than autoreactive, and represents 1/400–
1/150 of the total peripheral blood T lymphocytes, whereas autoreactive constitute 1/5000–
1/2200 of them.
The basic function of the MLRs is the production of suppressor “activity” or of suppressor/
cytotoxic T cells. The main part of the responder population are CD4+ helper/inducer T
lymphocytes and treatment of this population with an anti-CD4 monoclonal antibody,
practically abrogates all types of MLR. Conversely, treatment with an anti-CD8 antibody
quantitatively decreases the strength of both types of MLR. Thus, from the relative content of
the two major T-cell subpopulations AMLR has two different phases. Responder CD4+ T
lymphocytes undergo a proliferative reaction upon sensation of autologous signals (self-MHC
antigens: autoreactive T cells). CD4+ cell proliferative reaction is peaked on the third and fourth
day of the culture, when helper T-cell population dominates. This reaction is followed by a
secondary activation of the suppressor CD8+ T cells, which is quantitatively stronger, is peaked
on the sventh and eighth day of the culture and inhibits any further proliferation of the
autoreactive T cells. This serially fulfilled lymphocyte reaction is mediated through the
production of IL-2 by the CD4+ T cells. In the Allo-MLR the responder population (alloreactive
T cells) is activated through the recognition of the MHC alloantigens and is consisted of both
helper and suppressor T lymphocytes. Allo-MLR is always stronger than AMLR. Deficiency
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of AMLR and of Allo-MLR has been reported in various diseases and conditions, a list of which
is provided in Table 3.
Connective tissue disorders Autoimmune diseases
Rheumatoid arthritis Immunohemolytic anemia
Still's disease Immune thrombocytopenic purpura
Systemic Lupus Erythematosus Henoch-Schoenlein puprpura
Dermatomyosistis/polymyositis Insulin-dependent diabetes mellitus
Sjogren's syndrome Hashimoto's thyroiditis
Ankylosing spondylitis Chronic active hepatitis
Inflammatory bowel disease
Infectious diseases Primary biliary cirrhosis
Infectious mononucleosis Myasthenia gravis
Chronic mucocutaneous candidiasis Multiple sclerosis
Acquired immunodeficiecy syndrome Arthropathic psoriasis
Chronic Hepatitis C
Chronic periodontitis Allergic diseases and conditions
Allergic asthma
Neoplastic diseases Atopic dermatitis
Breast cancer Hay fever
Lung cancer Food allergy
Colon cancer
Head and neck cancer Various diseases and conditions
Gastric cancer Sarcoidosis
Bladder cancer with schistosomiasis Down's syndrome
Kaposi's sarcoma Congenital immunodeficiency
Myelodysplastic syndromes Idiopathic portal hypertension
Ataxia-telangiectasia
Lymphoproliferative disorders Congenital hyper-IgM syndrome
Chronic lymphocytic leukemia Mixed cryoglobulinemia
Hairy cell leukemia Hemophilic patients treated with fVIII concentrates
Hodgkin's lymphoma Transplanted patients
B-cell non-Hodgkin's lymphoma Patients in chronic hemodialysis
Peripheral T-cell lymphoma Advanced age
Multiple myeloma
Table 3. Diseases with an abnormal autologous mixed lymphocyte reaction.
Besides the immunoregulatory cell circuits, generated following “autorecognition” in the
AMLR, helper and suppressor T lymphocytes exert regulatory function in normal hemato‐
poiesis. T lymphocytes obtained at the early phase of the AMLR (third day) have promoting




activity on the formation of early (bursts) and late erythroid colonies (CFU-E) and this activity
is similar to that obtained by PHA-activated T lymphocytes. This activity, initially termed
Burst Promoting Activity, is attributed to the production of various hematopoietic cytokines
and particularly interleukin-3. Following the development of suppressor activity for damp‐
ening autologous reaction on the seventh culture day, this activity also induces suppression
of development of immature erythropoietic and other progenitor cells, similar to that gener‐
ated from activated lymphocytes following prolonged antigenic stimulation, as this happens
in chronic infections, inflammatory conditions, connective tissue diseases, and in aplastic
anemia. In these situations activated suppressor T lymphocytes produce suppressive cyto‐
kines, and particularly but not exclusively IFN-γ.
Cytotoxic activity, generated in the MLRs, is also directed against autologous and allogeneic
B lymphocytes, monocytes, and cells with an altered antigenic profile, either neoplastic or not.
Generation of cytotoxic activity against tumor cells as a result of immune activation is of
tremendous clinical significance. In AMLR and Allo-MLR the neoplastic cells may represent
the stimulant cell population, whereas responder populations might be both the suppressor/
cytotoxic CD3+CD16+ NK-T cells and the CD3-CD16+CD56+ NK cells. Activation of these
populations results in increased proliferation and the adoption of an activated profile. Thus,
cytotoxic T cells generated in AMLR may play an important role in antitumor surveillance [70].
6.2. Autologous and allogeneic MLRs of patients with myelodysplastic syndromes
AMLR and Allo-MLR were found significantly reduced on 12 MDS patients and the amount
of IL-2 produced during these reactions was severely depressed. Exogenous addition of IL-2
partially restored the strength of the reactions, which, however, continued to be substantially
reduced compared to normal controls. To investigate which cell population was primarily
affected, the authors compared the strength of Allo-MLR by using allogeneic non-T cells from
both normal controls and other MDS patients against T cells from MDS patients. They also
tested Allo-MLR of T lymphocytes from healthy controls against non-T cells obtained either
from normal subjects or from MDS patients. Allo-MLR of T cells from MDS patients was
substantially improved with the use of normal allogeneic non-T cells, but did not reach the
normal range. Conversely, Allo-MLR of T cells from normal subjects was severely deficient
when stimulant non-T cells had been obtained from MDS patients compared to the reaction
against non-T cells from normal subjects. Therefore, it appears that in MDS there is an impaired
stimulating capacity of the non-T-cell population consisting of B lymphocytes, monocytes, and
immature myeloid cells [26]. Almost concurrently the presence of “leukemia-inhibitory
activity” (LIA) of peripheral blood non-T cells of MDS patients mainly obvious in patients with
an excess of blasts, but also in some patients without an excess of blasts (RA-RARS) was
reported. Moreover, the majority of the patients without an excess of blasts, whose serum
contained LIA, evolved quickly to RAEB/AML. This “activity” of higher risk MDS patients
could be eluted from culture of PBMC in FCS-enriched media with the addition of GM-CSF
and IL-4 [71]. Cells responsible for the induction of suppression/inhibition of cell growth are
clonal macrophages, transformed in culture to “giant macrophages” or dendritic cells. The
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mediator of suppression was a soluble factor, other than IFN-γ or TNF-α, identified as acidic
isoferritin [72].
We investigated the MLRs in 20 MDS patients in paired experiments with sex- and age-
matched controls at baseline, before the administration of any interventional treatment. To
express the strength of reactions we used the Stimulation Index, i.e., the ratio of the incorporated
3H-thymidine in the MLR divided by the incorporated 3H-thymidine in an unstimulated
culture of equal number of purified CD3+ T lymphocytes. Patients with MDS exhibited
severely impaired AMLR in all experiments with a median value almost half as that of the
controls, without overlapping values, and the difference between the two groups was statis‐
tically very significant (p < 0.000001). Patients with RAEB showed that the most attenuated
reactions were significantly weaker than the remaining patients [73]. Cumulative results are
shown in Table 4.
FAB group N  (Mean ± SEM) cpm (Mean ± SEM) S.I. p AMLR patient/AMLR control
RA 4 2068 ± 205 2.64 ± 0.33 0.0023 0.58 ± 0.09
RAS 5 2301 ± 206 2.77 ± 0.18 0.0012 0.63 ± 0.06
RAEB 8 1837 ± 310 1.90 ± 0.07 <0.0001 0.40 ± 0.03
CMML 3 2562 ± 177 3.39 ± 0.21 0.0413 0.51 ± 0.08
All patients 20 2108 ± 154 2.49 ± 0.15 <0.0001 0.51 ± 0.04
Controls 20 4396 ± 404 5.31 ± 0.32
RAEB vs. other MDS pts (S.I.): 1.90 ± 0.07 vs. 2.88 ± 0.16 0.0004
Table 4. Results of the autologous mixed lymphocyte reaction in patients with MDS (counts per min and stimulation
index, S.I.) Bold letters/numbers indicate statistically significant differences.
To evaluate the capability of the stimulant cell population, Allo-MLR was performed against
non-T cells originating either from another MDS patient or from a healthy control. Moreover,
to evaluate the capability of the responder cells, Allo-MLR of the healthy controls was
performed against non-T cells from MDS patients or from other controls. In all cases, Allo-
MLR against normal non-T cells was substantially higher, and on average threefold as strong
as AMLR and Allo-MLR against “dysplastic” non-T cells was weaker, but always stronger
than AMLR of the same person. The difference between these two types of controls’ Allo-MLR
was significant (S.I.: 7.90 ± 0.89 versus 14.12 ± 1.59, p = 0.0035, unpublished data). When
compared to controls, Allo-MLR of MDS patients was significantly impaired in all comparisons
(S.I.: 4.53 ± 0.41 versus 14.12 ± 1.59, p = 0.000014, unpublished data). Significant difference was
maintained in the comparison of Allo-MLR between healthy controls and patients with RA,
RARS, and RAEB separately, whereas CMML patients exhibited the less, and RAEB patients
the most attenuated reactions, significantly weaker than the remaining MDS. In paired
analysis, alloreactivity of MDS patients was always weaker than that of the corresponding
control and the ratio Patient’s Allo-MLR/Control’s Allo-MLR was always <1 (median 0.36,
range 0.06–0.58). Among MDS patients, “dysplastic” origin of the non-T cells did not further




impair the already depressed alloreactivity. However, even in this Allo-MLR the difference
between patients and controls was still significant (S.I.: 3.64 ± 0.21 versus 7.90 ± 0.89, p = 0.026)
[73]. Results of the Allo-MLR are shown in Table 5.
Normal non-T cells Dysplastic non-T cells
FAB Group  N  × ±SEM p N  × ±SEM p
cpm S.I. cpm S.I.
RA 4 3562 ± 334 4.79 ± 0.64  0.020 3 2532 ± 407  3.01 ± 0.23  n.s.
RAS 5 4569 ± 702 5.86 ± 0.87 0.021 4 3859 ± 685 4.89 ± 1.16 n.s.
RAEB 8 2643 ± 328 3.04 ± 0.25 < 0.000 7 1865 ± 563 2.21 ± 0.49 n.s.
CMML 3 4215 ± 695 5.93 ± 0.62 0.070 1 3380 4.47 –
All Pts 20 3544 ± 312 4.53 ± 0.41 < 0.0001  15 2697 ± 389 3.63 ± 0.21 0.040
Controls 20 11,355 ± 1459 14.12 ± 1.59 12 6558 ± 869 7.90 ± 0.89
RAEB vs. all other MDS (S.I.) 3.04 ± 0.29 <0.001 5.52 ± 0.47 0.001
Table 5. Allogeneic mixed lymphocyte reaction in patients with myelodysplastic syndromes – counts per min and
stimulation index (S.I.) Bold letters/numbers indicate statistically significant differences.
Similar results were obtained by the Czech group who found significantly decreased MLRs
with lower TNF-α and IFN-γ production in the supernatants of patients with RA compared
to the MLRs of RARS patients. They also found less affected the allo-MLR against normal non-
T cells, and identified as more defective the second (effector) phase of the reaction [74].
Therefore, in the MLRs of MDS patients there is an impairment of both the responder (T cells)
and the stimulant population (non-T cells). The responder population reacts poorly to
autologous and allogeneic stimuli and exhibits a profile of immune tolerance, which is clearer
in the high-risk patients. Moreover, the stimulant population provides insufficient stimuli for
reaction to the T cells, since it also depresses the alloreactivity of normal T lymphocytes. The
possible, if any, clinical consequences of these findings are practically unknown or remain only
speculative.
6.3. Pathogenesis of immune dysregulation in MDS: immune abnormalities or immune
adaptation?
6.3.1. Autoreactivity against the clone: Autologous progenitor cell/T-lymphocyte reaction (APLR)
“Inhibitory activity” derived from serum and PBMC culture’s supernatants of MDS patients
has earlier been described and associated with poor prognosis [71]. Normal PBMC inhibit
autologous hematopoietic cell colony formation in short-term cultures, as did also PBMC of
patients with RA, but they induced a clear inhibitory activity later on day 10. Responsible cells
are probably cytotoxic T and NK cells, which may react against the clone and suppress the
growth of clonal cells at early stages of the disease. If this suppressor function develops early
and is effective, clonal growth may be arrested. Nevertheless, NK cells of MDS patients usually
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has earlier been described and associated with poor prognosis [71]. Normal PBMC inhibit
autologous hematopoietic cell colony formation in short-term cultures, as did also PBMC of
patients with RA, but they induced a clear inhibitory activity later on day 10. Responsible cells
are probably cytotoxic T and NK cells, which may react against the clone and suppress the
growth of clonal cells at early stages of the disease. If this suppressor function develops early
and is effective, clonal growth may be arrested. Nevertheless, NK cells of MDS patients usually
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exhibit impaired function and sometimes are clonal. However, since suppressor activity is
achieved through various soluble cytokines and mainly through TNF-α, it is not quite specific
and may also affect nonclonal cells, resulting in hematopoietic suppression, as this is observed
in hypoplastic MDS and aplastic anemia. Indeed, lymphocyte culture supernatants from MDS
patients exert suppressive activity on the growth of normal hematopoietic progenitors [75].
This form of cytotoxicity was also identified in high-risk MDS and in AML, and was attributed
to possible infection of leukemic cells by an oncogenic virus. However, viral infection is not
necessary for the generation of an immune reaction, since clonal cells contain and sometimes
express on their membrane many abnormal or mutated proteins, possibly representing
neoantigens capable to induce lymphocytotoxic reactions by CD8+ T cells. Autoantigens are
hardly found in MDS and may only be speculative but have been identified in some other
marrow failure syndromes, such as aplastic anemia and paroxysmal nocturnal hemoglobinu‐
ria. As possible antigens, the Wilms Tumor protein (WT1), moesin, a cytoskeleton protein,
KIF20B (kinesin), desmoplakin, and proteinase-3, an enzyme of blast-cell granules, have been
indicated [76]. T lymphocytes of some MDS/AML patients stimulated in vitro with WT1 and
proteinase-3 were polarized toward TH1 direction with the production of IFN-γ and the
enrichment of their cytoplasm with granzyme B [77]. Moreover, patients expressing defined
proteinase-3 aplotype generate stronger allogeneic lymphocytotoxic reactions following
allogeneic hematopoietic stem-cell transplantation (GVL effect).
A challenging hypothesis is that the adaptive immunity may rather “react” than be impaired
following various cellular interactions, and this immune “reaction,” or at least such cellular
interactions, might be a part of the pathogenesis of MDS. This “reaction” also may represent
a defensive mechanism of the immune system against the dysplastic/neoplastic clone and is
orchestrated specifically against clonal bone marrow cells. Specific CD8+ suppressor/cytotoxic
T cells recognizing progenitor cells with trisomy 8 have been identified in MDS patients with
this abnormality. Clonal inhibition is achieved via MHC class I recognition and through
induction of FAS-mediated apoptosis [78]. The possible contributing role of an altered marrow
microenvironment in the development of such immune alterations is also tempting.
The presence of increased number of immunocompetent T lymphocytes with an activated
cytotoxic immunophenotype CD8+CD25+CD28-CD57+ has been reported in the marrows of
patients with aplastic anemia and MDS. These cells do not to directly influence the severity of
peripheral blood cytopenias [79]. In our study on 41 patients, the percentage of activated
marrow suppressor/cytotoxic T lymphocytes was inversely correlated with marrow cellularity
and blast cell percentage, and positively with Fas antigen expression on CD34+ clonal pro‐
genitor cells [80]. The cytotoxic reaction against marrow CD34+ cells of MDS patients has a
well-defined signal transduction pathway in the T cells and can be augmented in vitro with
the exogenous addition of IL-2 [81]. The strength of this reaction has not been associated with
any TNF-α-, IL-10-, or lymphotoxin gene polymorphism, although as it is well-known that
these polymorphisms appear to influence the severity of acute GVHD, following allogeneic
hematopoietic stem-cell transplantation [82].
We also investigated the behavior of the clonal CD34+ progenitors as stimulant population in
mixed cultures with autologous T lymphocytes as responder cells, in other words the immune




reaction when T cells are in close contact with clonal stem cells. We compared this type of
reaction (autologous progenitor cell mixed lymphocyte reaction—APLR) with the classical
types of MLRs. APLR reflects the strength of the immune reaction against the clone in a
background of established relative immune tolerance. We tested APLR in 20 MDS patients and
10 healthy controls. We noticed significant differences in the strength of the reaction between
patients and controls, as well as between the various subtypes of MDS. Results are shown in
Table 6. Among normal subjects APLR was rather a mild proliferative reaction, less than half
strong as AMLR and about six- to sevenfold weaker than Allo-MLR. Among MDS patients,
APLR was significantly stronger than in controls (p = 0.048, unpublished data, see Table 6).
Stimulation index ranged between 1.8 and 26.0 in patients, and between 1.4 and 3.0 in controls.
Thus, APLR was the only MLR in which MDS patients exhibited stronger reactions than
controls and with high variability [83]. In particular, patients without excess of blasts had APLR
similar to normal subjects, whereas patients with RAEB showed significantly stronger
reactions. Specifically, a subgroup of four RAEB patients exhibited very strong reactions with
a SI >10, significantly higher than the remaining MDS patients, although the same patients
developed weak responses against autologous and allogeneic non-T cell stimuli. As mentioned
earlier, in all healthy controls the ratio APLR/AMPR was always <1. In patients with RA or
RARS this ratio was around 1 but in some of them higher than 1, whereas in patients with
RAEB, APLR/AMLR ratio was substantially higher than 1. Thus, the three subject groups tested
with MLRs (low-risk MDS, high-risk MDS, and controls) could be compartmentalized in three
different areas in the plot (see Figure 1).
FAB Group N  cpm (Mean ± SEM) Stim. Index (Mean ± SEM) p APLR pt/APLR control
RA 4 2334 ± 382 2.88 ± 0.41 0.173 1.21 ± 0.11
RAS 5 2365 ± 385 2.77 ± 0.18 0.109 1.34 ± 0.13
RAEB 8 7502 ± 1194 10.35 ± 2.46 0.001 3.92 ± 0.74
CMML 3 3488 ± 556 4.55 ± 0.25 <0.001 1.43 ± 0.12
All patients 20 4582 ± 735 6.09 ± 1.27 0.048 2.39 ± 0.85
Controls 10 1866 ± 308 2.21 ± 0.31
RAEB 8 7502 ± 1194 10.35 ± 2.46
Other MDS 12 3.26 ± 0.95 0.004
Table 6. Autologous progenitor cell mixed lymphocyte reaction (APLR) Counts per min and stimulation index Bold
letters/numbers indicate statistically significant differences.
Our results have been confirmed by Chamuleau et al., who demonstrated increased non-MHC-
restricted autologous cytotoxicity against clonal marrow precursors in eight patients with
lower risk MDS, possibly indicating immune surveillance against clonal expansion although
they have not provided clinical data on its significance [59]. Suppression may not be restricted
against the dysplastic clone and may also affect nonclonal (normal) hematopoiesis. Lympho‐
cyte-depleted long-term bone marrow cultures from patients with lower risk MDS also
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generated some nonclonal hematopoietic colony growth, which was abrogated when T
lymphocytes were present in the culture system [82]. Autologous lymphocytes were particu‐
larly cytotoxic in patients with hypoplastic MDS, trisomy 8, or bearing the DR15 allele [84].
The suppressive role of autologous T lymphocytes has been very nicely demonstrated in a
patient with MDS and cyclic hematopoiesis, in whom, the percentage of marrow CD3+
lymphocytes was inversely correlated with neutrophil and platelet count during the various
phases of ineffective hematopoiesis [85].
Figure 1. Correlation of AMLR to APLR in each subject tested with MLRs. By correlating AMLR to APLR an almost
complete, discrete compartmentalization of the three main subject groups was found. Normal controls exhibited high‐
er AMLR than APLR, patients with lower risk MDS had lower, both types of MLRs, whereas patients with an excess of
marrow blasts showed impaired AMLR and very increased APLR.
6.4. The role of clonal hematopoietic cells in the induction of immune dysregulation
The strong MLR against autologous clonal CD34+ progenitors observed in patients with RAEB
was inversely correlated with marrow cellularity. All four patients with a strong APLR had
marrow cellularity of <35% and marrow blast cell percentage of 5–10% (RAEB-1). These
patients, although severely pancytopenic and transfusion dependent, had a delayed evolution
to AML or they did not progressed at all. In two of them who progressed, marrow cellularity
was increased and in a new APLR, performed at the time of AML progression, lymphocyte
activation against autologous blasts had been abrogated [86]. Thus, it appears that lymphocyte




activation in patients with RAEB is rather inversely correlated with leukemic burden, but
immunologic memory for this reaction is maintained and patients who lose their immune
activation during leukemic transformation may regain it following the achievement of
remission. Moreover, maintenance of remission is completely dependent on the presence of
autologous cytotoxicity against leukemic cells, mainly exerted by NK cells. This cytotoxic
reaction is disappeared upon relapse of the leukemia [87]. Unfortunately, immune activation
against clonal cells is not the rule and T cells in MDS (particularly Tγδ cells) may respond poorly,
if not at all, even following IL-2 stimulation, despite normal IL-2R expression, demonstrating
impaired immune surveillance against the clone [51]. Indeed, the Czech group did not find
any significant lymphocyte activation in eight out of nine patients tested and confirmed the
nonclonal origin of the T cells [71].
Clonal dendritic cells can also induce T-cell stimulation in AML. Proliferative reaction against
these cells is high but results in the generation of cytotoxic T lymphocytes with low activity
against autologous or allogeneic nonleukemic targets [88]. Dendritic cells of MDS patients in
Allo-MLR systems are poor stimulators for both normal and MDS-derived T cells, indicating
an impaired antigen presenting capacity. These cells, generated from CD34+ cells, although
immunophenotypically normal, were significantly decreased as were also the populations or
circulating myeloid- and plasmacytoid-derived dendritic cells, confirming ineffective “den‐
dritopoiesis” [89] and produce less IL-12 and more IL-10 in response to LPS and IFN-γ showing
qualitative and quantitative defects of cytokine production.
Blast cells exert direct suppressor activity on the activation, TH1 polarization and proliferation
of T lymphocytes. This activity is mediated through protein substances transcribed via the NF-
AT and NF-kB signals by inhibition of transition from G0 to G1 phase [90]. Upon NK cells,
leukemic cells induce impaired killing capacity, reduced TNF-α and IFN-γ production,
reduced CD107α degranulation, downregulation of the NKp46- and upregulation of the
NKG2A receptor expression, effects directed via IL-10, and favoring clonal escape and
expansion [91]. In other instances, however, blast cells induce lymphocyte activation, as
previously described, with the production of IL-2, IL-4, IL-10, IL-13, and IFN-γ. Lymphocyte
culture supernatants, when further activated with IL-2, generate strong cytotoxic LAK and NK
cells inducing lysis of autologous and allogeneic leukemic cells [92]. In the majority of cases,
immune effector function of NK-T and NK cells, observed in some patients with MDS, are
abolished on leukemic transformation.
7. Immunopathogenetic aspects of myelodysplastic syndromes
From the pathogenetic point of view it appears that an initial, harmful event (viral, drug,
irradiation, etc.), affecting the pluripotent hematopoietic stem cell compartment in the bone
marrow, may antigenically alter a minor population of these cells. Even when the consequen‐
ces of the harmful event are negligible and maturation and differentiation processes might
remain almost intact, it is possible that an immunologic reaction could be initiated. This
reaction is directed against the even minimally modulated hematopoietic progenitor cell
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population. Indeed, the strength of the autologous cytotoxic immune reaction, frequently
accompanying the emergence of a dysplastic clone, is not related to the complexity/severity of
the cytogenetic abnormalities, and a minor genetic damage may induce a strong reaction.
Conversely, complex chromosomal aberrations and other gross genetic damage, leading to
hematopoietic failure, may induce a weak or not any immune reaction. This reaction may be
less specific and may also generate cytotoxicity, not only against the affected cells, but also to
the unaffected/normal hematopoietic progenitors, inducing apoptosis and resulting in stem-
cell depletion and hematopoietic failure. Soluble factors (cytokines) released by the activated
lymphocytes might also harm accessory/stromal cells. This cascade of events usually leads to
aplastic anemia. When the initial harmful event induces deeper genetic damage in a pluripo‐
tent stem cell and this cell, although genetically altered, succeeds in escaping from apoptotic
cell death may generate an abnormal (dysplastic) clone. Clonal cells continue to trigger the
immunocompetent cells, but the latter although activated cannot eliminate the clonal cells,
which continue to escape, gradually expand, and suppress the unaffected/normal stem cell
compartment through at least two mechanisms:
(1) Immune effector cytotoxic cells can destroy more easily the nonclonal/normal progenitor
cells as a result of clonal cell escape from the immune attack.
(2) Secondary genetic alterations occurring gradually provide growth advantage to the clonal
cells.
Thus, immune activation may perpetuate and when cytotoxic activity is ineffective and
incapable to eliminate clonal cells, it becomes an “immunologic abnormality.” The more
effective the immune activation, the higher the degree of apoptosis induced, affecting more
and more marrow cellularity and creating a syndrome mostly similar to aplastic anemia.
Therefore, the decreased marrow cellularity observed in some marrow failure syndromes
might be considered an “adverse event” of an effective immune reaction capable to restrict the
growth of the abnormal/mutated/genetically altered clonal cell population. On rare occasions,
the intensive immune activation, augmented by an infection or a blood transfusion, may be
capable to completely eradicate the dysplastic clone leading to spontaneous complete remis‐
sion even after evolution to AML. In contrast, when immune activation is ineffective, clonal
expansion and evolution continues unimpededly until the stage of AML. At this stage, either
passively, due to high “antigenic burden,” or actively, through mechanisms, induced by the
leukemic cells, immune tolerance or immune paralysis is established abrogating further
immune reaction [93]. In rare instances, even after evolution, immune activation may be
maintained and result in an oligoblastic/hypoplastic AML. Conversely, when immune
activation is abolished early or when the dysplastic/neoplastic clone achieves in earning
immune tolerance, the evolution might be uneventful and lead to a hypercellular AML.
About 10–15% of MDS patients at initial presentation have a hypoplastic marrow (cellularity
≤30%). These patients exhibit more severe cytopenias, various degrees of trilineage dysplasia,
more prominent immune abnormalities, and usually a normal karyotype or single chromoso‐
mal abnormalities. Although hypoplastic MDS share many similarities with aplastic anemia,
different molecular mechanisms of marrow damage have been identified between them and




other/nonhypoplastic MDS. Among them development of oligoclonal expansion of cytotoxic
T lymphocytes, overexpression of TRAIL- and Fas ligand-induced apoptosis, underexpression
of Flice-like inhibitory protein long isoform (FLIPL), and increased production of IFN-γ and
TNF-α are included. Patients with hypolastic MDS have more stable clinical course and lower
evolution rates in relation to patients with nonhypoplastic disease of the same FAB/WHO
categories. They show good response to treatment with corticosteroids, cyclosporine-A,
antithymocyte globulin, or alemtuzumab, and to various combinations of the above. Overall
survival varies and if patients will not succumb to a severe infection, they may retain a
prolonged leukemia-free survival [94, 95].
Suppressor/cytotoxic autoimmune reactions are more frequently identified among lower risk
MDS, have specificity against the pluripotent or an early committed, usually erythropoietic
progenitor cell, and are associated with higher degree of marrow apoptosis. In the majority of
cases, the autoimmune process includes the production of specific antierythroblastic antibod‐
ies without the positivity of direct antiglobulin test. The production of such IgG autoantibodies
can be provoked ex vivo following antigenic stimulation [96]. These patients show higher
caspace-3 activity and lower TNF-α and IL-4 production. Analysis of the total IgM and IgG
antibody repertoire in 10 MDS patients without prominent autoimmune disease or known
autoantibody and in 10 healthy controls revealed different patterns of antibodies against self-
antigens in MDS patients from those of controls, and patterns of IgG antibodies had distinct
profiles implying disturbed self-recognition related to pathogenetic mechanisms of the disease
[97].
Increased marrow apoptosis is a dominant feature of MDS and affects all hematopoietic cell
compartments from the more immature-undifferentiated to the mature and recognizable cells.
The apoptotic rate of CD34+ cells in normal subjects has been calculated at about 1%, whereas
in MDS, it ranges from 3 to 15%. Higher apoptotic rate is usually found in patients with early
MDS and in few patients with an excess of blasts [98]. Apoptotic rate may vary in the same
patient at different time points reflecting also the evolution of mutational status of the clonal
cells. Specific cytogenetic abnormalities, such as trisomy 8 have been associated with higher
degree of apoptosis. Apoptosis is a multifactorial process in MDS with a possible contribution
of the immune effector cells. Clonal cells’ death could create abnormal structures with
potentially (auto)antigenic properties and apoptosis can represent the causative factor of the
initiation of autologous cytotoxic immune reaction. Indeed, increased apoptotic cell rate has
been associated with higher marrow cytotoxic T-cell infiltration and in many instances by
oligoclonal T cells in MDS patients, who also express the TIA-1 antigen on their hematopoietic
cells [99]. The proapoptotic marrow microenvironment triggers stromal cells to produce IL-32,
which in turn induces further TNF-α transcription, thus establishing a vicious cycle. IL-32
expression has been found many folds higher in the stromal cells of MDS patients, rendering
this cytokine a specific stromal cell marker for MDS [100].
Although immune activation plays the dominant pathogenetic role for the generation of
marrow failure in aplastic anemia, in MDS this cannot be easily identified in every individual
patient. In other words, it is not identifiable which part of the hematopoietic failure results
from the clonal disorder per se and which is attributed to the immune activation. This fact could
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explain, at least in part, why there is not a uniform response rate to the immunosuppressive
treatment and this rate may vary widely in different series of patients, irrespective of FAB or
WHO category, cytogenetics, and the severity of the cytopenias [101].
8. Immunosuppressive/immunomodulating treatment applied to patients
with MDS
Corticosteroids are the most widely used immunosuppressive treatment administered to
patients with MDS and autoimmune diseases [17, 20]. Response rates vary broadly and the
required dose depends on the type of autoimmune disease, MDS subtype, chronicity of the
condition, and other factors. Although symptom resolution may be fast, autoimmune disease
may relapse during tapering, demanding higher doses, which may not be tolerable by elderly
patients. Thus, corticosteroids usually lead to partial or transient response and second-line
treatment with other agents is necessary. Steroids may also benefit hematopoiesis, improving
cytopenias and reducing RBC transfusion needs. Responses are mainly seen in patients with
lower risk IPSS, with a specific profile, but also by some patients with RAEB [102] and may be
long-lasting and maintained with small maintenance steroid doses.
Cyclosporin-A (Cy-A) is the second more widely used immunosuppressive agent and has also
been used in combination with cytotoxic chemotherapy as a modulator of multidrug resist‐
ance, which is commonly found in higher risk MDS and in AML following MDS. Cy-A is
effective even at lower doses, aiming to achieve serum levels lower than those desirable in
aplastic anemia and in allogeneic stem cell transplantation and therefore is well-tolerated and
induces durable remissions [103, 104]. Retrospective evaluation of 50 patients showed a
hematological improvement and particularly an erythroid response in 60%. Better response
was achieved by patients with hypoplastic marrow, favorable karyotype, or carrying the
DRB1*1501 allele [105]. The NIH group has reported more frequent expression of the HLA-
DR2/HLA-DR15 allele in patients with MDS and aplastic anemia compared to a control
population and an association of the expression of this allele with a favorable response to
immunosuppression [106]. Cy-A added to T-lymphocyte cultures decreases IFN-γ- but not
Fas-L production and lead to abrogation of the inhibitory activity of the supernatant on
hematopoietic colony formation. However, the growth of secondary colonies continues to be
decreased due to low number of pluripotent CD34+ progenitors.
Probably the most effective immunosuppressive treatment is antithymocyte globulin (ATG),
which has been given to MDS patients with any marrow cellularity [101, 104]. Hematopoietic
improvement is achieved following elimination of the autoreactive cytotoxic T cells and may
result in restoration of the dysplastic marrow and peripheral blood morphology. In many
instances cytogenetic complete remission has also been reported, whereas in others, hemato‐
logic remission is not accompanied by cytogenetic remission. In these cases, most probably
immune activation mainly suppresses nonclonal hematopoiesis without significantly disturb‐
ing the dysplastic clone. Finally, rapid evolution to AML or increase of marrow blasts despite
hematological improvement has occasionally been reported following treatment with Cy-A or




ATG [107]. In these cases, immune activation may effectively suppress clonal cells and its
abrogation has favored the unimpeded clonal expansion and evolution. Mofetil mycopheno‐
late (MMF) or alemtuzumab can be used when corticosteroids and/or Cy-A are ineffective or
contraindicated, or when severe adverse effects emerge, but the experience with these agents
is limited. The main drawback of immunosuppression is that combined with the usually
coexisting neutropenia substantially increases the risk for common and opportunistic infec‐
tions, even when all prophylactic measures are applied. Cy-A, in particular, may further impair
previously existed renal failure and may induce various adverse events as a result of phar‐
macodynamic interactions to patients concommittantly treated with many other drugs.
Immune-stimulating treatment, targeting NK-/NK-T cells and aiming to generate cytotoxic T-
cell activity and eliminate the dysplastic clone, has been associated with rather disappointing
results. A promising message is that newer immunomodulating drugs, such as lenalidomide,
appear to increase NK T cells and improve their function, including cytokine production,
although this is not the major mechanism of action of the drug [108]. Hypomethylating agents,
currently used particularly in higher risk patients, when effective and leading to complete
response may also benefit autoimmune or hyperimmune clinical syndromes associated with
MDS. It has also been suggested that 5-azacytidine has an independent immune-modulating
activity and that remissions of the auto-/hyperimmune syndrome may occur independently
of the induction of hematological and cytogenetic response, and might also be effective in cases
in which other immunosuppressive treatments have been proved ineffective [109].
The injudicious use of immunosuppressive treatment in MDS may become a trench knife [110].
Patients exhibiting overactive immune response, but clonal hematopoiesis, even when sharing
a hypoplastic bone marrow, might need even more effective immune activation to wear down
the dysplastic clone. Similarly, patients with an established clonal disease, but without any
immune activation, could potentially gain benefit with the administration of immune stimu‐
lation in an effort to eliminate the clone. On the other hand, abrogation of an overactive
immune stimulation should be attempted when this activation suppresses primarily the
residual normal/nonclonal hematopoiesis and minimally disturbs the development of the
abnormal/dysplastic clone. When immune activation/reaction status cannot be identified and/
or quantified, in the middle of established dysplastic hematopoiesis, a course of moderately
strong immunosuppressive treatment with corticosteroids and/or cyclosporine could be
administered, and in cases of a favorable response, careful tapering of the drugs should be
tested in an effort to maintain the obtained response.
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ATG [107]. In these cases, immune activation may effectively suppress clonal cells and its
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appear to increase NK T cells and improve their function, including cytokine production,
although this is not the major mechanism of action of the drug [108]. Hypomethylating agents,
currently used particularly in higher risk patients, when effective and leading to complete
response may also benefit autoimmune or hyperimmune clinical syndromes associated with
MDS. It has also been suggested that 5-azacytidine has an independent immune-modulating
activity and that remissions of the auto-/hyperimmune syndrome may occur independently
of the induction of hematological and cytogenetic response, and might also be effective in cases
in which other immunosuppressive treatments have been proved ineffective [109].
The injudicious use of immunosuppressive treatment in MDS may become a trench knife [110].
Patients exhibiting overactive immune response, but clonal hematopoiesis, even when sharing
a hypoplastic bone marrow, might need even more effective immune activation to wear down
the dysplastic clone. Similarly, patients with an established clonal disease, but without any
immune activation, could potentially gain benefit with the administration of immune stimu‐
lation in an effort to eliminate the clone. On the other hand, abrogation of an overactive
immune stimulation should be attempted when this activation suppresses primarily the
residual normal/nonclonal hematopoiesis and minimally disturbs the development of the
abnormal/dysplastic clone. When immune activation/reaction status cannot be identified and/
or quantified, in the middle of established dysplastic hematopoiesis, a course of moderately
strong immunosuppressive treatment with corticosteroids and/or cyclosporine could be
administered, and in cases of a favorable response, careful tapering of the drugs should be
tested in an effort to maintain the obtained response.
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Abstract
Myelodysplastic morphology of blood cells can be encountered not only in myelodys‐
plastic syndrome (MDS) but also in nonclonal disorders like viral, bacterial, parasitic
infections, juvenile rheumatoid arthritis, polyarteritis nodosa, immune thrombocyto‐
penic purpura (ITP), iron deficiency anemia, megaloblastic anemia, dysgranulopoietic
neutropenia,  congenital  neutropenia,  cases  with  microdeletion  22q11.2,  malignant
lymphoma, after administration of granulocyte colony stimulating factor, chemothera‐
py, steroids, smoking, alcohol, posttransplantation, copper deficiency also, together with
or without cytopenia. Absence of cytogenetic abnormality in 50–70% of cases with MDS,
some overlapping morphological and/or pathophysiological features make it challeng‐
ing to differentiate between MDS and other diseases/disorders like aplastic anemia,
refractory ITP, copper deficiency. Transient genetic abnormalities including monoso‐
my 7 in megaloblastic anemia; increased immature myeloid cells in bone marrow of cases
with  copper,  vitamin B12,  or  folic  acid  deficiency in  the  setting of  cytopenia  and
dysmorphism may also lead to the misdiagnosis of MDS. On the other hand, there are
also cases of transient MDS. In this chapter, a literature is be presented to draw atten‐
tion  of  the  readers  on  the  disorders  that  mimic  MDS.  Additionally,  our  personal
experiences are also be shared. Awareness of disorders mimicking MDS may prevent
over- or underdiagnosis of MDS.
Keywords: secondary myelodysplasia, cell death, cell cycle, transient MDS, apoptosis,
rapid cell senescence
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1. Introduction
Myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by ineffective
hematopoiesis in bone marrow and cytopenias in peripheral blood. It is heterogeneous reflected
by a number of subgroups with different characteristics both in adulthood and childhood [1–11].
A single diagnostic parameter specific to MDS has not been discovered yet, and a considerable
number of patients with MDS lack chromosomal abnormality [1, 4]. Currently, the diagnosis
of MDS is mainly dependent on quantitative and qualitative dysplastic abnormalities [5].
Establishment of special characteristics of dysplasia like the number of dysplastic cell lines,
the percentage of the dysplastic cells, and characteristic megakaryocytes as in del(5q)
syndrome are critical in order to be able to assess which subgroup of MDS the patient fits
according to the World Health Organization (WHO) classification. Because uni- or
multilineage dysplasia may be the only criterion that differentiates the subgroups refractory
cytopenia with unilineage dysplasia (RCUD) and refractory cytopenia with multilineage
dysplasia (RCMD) [1, 5, 6, 10, 11]. Additionally, for the lineage to be considered as dysplastic,
at least 10% of the lineage should display displastic findings [1, 2, 5, 6, 8, 10, 11] both in











































Table 1. Recent definitions of morphological features of myelodysplasia (adulthood) [2, 5].
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Nearly half of which is constituted by refractory cytopenia of childhood (RCC) [4]. Minimal
diagnostic criteria for childhood MDS require fulfillment of at least two of the following
criteria: sustained, unexplained cytopenia (neutropenia, thrombocytopenia, or anemia); at
least bilineage morphologic myelodysplasia; acquired clonal cytogenetic abnormality in
hematopietic cells; increased blast count (>5%) [3].
Dyserythropoiesis Dysgranulopoiesis Dysmegakaryopoiesis
Abnormality -Megaloblastic changes1




-Multinuclearity (two or more
distinctly separated nuclei of the same
or of different sizes)













1Megaloblastic changes: At least 1.5 times the size of a normal poly- or orthochromatic erythroblast with coarse
condensation of chromatin and an increased nuclear-to-cytoplasmic ratio or orthochromatic erythroblasts with
decreased nuclear-to-cytoplasmic ratio and at least double the size of a normal erythrocyte of the same maturational
state.
2Cytoplasmic granules or inclusions: Presence of granules or nuclear fragments that can be definitely differentiated
from ribosomal RNA.
3Bizarre nuclear shape: Abnormal nuclear shape, including irregularly lobulated nuclei of segmented granocytes with
chromatin clumping or large twisted bands, large bands or metamyelocytes, multinuclearity (two distinctly separated
neutrophilic bands or segmented nuclei).
4A- or hypogranularity: Neutrophilic or azurophilic granules should be markedly or completely absent and the
cytoplasm of mature neutrophilic granulocytes has to stain pale blue/gray or translucent in the Romanowsky-Giemza
stain. All maturation stages except blast cells should be affected.
5Nuclear/cytoplasmic (N/C) asyncrony: Mature neutrophilic granulocytes and metamyelocytes with basophilic
cytoplasm and myelocytes with neutrophilic cytoplasm.
6Pseudo-Pelger anomaly: Mature granulocytes with either a centrally located round to ovoid nucleus (monolobated
type) or two round nuclei of similar size connected by a slender chromatin bridge (bilobated type).
7Micromegakaryocytes: Mononucleated megakaryocyte with a size comparable to that of a promyelocyte or less,
lacking features of a blast cell.
8Small binucleated megakaryocyte: Small megakaryocyte with the size of a micromegakaryocyte or slightly larger,
with two round well-separated nuclei.
9Megakaryocyte with small round separated nuclei: Megakaryocytes of any size with multiple, at least three, round
separated nuclei.
10Megakaryocytes with nonlobated round nucleus: Megakaryocytes of normal or reduced size with a nonlobated
round nucleus and a mature granular cytoplasm.
Table 2. Morphological features of myelodysplasia (childhood-EWOG-MDS Group, 2005) [13].
The unilineage dysplasia in RCUD of adult MDS should have lasted for at least 6 months if no
clonal cytogenetic abnormality is found and/or ring sideroblasts are less than 15% [12], so for
these patients a repeated bone marrow examination is recommended after a 6 months’
observation [5].
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The dysplastic changes have been standardized in childhood [13, 14] and adulthood MDS [2,
5, 15, 16] (Tables 1–4) being restricted to three lineages as erythroid, granulocytic, and
megakaryocytic lineages. Although monocytes are rarely affected in MDS, their presence








-Giant bands (in severe
neutropenia, this criteria may
not be complied)
-Megakaryocytes with variable size and separated
nuclei or round nuclei (absence of megakaryocytes
does not rule out RCC)
Table 3. Morphological features of myelodysplasia in refractory cytopenia of childhood (RCC) (WHO, 2008) [14].
Dyserythropoiesis Dysgranulopoiesis Dysmegakaryopoiesis
-Polychromasia





-Macropolycyte (PMNL >14 μm)
-Ring nucleus








-Charcot-Leyden crystals in nucleus
-Basophilic granules
-Megakaryocyte fragments
-Giant granules in thrombocyte
-Bothryoid nucleus in megakaryocytes
-Hypogranulation in megakaryocytes
Table 4. Other parameters for myelodysplasia that were suggested previously but had not been included in the recent
guidelines [15, 16].
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the course of normal differentiation and therefore these changes can be encountered not only
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(juvenile rheumatoid arthritis, polyarteritis nodosa, systemic lupus erythematosis, immune
thrombocytopenic purpura) [17, 28–32], hemophagocytic histiocytosis (HLH), nutritional
problems (malnutrition, iron deficiency anemia, megaloblastic anemia, copper deficiency,
vitamin D deficiency, hyper vitaminosis A) [27, 33–43], neutropenia (congenital dysgranulo‐
poietic, congenital severe, idiopathic) [32, 44, 45], inherited disorders [27, 46, 47], malign
lymphoma [48], due to effects of drugs and toxins [17, 27, 49–54], during posttransplantation
period [27, 55], and other reasons [27] also and called “secondary myelodysplasia” [27]. These
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The dysplastic changes have been standardized in childhood [13, 14] and adulthood MDS [2,
5, 15, 16] (Tables 1–4) being restricted to three lineages as erythroid, granulocytic, and
megakaryocytic lineages. Although monocytes are rarely affected in MDS, their presence
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findings are neutrophils with nuclear shape, hypoagranulation, abnormal nuclei, cytoplasm
and granulation, anisocytosis, poikilocytosis, microspherocytes, giant thrombocytes, lympho‐
cytes with cytoplasmic protrusions and vacuoles, monocytes with dysmorphic nuclei,
cytoplasmic vacuoles and cytoplasmic protrusions, chromatin clumping, nucleocytoplasmic
asyncrony, interchromatin bridges between erythroid precursors, oligonuclear megakaryo‐
cytes, naked megakaryocyte nuclei and cytoplasm, most of which have been included in the
dysplasia criteria in MDS of childhood [13, 14], and adulthood [2, 15, 16].
While MDS is potentially preleukemic, disorders with secondary myelodysplasia are not
neoplastic or preleukemic and are reversible when the underlying factor is removed [27].
Such cases with additional cytopenia in one or more cell lines, due to transient suppression of
hematopoiesis may erroneously lead the physician to the diagnosis of MDS, especially when
no cytogenetic abnormality can be attained. Additionally, assessment of morphological
abnormalities in MDS is still not completely objective [56], in spite of that a number of
dysmorphic findings were simplified, categorized [2, 13–16] and cut-off values were estab‐
lished [5]. This situation is valid especially for low-risk MDS cases without excess blasts and
any detectable cytogenetic abnormalities. Additionally, necessity to wait without definite
diagnosis and therefore therapy for at least 6 months in cytopenia cases with unilineage
dysplasia [5, 12] is distressing for the patient and the family.
On the other hand, it is also challenging to differentiate cases which present as ordinary aplastic
anemia, refractory immune thrombocytopenic purpura (ITP) [31], chronic neutropenia [44,
45] from MDS [4, 9, 14, 57–60]. Transient MDS or MDS-like disorders with or without [61–70]
chromosomal abnormalities, acute myeloblastic leukemia (AML) cases with low blast cell
count [71] should also be considered for accurate diagnosis. Additionally, it should not be
forgotten that autoimmune disorders may also be a component of MDS itself [72–74] and there
may be cases complying the criteria of other MDS subtypes like idiopathic cytopenia of
undetermined significance (ICUS), idiopathic dysplasia of undetermined significance (IDUS)
[5, 7, 58].
This chapter reviews on these diagnostic problems, in the following order:
• Nonclonal disorders which present as dysplasia and cytopenia
• Cases with hypoplastic bone marrow mimicking hypocellular MDS
• Transient chromosome abnormalities in the setting of cytopenia/spontaneous remission in
MDS
• Mutations in the elderly and other cases
• Acute myeloblastic leukemia
• ICUS-IDUS
• Autoimmune disorders
• Common features in pathogenesis




• Conclusion and future recommendations
2. Nonclonal disorders which present as dysplasia and cytopenia
2.1. Viral and bacterial infections
In a pilot and unpublished study that we carried on in our clinic, we compared the dysmorphic
parameters in the neutrophils of patients with viral (n:6; infections: rubella, rubeola, viral
eruption of unknown origin, Ebstain Barr virus infection), bacterial (n:7; infections: preseptal
cellulitis, urinary infection, tonsillitis, maxillary sinusitis, lymphadenitis, otitis media)
infections and those of healthy controls. We found that the neutrophil diameter of those with
bacterial infections; the percentage of pseudo Pelger-Huet cells and irregular distribution of
granules in both viral and bacterial infections; the percentage of chromatin clumping in viral
diseases were higher than the control. These findings showed that nonspecific infections can
also give rise to dysmorphic findings in neutrophils.
In another study, we reported that those with bacterial diseases additionally displayed
comparable diameter, macropolycyte (neutrophils with diameter >14 μm) percentage, bizarre
nucleus, irregular distribution of granules with those of pretreatment ITP who also displayed
myelodysplasia [17].
Striking dyserytropoiesis was reported in tuberculosis [27]. Several viral infections which
closely mimick MDS will be delineated below.
2.1.1. Parvovirus infection
In the literature, there are cases of parvovirus infection, with [19–21] or without [22] immu‐
nodeficiency or chronic hemolytic anemia which transiently or chronically mimicked MDS or
dyserythropoietic anemia [22]. Among them the two [19, 20] are of note.
The reported case of Hasle et al. [19] was an 8-year-old, previously healthy boy who admitted
to the hospital with severe anemia, moderate thrombocytopenia, and granulocytopenia and a
2 weeks’ history of intermittent fever. Physical examination was normal except for pallor. Bone
marrow was hypercellular with marked erythroblastopenia and maturation arrest of the
erythropoietic cell line. No giant pronormoblast and hemophagocytosis was noted. Dysplasia
in myeloid and megakaryocytic lineage was evident. He had increased immunoglobulin (Ig)
M, low IgG, slightly decreased natural killer (NK) cells which reduced during follow-up;
impaired in vitro proliferation of blood mononuclear cells on stimulation.
The patient was assumed as MDS and was administered prednisolon, androgenic steroid,
cyclophosphamid and cyclosporine, IgG infusion and frequent blood transfusions and
developed hemochromatosis and hepatosplenomegaly. Thrombocytopenia deepened;
hemoglobin transiently normalized. Parvovirus antibody studies revealed negative but when
polymerase chain reaction technique became available, serum samples of the previous two
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The reported case of Baurmann et al. [20] was a 36-year-old, previously healthy woman who
admitted to the hospital with fever, pancytopenia, and atypical lymphoid cells with dysplastic
hematopoietic changes. She had frank splenomegaly, slightly increased bilirubin, lactate
dehydrogenase (LDH), negative Coombs test. Since the bone marrow was hypocellular with
multiple abnormal megakaryocytes, absence of erythropoiesis and 15% blasts carrying
monocytic and histiocytic characteristics, she was diagnosed as MDS-refractory anemia with
excess blasts (RAEB). A second bone marrow aspiration performed 6 days after admission
revealed hypercellularity, no excess of blasts, erythropoietic hyperplasia with giant proery‐
throblasts, megakaryocytes which were in normal number but still dysplastic.
Parvovirus antibodies and DNA were positive while the serologic tests for other viruses were
negative. Reticulocytosis, spherocytes, increased osmotic fragility test, and persistent subclin‐
ical hemolysis indicated at transient aplastic crisis mimicking MDS-RAEB due to parvovirus
infection in the setting of hereditary spherocytosis.
2.1.2. Cytomegalovirus (CMV) infection
Miyahara et al. [23] reported a 41-year-old, previously healthy man who developed severe
thrombocytopenia with myelodysplastic changes of bone marrow and multiple autoimmune
abnormalities, low CD4/CD8 ratio following CMV infection. The bone marrow aspiration was
hypocellular with decreased megakaryocytes, atypical lymphocytes, and trilineage dysplasia.
After a short-course prednisolone therapy, he improved.
It was suggested that direct CD34+ multipotent stem cells were infected with CMV giving rise
to injury to the bone marrow cells. The inhibitory effect of cytokines [tumor necrosis factor
alpha (TNF-α), interferon gamma (IF-)] produced by CMV-infected leukocytes and stromal
cells on hematopoiesis and autoimmunity might have been responsible for myelodysplastic
changes and thrombocytopenia.
2.1.3. Human immunodeficiency virus (HIV) infection
At the time of primary infection, transient pancytopenia, lymphocytosis, increased hemato‐
gones, increase in CD8+ lymphocytes, isolated autoimmune thrombocytopenia, anemia,
reticulocytopenia, neutropenia, trilineage myelodysplasia both in the peripheral blood and
bone marrow were reported. Megakaryocytes which were in normal or increased numbers
showed apparent naked nuclei and were occasionally dysplastic [18]. Dysplastic findings were
found increased and erythropoiesis became megaloblastic during antiretroviral therapy.
2.1.4. Hepatitis C virus (HCV) infection
HCV-infected patients frequently had varying degrees of bone marrow dysplasia and patients
with pancytopenia were those who had the most frequent bone marrow abnormalities. In the
cohort of HCV-infected patients, those with hematopoietic malignancy also existed [24].
However, bone marrow was a site where HCV replicated extrahepatically which contributed
to the etiology of HCV-associated neutropenia and thrombocytopenia. Peripheral clearance or
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consumption of platelets might have increased in HCV infection also [75, 76] like in other
abnormalities in infections [77].
2.1.5. Virus infections in MDS
It should not be forgotten that more than 50% of patients with myelodysplasia and chronic




Yaralı et al. [25] reported seven cases with leishmaniasis all of whom had pancytopenia,
dysplasia in erythroid myeloid, and megakaryocytic lineages. The all qualitative and quanti‐
tative findings disappeared after 2 months’ therapy.
The authors postulated that increased TNF-α which was shown to be associated with increased
macrophages, increased oxidized pyrimidine nucleotides, decreased glutathione concentra‐
tion and presumably reduced clearance of free oxygen radicals might be responsible for
myelodysplasia in visceral leishmaniasis, and other hematological findings.
Dhingra et al. [26] also reported 18 cases with leishmaniasis who had various combinations of
cytopenia with increased bone marrow cellularity. Trilineage myelodysplasia (22%), bone
marrow fibrosis (16.6%), hemophagocytosis (11.1%), and increased iron stores (33.3%) were
evident.
It was thought that infected bone marrow stromal macrophages with leishmania, selectively
enhanced myelopoiesis by granulocyte macrophage colony stimulating factor (GM-CSF) and
TNF-α overproduction, giving rise to hypercellularity and trilineage myelodysplasia. In‐
creased iron stores were attributed to cytokine overproduction which also led to anemia.
2.2.2. Others
Secondary myelodysplasia due to plasmodium falciparum and P. vivax infection was also
reported [27].
2.3. Autoimmune disorders
2.3.1. Juvenile rheumatoid arthritis (JRA)
Yetgin et al. [28] reported myelodysplasia in 17 patients with JRA, none of whom had received
iron, corticosteroids, immunosuppressive drugs, or any transfusions, and none had acute
infection or gross bleeding. Bone marrow of all cases revealed normal along with abnormal
maturation at different levels, like left shift, along with trilineage dysplasia, the most promi‐
nent dysplasia being in myeloid lineage. Increased bone marrow cellularity, fatty changes,
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erythroid hypoplasia, myeloid and mild-moderate megakaryocytic hyperplasia were detected.
They all had anemia, mostly being microcytic; the most had leukocytosis and thrombocytosis.
Figure 1. Dysmorphic hematological features of the peripheric blood smears of the patient ASİ with chronic ITP (a–g),
patient MEY with JRA (h–n), patient TÇ with JRA (o–x). Courtesy of Turk J Med Sci [79]. Neutrophils: Macropolycytes
(neutrophil > 15 μm) (b, c, h, i), hypersegmentation (c), cytoplasmic vacuoles (a), hypogranulation (d, o), cytoplasmic
protrusions with or without granules (h, k), irregular distribution of granules (a, c, j), abnormal nuclei with nucleic
protrusions (q, r), neutrophils with long chromatin between the nuclei (j, o), pseudo Pelger-Huet cells (o, p) Lympho‐
cytes: Cytoplasmic protrusions (e, n, u, v, w). Basophils: Centralization of granules (f), abnormal nuclei and hypogra‐
nulation (x). Monocytes: Abnormal nuclei (g, s, t), cytoplasmic vacuoles (g, s), cytoplasmic protrusion (g). Platelets:
Big or giant platelets (l, m) β-gal staining photographs of the patients. Patient TÇ JRA (y), patient MBY with JRA (z),
patient KÇ with SLE (aa), patient HA with acute ITP (ab), patient ASİ with chronic ITP (ac), control (ad) (×100).
The score of myelodysplastic peripheral blood findings but not those of bone marrow corre‐
lated significantly with CRP and ferritin.
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It was postulated that abnormally regulated cytokines and other local intracellular messengers
by cellular immune system lead to alterations of the microenvironment of bone marrow giving
rise to the myelodysplastic features (Figure 1).
On the other hand, clinicians should keep cautious since rheumatoid arthritis and other
rheumatoid disorders may present as a part of immune abnormalities in MDS also [72–74].
2.3.2. Polyarteritis nodosa (PAN)
Yetgin et al. [29] reported a child with hematopoietic dysplastic characteristics in an 11-year-
old girl with PAN. While her blood smear revealed occasional trilineage dysplasia, her bone
marrow displayed moderate cellularity, fatty changes, and trilineage dysplasia in addition to
blast and blast-like mononuclear cells. She received therapy of methyl prednisolone and
cyclophosphamide and all of the hematologic abnormalities were found to have resolved after
6 months. It was suggested that these dysplastic findings were associated with the primary
inflammatory process and increased cytokines.
2.3.3. Systemic lupus erythematosis (SLE)
Voulgarelis et al. [30] reported bone marrow biopsy and aspiration findings of 40 SLE cases in
comparison with 10 MDS-refractory anemia (RA) cases. The patients had mono-bi- or triline‐
age cytopenia. The bone marrows were hyponormocellular with increased erythroid and
megakaryocytic lineages in the majority of cases. All patients had dyserythropoiesis and
dysmegakaryopoiesis. Dysmyelopoiesis was less striking with a left shifting. While the rate of
dyserythropoiesis and dysmegakaryopoiesis were similar in patients with SLE and MDS-RA
(100% vs 100%), the features of bone marrow biopsy specimens differed in that normo-
hypercellularity and abnormal localization of immature progenitors (ALIP) aggregates were
less but bone marrow necrosis was higher in SLE. Dilated sinuses (20%) were seen in SLE while
no dilated sinus was noted in MDS-RA (0%). Increased reticulin, striking stromal edema, lack
of inflammatory vascular damage and lack of microvascular obstruction by thrombus plugs,
aggregates of T and B lymphocytes with polyclonal immunoglobulin expression were other
striking features of SLE [30]. Specific lupus erythematosus (LE) cells (neutrophils containing
a round, amorphous mass of purple, degraded nuclear material) were reported to be rarely
seen when the bone marrow aspirate is anticoagulated and spreading of films were delayed
[27]. These findings showed that bone marrow was a main target in SLE.
In SLE, it was shown that bone marrow fibroblasts could not produce enough hematopoietic
growth factors and stromal cells of SLE patients failed to support allogenic progenitor cell
growth in culture leading to defective hematopoietic microenvironment and altered cytokine
expression. Additionally, autoreactive lymphocytes in the bone marrow of SLE patients might
have directly caused immune destruction of both stromal cells and hematopoietic cells and
indirectly affected them via releasing pro-inflammatory cytokines like TNF-α [35]. Secondary
dysplastic changes in autoimmune diseases, in particular SLE, were demonstrated to closely
mimick those in HIV [27] (Figure 1).
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MDS (RCC, RCUD, RCMD with
unilineage cytopenia as thrombocytopenia)
Chronic ITP
Increased platelet destruction -Present (peripheral) [81] -Present (intrasplenic) [82]
Thrombocyte life span -Short [81, 91] -Short [82]
Thrombocyte production rate -Decreased [81, 91] -Decreased/normal [82]




-Present (more prominent) [31] -Present (less prominent) [31]
Other dysplastic changes -Present [14, 31] -Present [17, 79]
Megakaryocyte apoptosis -Only in micromegakaryocytes [31, 83]
-Necrosis-like programmed cell death
(mature + immature MKs) [81]
-Stage 3 megakaryocytes (apoptosis/
paraapoptosis) [82]
-No apoptosis [85]
Apoptosis in other cell lines -Apoptosis in all cell lines [86, 87] -Lymphocytes: Resistant to apoptosis [88]




-Present (TMPs/thrombocyte > normal)
[90]
-Present (TMPs/thrombocyte > normal
both in acute and chronic ITP) [90]
Response to splenectomy -Response in several patients with different
rates* [91, 92]
-Sustained response (70–80%) [93]
*Complete thrombocyte response in 50% (at 3 months) and 33% (at 12–54 months) of patients with short thrombocyte
lifespan (<3.5 days), no transfusion requirement, but sustained neutropenia [91, 92].
Table 5. Characteristics of chronic ITP and MDS with unilineage cytopenia as thrombocytopenia (RCC subgroup of
childhood MDS and RCUD, RCMD in adulthood MDS).
2.3.4. Immune thrombocytopenic purpura
In a previous study, we established neutrophil and eosinophil dysmorphism and increased
macropolycytes in patients with acute and chronic ITP before treatment, in comparison with
normal children. Several dysplastic features increased at the end of mega dose steroid (methyl
prednisolone 30 mg/kg/day × 3 days followed by 20 mg/kg/day for the consecutive 4 days)
therapy but decreased within 1–4 weeks after therapy was stopped. Hyperdiploidy in
neutrophils which developed during steroid therapy normalized 7 days after therapy was
stopped [17]. Dysplastic features were noted in other cell lines too [79].
These findings suggested that not only an intrinsic megakaryocyte proliferative defect giving
rise to deficient platelet production were present in refractory chronic ITP patients but a defect
before or at the level of colony forming unit-granulocyte-erythroid-monocyte-megakaryocyte
(CFU-GEMM) also. The antiplatelet antibodies and the increased cytokines in ITP [80] might
have been effective at this level (Figure 1).
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2.3.4.1. Differentiation between MDS (refractory thrombocytopenia) and chronic ITP
Myelodysplastic syndrome with isolated thrombocytopenia (RCC subgroup of childhood
MDS and RCUD, RCMD, MDS-U subgroups of adulthood MDS) can be masqueraded as
refractory chronic ITP and the accurate diagnosis may be challenging due to close similarities
between the two entities like decreased life span, decreased production rate in thrombocytes,
increased thrombocyte destruction, presence of dysplastic findings in myeloid and megakar‐
yocytic cell lines including micromegakaryocytes, naked megakaryocyte nuclei and megakar‐
yocyte emperipolesis; and additionally megakaryocyte apoptosis, platelet microparticles and
good response to splenectomy in several patients [17, 31, 81–93] (Table 5).
Figure 2. Myelodysplastic findings in a patient with MDS (refractory thrombocytopenia). Courtesy of Ped Hemat On‐
col [31]. Erythroid serie: Interchromatin bridge between erythroblasts (a), spherocytes (b). Neutrophilic serie: Bizarre
nucleus, nuclei with striking chromatin clumping, abnormal projections, cytoplasm with irregular distribution of gran‐
ules and vacuoles (c), nucleocytoplasmic asyncrony (c, d). Eosinophilic serie with micronuclei, cytoplasmic vacuola‐
tion, cytoplasm with both eosinophilic and basophilic granules (e). Monocytic serie with cytoplasmic vacuoles (f).
Blast-like cells (g). Histiocytic serie: Sea-blue histiocyte (h). Mitotic cells: Mitosis in an unknown cell (i). Apoptotic
cells with condensed and fragmented nuclei and condensed cytoplasm (j).
Thrombocyte microparticles per thrombocyte were reported more than normal in both
disorders [90] and the both can benefit from splenectomy although with different success rates
[91–93]. Two of these characteristics can be used to differentiate between the two entities. The
first is that, while megakaryocyte apoptosis in ITP starts at stage 3 (mature) megakaryocyte
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cells with condensed and fragmented nuclei and condensed cytoplasm (j).
Thrombocyte microparticles per thrombocyte were reported more than normal in both
disorders [90] and the both can benefit from splenectomy although with different success rates
[91–93]. Two of these characteristics can be used to differentiate between the two entities. The
first is that, while megakaryocyte apoptosis in ITP starts at stage 3 (mature) megakaryocyte
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level [82] (or apoptosis does not take place in megakaryocytes of ITP patients [85], megakar‐
yocyte apoptosis in MDS is detected in micromegakaryocyte level [31, 83]. The second is that
while apoptosis takes place in myeloid, lymphoid, and monocytic cell lines in MDS [86, 87],
no increase in apoptosis (in granulocytes and lymphocytes) on the contrary resistance to
apoptosis (in lymphocytes) [88, 89] were reported in ITP (Table 5). We followed a patient with
RCC that mimicked therapy resistant chronic ITP, who developed intracranial hemorrhage
twice but underwent a successful bone marrow transplantation [31] (Figures 2–4).
Figure 3. Dysmorphism in megakaryocytic serie, in a patient with MDS (refractory thrombocytopenia). Courtesy of
Ped Hemat Oncol [31]. Evaluation by light microscopy: Mononuclear megakaryocytes (a, b), megakaryocyte with
ring-shaped nucleus (b), megakaryocytes with nuclei that are being extruded out of the cell (i–k, o), the cytoplasm
which is lobulated (i), basophilic and condensed (i, k), naked megakaryocyte nuclei (f–h) with abnormal nuclear shape
(g–i), macroplatelets (c–e, m), dysmorphic platelets (e, l, m) are seen (×100). Evaluation by transmission electron mi‐
croscopy: Stage I megakaryocyte with large, oval, and intended nucleus and a cytoplasm containing abundant ribo‐
somes and granules. Demarcation system of membranes and granules are abundant in cytoplasm, all of which
indicates nucleocytoplasmic asyncrony. The granules were identified as azurophilic granules (single arrow) and un‐
identifiable, large, oval, and electron lucent, abnormal granules (double arrow) (×10,000) (p) and lots of free ribosomes,
azurophilic (single arrow) and abnormal unidentifiable, large, oval, electron lucent granules (double arrow) with de‐
marcation membranes in the cytoplasm of the same cell (×27,800) (q). A megakaryocyte that shows abundant demarca‐
tion membranes, ribosomes, and granules. The granules are heterogenous as to both size and electron density. A
phagosome (emperipolesis) is also seen (×12,930) (r). A stage I megakaryocyte with double nucleoli and abundant de‐
marcation membranes, abundant azurophilic (single arrow) and unidentifiable, large, oval, electron lucent abnormal
granules (double arrow) (s). Apoptotic stage I megakaryocyte that shows a condensed nuclear fragment and con‐
densed cytoplasm, but mitochondria, mitochondrial crystae, and demarcation membranes are still intact (×16,700) (t).
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Figure 4. Fas, annexin and bcl-2 values in lymphocytes (R1), monocytes (R2), granulocytes (R3) from the bone marrow
of the child with MDS (refractory thrombocytopenia), established by flow cytometry (Coulter Elite). Courtesy of Ped
Hemat Oncol [31].
2.3.5. Autoimmune neutropenia
Although chronic idiopathic and autoimmune neutropenia are considered as benign disorders,
it was reported that the bone marrow of these patients displayed dyserythropoiesis by 55%
and they transformed to clonal hematological diseases including NK expansion, hairy cell
leukemia, myelomonocytic leukemia, and MDS (RCUD, RCMD) within 30 months, with a rate
up to 6.5%. Therefore, these patients should be closely followed up [32].
2.4. Hemophagocytic lymphohistiosis (HLH, hemophagocytic syndrome)
All patients whom we followed in our clinic due to primary or secondary HLH had myelo‐
dysplastic features in addition to cytopenia involving at least two cell lines. The common
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findings in the bone marrow were erythroid hyperplasia, chromatin bridges between erythroid
precursors, multiple nuclei in erythroblasts, mild megaloblastic changes, vacuoles in erythro‐
blasts, myeloid precursors and monocytes, sometimes in thrombocytes; hypogranulation in
neutrophil myelocytes, micromyelocytes, irregular distribution of cytoplasmic granules, large
and sometimes hybrid granules in eosinophils; anisocytosis in thrombocytes including giant
thrombocytes, naked megakaryocyte cytoplasm, megakaryocyte emperipolesis, oligomono‐
nuclear megakaryocytes. These changes were probably due to the cytokine storm that played
the major role in the pathogenesis of HLH (Figure 5).
Figure 5. Myelodysplastic bone marrow findings of two patients with secondary (a, b) and primary (c–o) hemophago‐
cytic histiocytosis (HLH) (personal archives). Megakaryocytes with mononuclear nuclei that have irregular edges and
condensed cytoplasm are seen just after (a) and during (b) the process of extruding the nuclei out of the cell, develop‐
ing naked megakaryocyte cytoplasm and nucleus (a). Bilobed erythroid precursor (c), eosinophil myelocytes with cyto‐
plasmic vacuolation and rare basophilic granules, cytoplasmic protrusion (d), a naked nuclei of an unknown cell (e),
cells or formations with heterogenous morphology consisting of numerous vacuoles with various sizes (f, g, i), indis‐
tinguishable from abnormal trombocytes and detached cytoplasm of hemophagocyting histiocyte (h), hypogranulated
and vacuolated band (h), ringed nuclei in eosinophilic myelocytes (j, k), internuclear chromatin bridge (slightly dim)
(l), cytoplasmic protrusions in basophilic erythroblasts (m), bilobed normoblast (n), cytoplasmic vacuolation in a proer‐
ythroblast (o) (vitamin B12, folic acid, Cu, Zn levels were normal).





Mono-, bi-, pancytopenia, and hematopoietic dysplasia were reported in patients with
malnutrition, who were generally deficient in iron, vitamin B12, folate, and trace elements also.
Bone marrow cellularity was reduced with normoblastic dyserythropoiesis. Giant metamye‐
locytes, vacuolation in erythroid and granulocytic precursors, abnormal sideroblasts including
ring sideroblasts [27], hemophagocytosis, necrotic cells, and rarely dysmegakaryocytosis were
reported.
Figure 6. Myelodysplastic bone marrow findings of a child with malnutrition and gelatinous transformation (personal
archives). Basophilic erythroblasts with cytoplasmic protrusions (a) and vacuoles (b), agranular neutrophil (c, i) with
numerous cytoplasmic vacuoles and hypersegmented nucleus (c), hypoagranular neutrophils with hypolobulated nu‐
clei with abnormal protrusions, mild chromatin clumping (d, h), eosinophil with abnormal nucleus, irregular distribu‐
tion of granules (g), eosinophilic band with few basophilic granules distributed irregularly (j), vacolated monocytes (e,
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Figure 6. Myelodysplastic bone marrow findings of a child with malnutrition and gelatinous transformation (personal
archives). Basophilic erythroblasts with cytoplasmic protrusions (a) and vacuoles (b), agranular neutrophil (c, i) with
numerous cytoplasmic vacuoles and hypersegmented nucleus (c), hypoagranular neutrophils with hypolobulated nu‐
clei with abnormal protrusions, mild chromatin clumping (d, h), eosinophil with abnormal nucleus, irregular distribu‐
tion of granules (g), eosinophilic band with few basophilic granules distributed irregularly (j), vacolated monocytes (e,
j) and histiocytes (f), degenerating histiocytes (j), hypha and amorphous material representing the gelatinous material
(i, k).
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In anorexia nervosa, severe diseases with cachexia and starvation, acantocytosis in the
peripheral blood, hypocellularity with/without “gelatinous transformation” were noted. In
gelatinous transformation, the fat cells in the bone marrow are lost, and hematopoietic cells
are replaced by extracellular matrix material composed of acid mucopolysaccharide rich in
hyaluronic acid is detected [18, 33]. All the reported cases had anemia, leukopenia ± throm‐
bocytopenia [33, 34], rarely only anemia [35] (Figure 6).
Trilineage dysplasia in peripheric blood of iron deficient patients were reported, being higher
than the control group. In addition, microspherocytes which were observed in 20% of iron-
deficient patients were not noted in the control group [36]. Leukopenia and thrombocytopenia
may accompanied these changes as iron deficiency deepened, making the differential diag‐
nosis between iron deficiency anemia and MDS more difficult. Alcantara et al. [94] showed
that iron supported 11 genes in phorbol myristate acetate-induced HL-60 cell lines which were
involved in critical cell decision points to pursue a differentiation or cell death pathway.
Additionally, increased erythropoietin in iron deficiency anemia might also have activated
hematopoietic lineages. Presence of microspherocytes was attributed to a putative involve‐
ment of Rac1 and Rac2 GTPase, also known as Ras-related C3 botulinum toxin substrates 1
and 2 GTPase deficiency which reportedly altered actin assembly in red cells in mice. Further
factors like cellular metabolic enzyme changes, cell growth and differentiation, and gene
expression regulation might have been involved in the pathogenesis [36].
On the other hand, leukemia cases who were under chemotherapy and had myelodysplastic
features were shown to have hypochromic macrocytes and increased serum iron and ferritin
levels and increased soluble transferrin receptor implying at a disturbance in utilizing iron




Copper is a cofactor of a number of enzymes (cuproenzymes) including those important for
hematologic system like hephaestin, seruloplasmin (ferroxidases) and others like cytochrome
c oxidase, superoxide dismutase 1, extracellular superoxide dismutase, and zyklopen, a new
member of the vertebrate multicopper ferroxidase family
Pregnant and lactating women, premature infants, those with malabsorption, inflammatory
bowel diseases, celiac disease, long lasting diarrhea, short bowel syndrome, those under total
parenteral nutrition, or nutrition through jejunal tube, those who underwent gastric resection,
bariatric surgery; Wilsons’ disease patients who consumed copper-depleting drugs, conditions
with excess zinc are under risk of copper deficiency [37–41].
The most important problem in copper deficiency lays in its diagnosis. It may be misdiagnosed
as MDS or underdiagnosed. The time which lapses until appropriate diagnosis is made was
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reported as approximately 1 year. Early diagnosis is important since therapy after neurological
symptoms have developed is difficult [40].
On the other hand, it is of note that 11 out of 32 MDS patients were found to have copper
deficiency [95].
The most striking hematologic findings in copper deficiency are mono-, bi-, and pancytopenia
[39–41]. Anemia which is the most common hematologic finding (97.5%) in copper deficiency
is generally normochromic or macrocytic but rarely microcytic, being dependent on the
severity of the deficiency. When the activity of copper-dependent enzymes decrease, iron
absorption is expected to be impaired, iron transport across intestinal cells be decreased,
conversion of ferrous iron to the ferric form which is necessary for transport of iron by
transferrin be impaired, conversion of ferric iron to ferrous iron which is necessary for
incorporation of iron into the protoporphyrin molecule during hemoglobin synthesis be
inadequate. The latter defect gives rise to both formation of ring sideroblasts and possibly
erythrocyte membrane defect due to low levels of antioxidant zinc/copper dismutase activity
necessary to convert superoxide-free radicals to hydrogen peroxide [37, 39]. However, the
mechanism of anemia is not fully understood [37].
Copper deficiency MDS
Vacuolization -In erythroid + myeloid lineages
[39]






-Generally present [2, 5, 14, 39]
Dysplasia -No [39]
-Bilineage [38]
-Three lineage dysplasia [37]
-Unilineage: RCUD; RARS (erythroid)
-Two or more lineages (RCC, RCMD; MDS-U) [2,
5, 14, 39]
Increased hematogones -Present [37] -Absent [39]
Other -Left shift in myelopoiesis
-Reduced terminally differentiated 
myeloid cells, myeloid arrest [39]
-Erythroid arrest at proerythro
blast stage [37]
-Erythroid hyperplasia (generally) [15]
-Myeloid arrest or left shift (generally in RAEB)
[96]
Ring sideroblast -Present [37–39] -Present only in RARS subgroup [2, 5]
Table 6. Bone marrow findings in copper deficiency in comparison with MDS.
Leukopenia in copper deficiency is together with neutropenia which was reported to be the
most frequent and earliest manifestation of copper deficiency [41]. The neutrophils in pe‐
ripheric blood smear are dysplastic. Impaired and delayed maturation, differentiation and
regeneration of hematopoietic precursor cells, increased destruction of myeloid precursors in
the bone marrow, defective neutrophil egress from the bone marrow, shortened life-span of
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neutrophils, and presence of antibodies to neutrophils are the possible etiologic factors for
neutropenia [39, 41].
The bone marrow is generally hypercellular [40] with increased myeloid and/or erythroid
precursors mimicking myeloid and erythroid arrest, vacuolization in erythroid and myeloid
precursors, increased iron stores, prominent ring sideroblasts, plasma cells in which hemosi‐
derin is incorporated, increased hematogones [37] with [37, 38], without [39] myelodysplasia.
In MDS, generally erythroid hyperplasia [15] is encountered. Myeloid arrest or left shift in
granulopoiesis is seen generally in RAEB subgroup of MDS [96]. Characteristics of MDS and
copper deficiency are summarized in Table 6.
2.5.4. Vitamin D deficiency
Vitamin D has both proliferating and differentiating effect on hematopoiesis [42]. The bone
marrow taken from infants with vitamin D deficiency rickets and anemia showed early signs
of myelofibrosis with increase of reticulin which was reversed by vitamin D treatment [97].
Anemia, thrombocytopenia, hepatosplenomegaly, hypocellularity and increased osteoblast
count in bone marrow, and hematopoietic precursors in spleen aspirates were striking.
Hypochromia, macrocytosis, tear drop cells, young myeloid elements along with nucleated
red blood cells were evident [98]. Dysdifferentiation due to its deficiency might have been
aggravated by coexistent malnutrition in many of several patients.
2.5.5. Hypervitaminosis A
An infant with hypervitaminosis A reportedly had eversible severe anemia, thrombocytope‐
nia, and dyserythropoiesis. It was shown that in overdoses, vitamin A strongly inhibited the
proliferation of multipotent hematopoietic cell line and bone marrow mesenchymal stem cells,
through upregulating p21Cip1 and p27Kip1, cyclin-dependent kinase inhibitors [43].
2.6. Severe congenital neutropenia (SCN)
We, previously detected hematopoietic dysmorphism in congenital neutropenia, their non-
neutropenic parents and one sibling, irrespective to the neutropenia mutation that the patients
had [45, 99]. All the tested patients were negative for molecular genetics of MDS and were
normal in conventional cytogenetics. Apoptosis of lymphocytes, granulocytes [45, 99], and
monocytes [45], of both patients and parents and rapid cell senescence (RCS) in leukocytes of
a few patients and their mothers were established [45, 99]. A substantial portion of cases had
clinical or laboratory evidence of hemorrhagic diathesis and low NK and CD4+ cells.
These findings showed that pluripotent stem cells were involved in SCN irrespective to the
genetic defect and non-neutropenic family members were also affected ([45, 99], study in
submission) and congenital neutropenia and MDS shared the same death types and involved
pluripotent stem cells.On the other hand, it should not be forgotten that MDS can present as
isolated neutropenia (RCC, as refractory neutropenia). In our clinic, we followed a 4-year-old
girl who was admitted to our hospital for chronic neutropenia, but the genetic evaluation
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revealed trisomy 8 and a complex karyotype; while the molecular genetic studies for congenital
neutropenia (HAX1, ELANE, and G6PC3) were negative (unpublished data).
Figure 7. Myelodysplastic bone marrow findings of a 5-year-old patient with ALL who was on chemotherapy and had
coexistent autoimmune hemolytic anemia [100] (personal archives). A Gaucher-like histiocyte that is hemophagocytos‐
ing a cell (a), internuclear chromatin bridge between two erythroblasts (b) (arrow), multinucleated erythroblasts with
various sizes (c, e, g, h), striking megaloblastic changes (d), basophilic stippling (b, e–h).
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2.7. Inherited conditions
Özbek et al. [46] reported myelodysplastic features in myeloid and erythroid cell lines, in 20
patients with microdeletion 22q11.2 (del22q11.2) with slight cytopenia. Their smears showed
dysmorphism in erythroid and myeloid cell lineages, in addition to a few vacuolated plasma‐
toid lymphocytes; monocytic cells mimicking hypogranular myelocytes with cytoplasmic
vacuoles and protrusions and blast-like cells.
Myelodysplasia scores in the myeloid cells and eosinophils and macropolycyte percentages
were higher than those with conotruncal heart defects, viral and bacterial infections, and
healthy children. Genes in the deleted region, like human cell division cycle-related (hCDCrel)
gene was proposed to be responsible for these changes.
Other inherited conditions which present as dyserythropiesis and anemia are congenital
dyserythropoietic anemia, thalassemia, congenital dyserythropoietic porphyria, mitochondri‐
al myopathies, hereditary sideroblastic anemia, homozygous hemoglobin C, heterozygous
unstable hemoglobins, some cases with thiamine-responsive anemia with diabetes and
deafness, homozygote pyruvate kinase deficiency, stress erythropoiesis like severe hemolytic
anemia [100] (Figure 7).
Those who present as dysgranulopoiesis with/without neutropenia are mitochondrial
cytopaties, myelokathexis, and congenital neutropenia [45]. Those with dysmegakaryopoiesis
and thrombocytopenia are inherited thrombocytopenias. Patients with GATA1 mutations
have anemia and neutropenia together with trilineage dysplasia [27]. Patients with mevalonc
aciduria due to mevalonate kinase deficiency have anemia, thrombocytopenia with/without
fluctuation, dysplasia in erythroid and myeloid lineages [47].
2.8. Malignant lymphoma
In non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) patients, myelodysplasia in
granulocytic and erythroid lineages were noted without any marked myelodysplasia in
megakaryocytic lineage. The myelodyspastic features were found comparable in patients with
and without bone marrow infiltration of lymphoma cells.
The bone marrow was normal or hypercellular, with normal, reduced number of erythroid
and increased number of myeloid cells, normal, or increased megakaryocytes; ALIP was not
encountered. Reticulin fibrosis was rare (6.1%).
The myelodysplasia in lymphoma was thought to be a reaction to the lymphoma or to result
from an impaired bone marrow stem cell [48].
2.9. Effect of drugs and toxins
2.9.1. Chemotherapy
Most of chemotherapeutic and immunosuppressive agents give damage to the bone marrow,
inducing megaloblastic dyserythropoiesis in low doses, and hypoplasia in high doses. Drugs
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that cause megaloblastosis are methotrexate, cyclophosphamide, daunorubicin, doxorubicin,
cytarabine, hydroxyurea, azathioprine, and zidovudine [27]. Mycophenolate mofetil is known
to cause Pelger-Huet anomaly, abnormal chromatin clumping, detached nuclear fragments in
granulocyte lineage. Alemtuzumab was also reported to be associated with increased dys‐
plastic features and virus-related hemophagocytic syndrome [27]. In our experience, the most
consistent finding of dysplasia in patients who receive chemotherapy was hypoagranulation
of myeloid cells (Figures 7 and 8).
We previously showed that leukemia patients displayed hypochromic macrocytes in their
peripheric blood due to failure to utilize iron ([49], study in submission). Additionally, serum
reticulocyte counts in the beginning of chemotherapy blocks declined significantly in the end
of the blocks when erythropoiesis was markedly depressed and were found to have increased
significantly at the beginning of the next chemotherapy block when the bone marrow regen‐
erated and erythropoiesis increased [49].
Increased apoptosis, increased hemophagocyting macrophages, erythroid and megakaryo‐
cytic regeneration generally preceding granulocytic regeneration, megakaryocytic clustering
and ALIP together with myelodysplasia were described after intensive chemotherapy and
persisted for months [27]. The infections that the patients could have developed, possibly
aggravated the myelodysplasia.
Figure 8. Neutrophils of a pediatric ALL patient while he was on maintenance chemotherapy (a, b), and 6 months after
cessation of therapy (c, d) (personal archives). Cytoplasmic agranulation (a–d), large size (a–d), chromatin clumping (b,
c), long chromatin string between the nuclear lobes (d) are striking.
On the other hand, these findings closely overlap with those in therapy-related MDS (t-MDS)
or therapy-related myeloid neoplasms (t-MN) in the new nomenclature. It was reported that
t-MN followed treatment of lymphomas and solid tumors but more rarely leukemias [101].
Appearance of new dysplastic changes after complete remission of leukemia [102] or solid
tumors should alert the physician for development of t-MN.
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2.9.2. Steroids
Steroids give rise to hyperdiploidy, and therefore macropolycytes in neutrophils [17] in
addition to abnormal nuclear lobulation (Figures 9 and 10).
Figure 9. Peripheric blood neutrophils of children who were on high dose or long-term steroid therapy for acute and
chronic ITP (personal archives). On the seventh (last) day of mega-dose methyl prednisolone therapy [116] of patient
IY (a–g, i, j, l, o) and OI (k); during the phase of tapering down long-term prednisolone therapy of patient YP (n, h, p);
6 months after the last steroid therapy in YP (m). Macropolycytes (neutrophils with >14 μm diameter) in 15–20 μm
diameter (a, c, h, m, n, p), pseudo-Pelger-Huet/like cells (a, c, j), chromatin clumping (c, f, k, n, p), bizarre nucleus (b, c,
d, e, g, j, o), vacuolated eosinophil with both basophilic and eosinophilic granules (l).




Anemia with/without other cytopenias or pancytopenia were reported in alcohol dependent
patients. Anemia was normochromic or macrocytic with round macrocytes (unlike oval
macrocytes of megaloblastic anemia) [27, 50]. Vacuolated neutrophils, stomatocytes,
sometimes target cells were evident. In hemolytic anemia and hyperlipidemia due to alcoholic
liver disease, spherocytes, irregularly contracted cells (Zieve’s syndrome) were demonstrated
[27].
Figure 10. Various cell cycle configurations in patients with myelodysplasia (personal archives). Cell cycle analysis of
granulocytic and mononuclear cells of children with acute or chronic immune thrombocytopenic purpura (ITP) before,
during and after therapy (a–h), and granulocytes of a non-neutropenic mother of a dygranulopoietic neutropenia pa‐
tient with dysgranulopoiesis (i). Normal cell cycle of granulocytic cells (G0 phase) (a). Granulocytes of patient YP with
chronic ITP while taking oral steroids on different occasions (b, c). Mononuclear cells (d) tested on the same occasion
with (c). Granulocytes of patient AT with chronic ITP. Tested 10 days after he received anti-D therapy (e). Granulo‐
cytes of IY with acute ITP, before mega dose methyl prednisolone (MDMP) therapy (f, g); 1 week after MDMP therapy
ended (h). Granulocytes of non-neutropenic mother of a congenital dysgranulopoietic neutropenia patient who had
myelodysplasia (i).
The most striking changes in the bone marrow was in the erythropoietic lineage as erythroid
hyperplasia, ineffective erythropoiesis and dysmorphism in erythroid lineage including ring
sideroblasts (positive by 75%) and dysmorphic granulopoietic cell lineages. There was no
morphologic abnormality in megakaryocytes [50], but the megakaryocytes reportedly
increased or markedly decreased [27]. Megaloblastic changes were associated [103] and not
associated [50] with folic acid and/or vitamin B12 levels.
Serum iron levels which were elevated in the majority (being the most prominent in those with
fatty liver and typical cirrhosis), iron granules in plasma cells [50] macrophages and endothe‐
lial cells [27], large numbers of sideroblasts along with ring sideroblasts [50] were other
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Figure 10. Various cell cycle configurations in patients with myelodysplasia (personal archives). Cell cycle analysis of
granulocytic and mononuclear cells of children with acute or chronic immune thrombocytopenic purpura (ITP) before,
during and after therapy (a–h), and granulocytes of a non-neutropenic mother of a dygranulopoietic neutropenia pa‐
tient with dysgranulopoiesis (i). Normal cell cycle of granulocytic cells (G0 phase) (a). Granulocytes of patient YP with
chronic ITP while taking oral steroids on different occasions (b, c). Mononuclear cells (d) tested on the same occasion
with (c). Granulocytes of patient AT with chronic ITP. Tested 10 days after he received anti-D therapy (e). Granulo‐
cytes of IY with acute ITP, before mega dose methyl prednisolone (MDMP) therapy (f, g); 1 week after MDMP therapy
ended (h). Granulocytes of non-neutropenic mother of a congenital dysgranulopoietic neutropenia patient who had
myelodysplasia (i).
The most striking changes in the bone marrow was in the erythropoietic lineage as erythroid
hyperplasia, ineffective erythropoiesis and dysmorphism in erythroid lineage including ring
sideroblasts (positive by 75%) and dysmorphic granulopoietic cell lineages. There was no
morphologic abnormality in megakaryocytes [50], but the megakaryocytes reportedly
increased or markedly decreased [27]. Megaloblastic changes were associated [103] and not
associated [50] with folic acid and/or vitamin B12 levels.
Serum iron levels which were elevated in the majority (being the most prominent in those with
fatty liver and typical cirrhosis), iron granules in plasma cells [50] macrophages and endothe‐
lial cells [27], large numbers of sideroblasts along with ring sideroblasts [50] were other
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characteristics of alcohol effect. In Zieve’s syndrome, excess iron-laden foamy macrophages
were encountered [27]. No correlation was found between serum iron and ring sideroblasts in
the bone marrow [50].
The normal colonies of all hemopoietic cell lines and cell culture ratios in alcohol-dependent
individuals showed that alcohol exerted its toxic effect not on committed stem cells but
peripheral cells also [50]. Reversible bone marrow aplasia due to alcohol was also reported [27].
Cytoplasmic vacuolization was reported to be due to inhibition of acetaldehyde dehydrogen‐
ase and thus reduced rate of degradation of acetaldehyde.
Alcohol has toxic effect on cell division giving rise to arrest in cell division and multinucleated
erythroblasts; direct antifolate effect on nucleic acid metabolism leading to development of
megaloblasts. Additionally, it impairs iron utilization giving rise to large number of sidero‐
blasts and ring sideroblasts through disrupting pyridoxine kinase inhibiting delta aminole‐
vulinic acid synthetase which is necessary for heme synthesis [50].
Alcohol-induced hematopoietic abnormalities closely mimick those of MDS-RARS. That
alcohol-induced bone marrow damage is always reversible if the patient stops to drink alcohol,
and that cell culture of alcohol dependent people show normal colonies of all hematopoietic
cell lines are two important points for differentiation between alcohol-induced cell damage
and MDS-RARS [50].
2.9.4. Smoking
Moderate leukocytosis being mainly due to neutrophilia and lymphocytosis was reported.
Bone marrow biopsies of 32 smokers showed normal or slightly increased cellularity, modest
and mild increase in granulopoiesis and erythropoiesis respectively, right shift of granulo‐
poietic cells (the half being mature segmented neutrophils).
The special appearing macrophages with intracytoplasmic small, polygonal corpuscles
showing neutrophils were striking. It was postulated that smoking inhibited locomotion of
the segmented neutrophils leading to granulocytopoietic hyperplasia and accumulation of
mature neutrophils in the bone marrow. These neutrophils were broken-down when they got
senescent and were phagocytosed by these macrophages, resulting in “smokers’ dysmyelo‐
poiesis” [51].
On the other hand, both smoking and alcohol intake were shown to constitute risk factors for
MDS [104].
2.9.5. Arsenic
Arsenic can cause mono-, bi-, and pancytopenia with marked dyserythropoiesis or megalo‐
blastosis. Pancytopenia with trilineage dysplasia in the bone marrow mimicking MDS was
reported. Associated symptoms like long-lasting gastrointestinal and neurological symptoms,
arsenic in the urine analysis, favorable response to British anti-Lewisite (BAL) help the clinician
distinguish between the two entities, although neurological symptoms may progress [27, 52].




Lead poisoning leads to sideroblastic anemia, microcytosis in addition to basophilic stippling
and hemolytic anemia [27]. It can mimick MDS.
2.9.7. Other drugs
Isoniazid causes sideroblastic anemia. Antibiotiotic linezolid can give rise to vacuolization in
elytroid precursors and ring sideroblasts together with anemia or pancytopenia. Chloram‐
phenicol makes mild bone marrow suppression with ring sideroblasts and vacuolation in
erythroid and granulocyte precursors. Sodium stibogluconate, prescribed in leishmaniasis
causes erythroblast karyorrhexis and severe anemia [27]. Nitrous oxide (laughing gas) which
has an anesthetic and recreational use and inactivator of hydroxycobalamin may give rise to
megaloblastic anemia and vitamin B12-deficiency related neurological and hematological
effects associated with heavy use by healthcare workers who inhalate it in operating rooms or
intensive care units [27, 53].
Granulocyte colony stimulating factor (G-CSF) and GM-CSF cause neutrophil vacuolation and
dysplastic neutrophils with abnormal lobulation and development of macropolycytes, in
addition to neutrophilia, eosinophilia, toxic granulation and blasts in the peripheral blood, the
latter mimicking progression of leukemia or MDS [54]. Antiepileptic drugs also can give rise
to cytopenia and multilineage dysplasia (personal experience).
2.10. Posttransplantation
Dysplastic findings were demonstrated after solid organ transplantation, like liver, kidney,
heart, and lung. Clatch et al. [55] reported bone marrow findings of 17 liver transplantation
patients taken before or 1–1288 days after orthotopic liver transplantation (post-OLT) when
they developed mono-, pancytopenia or fever. The patients had received cyclosporine A and
prednisolone, numerous antibiotics intermittently and a few additionally received Muromo‐
nab-CD3 and/or antilymphocyte globulin.
While dysplastic hematopoiesis was completely absent from biopsies of patients with end-
stage liver disease obtained before transplantation, significant trilineage dysplasia was a
consistent finding in all patients who underwent OLT. Megaloblastic erythropoiesis, the most
characteristic finding, macrocytosis, dysynchronous nuclear-to-cytoplasmic maturation and
significant nuclear budding or bilobation were striking. Typical megaloblastic changes of the
myeloid series were absent. Dysynchronous myeloid maturation, as a left shift giving rise to
decreased bands and mature neutrophils, additionally dysmyelopoiesis and dysmegakaryo‐
poiesis were evident [55].
The authors postulated that iatrogenically-induced T-cell dysfunction in transplanted patients
which gave rise to alterations in microenvironment, direct pharmacological toxicities and the
effects of secondary infections on hematopoietic cells might have had roles in the etiology [55].
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After bone marrow or hematopoietic stem cell transplantation, bone marrow was severely
hypoplastic and after successful engraftment was achieved, all hematopoietic cells, mostly the
erythropoietic cells appeared dysmorphic. During the following months, striking and transient
increase in hematogones, mimicking leukemia was observed. During engraftment, bone
marrow architecture showed various alterations, some of which were more striking in
leukemia patients whose stromal cells had been damaged during previous chemotherapies
[27].
Secondary MDS may develop after autologous stem cell transplantation, due to previously
damaged stem cells by chemotherapy. Cytogenetic and molecular studies are useful for
distinction between secondary MDS and usual secondary myelodysplasia of early posttrans‐
plantation [27].
2.11. Other disorders with secondary dysplastic features
Multiorgan failure, autoimmune lymphoproliferative syndrome associated with Fas or Fas
ligand deficiency can give rise to secondary myelodysplasia. Hypothermia can lead to
sideroblastic anemia with recurrent thrombocytopenia [27].
3. Cases with hypoplastic bone marrow mimicking hypocellular MDS
3.1. Hypoplastic MDS and severe aplastic anemia (SAA)
In childhood MDS, RA (RCC) subgroup constitutes the majority of patients and bone marrow
cellularity was reported decreased in nearly 50% [9] and 81% [4] of children with low-grade
MDS. On the other hand, hypocellular MDS (H-MDS) in adulthood is encountered in the
elderly.
Differentiation between H-MDS/hypocellular RCC and AA may be challenging both in adults
and children.
There are many nonhematological factors that can give rise to bone marrow hypoplasia in
childhood like any type of infections (vitamin deficiencies, metabolic disorders like mevalo‐
nate kinase deficiency, rheumatic disease, mitochondrial deletions (Pearson syndrome)).
Moreover, there are many hereditary or nonhereditary hematological disorders that should
be differentiated from RCC in the setting of hypoplastic bone marrow like inherited bone
marrow failure syndromes [4].
The most recent histopathologic criteria to distinguish RCC from SAA in childhood is
presented in Table 7 [14, 57].
In adulthood, a similar study described standardized criteria to distinguish hypocellular AML
from H-MDS and aplastic anemia (AA) (Table 8) [59].
Disorders Mimicking Myelodysplastic Syndrome and Difficulties in its Diagnosis
http://dx.doi.org/10.5772/64422
71
Refractory cytopenia of childhood (RCC) Severe aplastic anemia (SAA)
Differences  1. Erythroid lineage




-Increased proerythroblasts (left shift)
1. Erythroid lineage
-Missing or a single and small cluster
-Clusters consist of <10 erythroid cells





-Missing or marked decrease






-Missing or very few
-No dysplastic changes
-No micromegakaryocytes
Similarities 1. Lymphoid lineage
-May be increased focally or dispersed
1. Lymphocyte lineage





Table 7. Histopathologic criteria for differential diagnosis of SAA and RCC [4, 14, 57, 105].
Manifestation Indicative of
Presence of unequivocal blasts in the peripheral blood MDS or AML
Hypogranular neutrophils or pseudo-Pelger neutrophils (>10%) MDS or AML
Presence of >1–20% blasts in the bone marrow + dysplasia MDS
Dysplasia of either granulocytes or megakaryocytes in the bone marrow
(if erythroid hyperplasia is the sole finding, dysplasia in erythroid lineage
should be moderate to severe)
Inconsistent with AA
Presence of any abnormal sideroblasts (>5 granules around the nucleus
or constituted at least 1/3 of the circumference
Excludes AA
1–2 cm core biopsy demonstrating four to five undistorted fields (×100 magnification) Reliability in diagnosis
Presence of two or more clusters of immature precursors (being minimum three blast per
cluster) in bone marrow biopsy
MDS or AML
Consensus diagnosis required by at least 5/7 participants Reliability in diagnosis
Table 8. Recommendation for standardized approach to distinguish hypocellular AML from hypocellular MDS and
AA [59].
In addition to the parameters listed in Tables 7 and 8, presence of ALIP, abnormal localization
of megakaryocytes, erythroblast clusters, fibrosis, abnormal karyotype were also reported as
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parameters to be used to distinguish H-MDS and SAA (Table 8) [59]. Nevertheless, further
studies are needed to examine the validity of histopathologic approach to hypocellular RCC
and AA [60].
3.2. Inherited bone marrow failure (IBMF) disorders in the differential diagnosis of
hypocellular RCC
Several children who are diagnosed with hypoplastic RCC, may actually have one of inherited
bone marrow failure (IBMF) disorders which have not been diagnosed yet. Hence, 15% of
patients diagnosed with hypoplastic RCC and 2, 5, and 10% of patients diagnosed with
hypoplastic RCC or aplastic anemia were later diagnosed as Fanconi anemia and heterozygous
or homozygous dyskeratosis congenita [4, 9]. Inherited bone marrow failure syndromes with
pancytopenia like Fanconi anemia, dyskeratosis congenita, Shwachman Diamond syndrome,
amegakaryocytic thrombocytopenia (in progression), and pancytopenia with radio-ulnar
synostosis display common manifestations with hypoplastic RCC, such as macrocytosis,
elevated HbF, common bone marrow features. Therefore, a careful family and past history,
physical examination is essential. Laboratory and molecular studies like chromosome break‐
age test and telomere length assay should be carried on, since not all children with IBMF
syndromes have phenotypic characteristics [4, 9]. These diseases can progress to MDS gaining
chromosomal abnormalities specific to MDS and 3q26 segment in Fanconi anemia. However,
abnormal clones can also regress in any IBMF syndrome [4].
In childhood, in the setting of hypocellular bone marrow with absence of cytogenetic abnor‐
mality [4] or a bone marrow biopsy with topography and cellularity of the local hematopoiesis
[9], two bone marrow biopsies at least two weeks apart are necessary [4].
4. Transient chromosome abnormalities in the setting of cytopenia/
spontaneous remission in MDS
4.1. Transient MDS with/without chromosomal alterations
Monosomy 7 is an harbinger of poor prognosis and higher risk of transformation to high-risk
MDS and AML [4, 61–67, 69, 70] than other chromosomal abnormalities and normal karyotype
[4, 105]. The estimated time of progression in children with monosomy 7 was reported as
1.9 years, with a cumulative progression incidence of 80% at the sixth year of diagnosis [4].
In the literature, we found 13 patients who presented with MDS (n:12) or MDS-like features
(n:1) and had genetic abnormalities but achieved remission only after symptomatic (n:12) and
vitamin B12 and folic acid (n:1) therapies. The patients had abnormalities of chromosome 7 (12
out of 13, as −7, −7q, i7) and 11q23 translocation (1 out of 13), and +21 (1 out of 13, coexistent
with −7). Two additional MDS patients (RA, RAEB) with normal karyotype achieved sponta‐
neous remission (Table 9).
Spontaneous disappearance of abnormal clones were reported previously in AML, EBV-
associated myeloproliferative disorder and Fanconi anemia [65]. Development of cytogenetic
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abnormality is only one step (first hit) in the progression of malignant clone. In order to gain
growth advantage, the transforming cells need other molecular changes within the cells and
in the marrow microenvironment (second hit). The cases who attained spontaneous remission
suggest that the development of cytogenetic abnormality might have not been supported by
the other cellular and microenvironmental changes [65, 66]. Additionally, the mutation may
have developed in a hematopoietic cell with limited self-renewal capacity and may not have
involved the whole stem cell pool [66]. Two cases of Bader-Meunier et al. [68] suggest that
patients with MDS who do not show any chromosomal abnormality can also achieve complete
remission (Table 9). These cases show that patients who are stable should be closely observed
for some time before potentially toxic therapies are started.
Cases Diagnosis Age/
sex 





































































































19, M 46,XY,(11;16)(q23;p13.3) [13]








abnormality is only one step (first hit) in the progression of malignant clone. In order to gain
growth advantage, the transforming cells need other molecular changes within the cells and
in the marrow microenvironment (second hit). The cases who attained spontaneous remission
suggest that the development of cytogenetic abnormality might have not been supported by
the other cellular and microenvironmental changes [65, 66]. Additionally, the mutation may
have developed in a hematopoietic cell with limited self-renewal capacity and may not have
involved the whole stem cell pool [66]. Two cases of Bader-Meunier et al. [68] suggest that
patients with MDS who do not show any chromosomal abnormality can also achieve complete
remission (Table 9). These cases show that patients who are stable should be closely observed
for some time before potentially toxic therapies are started.
Cases Diagnosis Age/
sex 





































































































19, M 46,XY,(11;16)(q23;p13.3) [13]
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†The subgroup has not been reported. Probably corresponds to RCC subgroup in childhood and RCMD or MDS-U
subgroups in adulthood MDS, according to the WHO 2008 classification.
©Cytogenetic abnormality found sustained on 13th month after hematologic recovery.
*End-stage renal failure.
**The patient received long-term immunosuppressive therapy with cyclosporine (for 19 months), later azacytidine
(Aza) (for 6 years).
#Not stated.
***The patient had pancytopenia persisting after the 1st course of Hodgkin’s disease therapy.
Table 9. Patients with MDS who achieved remission spontaneously, after supportive or vitamin B12 and folic acid
therapy [61–70].
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4.2. Vitamin B12 (VB12) and folic acid deficiency and transient chromosome abnormalities
which mimick MDS
Vitamin B12 and folic acid deficiencies can present as mono-, bi-, and pancytopenia [106],
myelodysplasia, genetic abnormalities like increased frequency of spontaneous chromosome
breakage and centromere spreading [107, 108], elongation and despiralization of chromosomes
[107], multiple rearrangements and deletions of different chromosomes [108] which can
mimick that of MDS (Table 9, patient 11) [67].
Many of these chromosomal abnormalities were reported to reduce [107], completely disap‐
pear [67, 107, 108] or persist up to 6–12 months after hematological remission was attained
[107] after therapy.
These cases show that defective synthesis and repair of DNA which were reversed by VB12
and folate plays role in the pathogenesis of genetic abnormalities in megaloblastic anemia.
Increased immature myeloid cells indistinguishable from myeloblasts in the bone marrow of
patients with vitamin B12 and folate deficiency make the differentiation between megaloblastic
anemia and MDS more difficult [109].
On the other hand, in our clinics, we have encountered considerable number of patients who
had VB12 and/or folic acid deficiency coexistent with MDS or leukemia.
5. Mutations in the elderly and other cases
In more than 10% of healthy people older than 70 years, clonal hematopoiesis is present [10].
Additionally, loss of Y chromosome in hematopoietic cells in association with aging was also
reported [1]. Therefore, clinicians should keep reserved when abnormalities in molecular
genetics and karyotype are found in the elderly when dysplasia is absent [10].
Mutations like del(20q), +8, −Y have been reported in patients with aplastic anemia or other
cytopenic syndromes who were good responders to immunosuppressive therapy and/or no
evidence of MDS findings in the follow-up [1].
6. Acute myeloblastic leukemia
6.1. AML with low blast cell count
AML is distinguished from MDS by the percentage of the blasts which is higher than 30% in
AML in children (>20% in adults) and lower than 30% (lower than 20% in adults) in MDS.
However, patients that have blast cells lower than 30%, but cytogenetic features characteristic
of childhood de novo AML [t(8;21), inv(16), t(11;17), t(9;11), i(1)] is designated as AML with
low blast cell count (AML-LBC).
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Those with AML-LBC were significantly younger than MDS cases (3.7 vs 7.4); their dysplasia
score was lower and the response to AML type chemotherapy was higher than that of MDS
patients. The authors encountered chloroma only in AML-LBC [71].
6.2. AML with myelodysplasia-related changes (AML-MRC)
In a subgroup of leukemia that was introduced by WHO is AML with myelodysplasia-related
changes (AML-MRC) which defines AML arising from previous MDS or MDS/MPN, with an
MDS-related cytogenetic abnormality and/or AML with multilineage dysplasia (AML-MLD).
This group was reported to have worse overall survival when compared with patients with
AML-not otherwise specified [110].
6.3. MDS with myelofibrosis, AML-M7, and other disorders
The blast cell percentage in the bone marrow (>30% in children and >20% in adults) and t(1;22)
(p13;q13) differentiated AML-M7 from MDS.
Although hypoplastic MDS with increased reticulin ± collagen fibers is rare in childhood [4],
hypoplastic myelofibrosis may be encountered in childhood [111].
7. Idiopathic cytopenia of undetermined significance (ICUS) and
idiopathic dysplasia of undetermined significance (IDUS)
Patients with persistent (marked constant) cytopenia(s) involving one of more hematopoietic
lineages, for at least 6 months, in the setting of absent multiunilineage dysplasia and cytoge‐
netic abnormality except –Y, +8, del(20q) were suggested to be termed as idiopathic cytopenia
of undetermined significance (ICUS) [5, 58, 112–116]. Criteria of cytopenia for diagnosis of both
MDS and ICUS according to the 2007 Consensus Group are: Hemoglobin (Hb) <11g/dl and/or
neutrophils <1500/mm3, and/or thrombocytes <100,000/mm3. The cut off levels for Hb is
10 g/dl, for neutrophils 1800/mm3 according to WHO and International Working Group on
Morphology of MDS (IWGM-MDS) [58, 114].
The terms “ICUS-anemia, ICUS-neutropenia, ICUS-thrombocytopenia, ICUS-bicytopenia, or
bi/pancytopenia” were also proposed in which the cut-off levels of cytopenia were the same
of those in 2007 Consensus Group, except that of neutropenia which was proposed as
<1000/mm3 [114].
For patients with morphological dysplasia (>10% in a major cell line) with/without karyotypic
abnormalities but no or mild cytopenia, idiopathic dysplasia of undetermined significance
(IDUS) has been proposed [5, 7]. Criteria of mild cytopenia has been reported as Hb ≥ 11 g/dl,
neutrophils ≥ 1500/mm3, thrombocytes ≥ 100,000/mm3 [113] (Table 10).
Patients with both ICUS and IDUS may progress to overt MDS, MPN, MDS/MPN overlap
disease, chronic myelomonocytic leukemia, AML after a variable period. ICUS can also
reportedly transform to systemic mastocytosis, non-Hodgkin lymphoma, aplastic anemia [5,
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113, 114]. There is no proof that every patient with ICUS or IDUS will develop neoplasia [114].
ICUS was reported to resolve spontaneously also [112]. However, the median overall survival
in ICUS group was reported 44.3 months, being shorter than RA but longer than RCMD [116].
Idiopathic cytopenia of unknown
significance (ICUS)
Idiopathic dysplasia of unknown
significance (IDUS)
Constant marked cytopenia* Present [5, 58, 112–116] Absent [5, 58, 112–116]
Diagnostic criteria of MDS Absent [5, 58, 112–116] Absent [5, 58, 112–116]
Diagnostic cocriteria of MDS**,† Absent [113]; flow cytometric abnormalities:
not known [112]
–?
Dysplasia (>10% of cells) Absent [112–115] Present [112–116]
Karyotype typical for MDS Absent but FISH may reveal a very small
clone carrying MDS-related cytogenetic defect
[113, 114]
Present in a minority [112]
Clonality by HUMARA In a minority of patients [112] (CCUS) Not known [112]
Other diseases leading to
cytopenia
No [113] –
Other diseases leading to
dysplasia
– No [113]
Age Older [113] Younger [113]
Erythropoietin level Low [113] Adequate [113]
Marked reduction in BFU-E In a minority of patients [112] In a minority of patients [112]
Ring sideroblasts >15% Absent [114] In a majority of patients [114]
*Cytopenia in one or more of hematopoietic lineages lasting for at least 6 months, with Hb <11 g/dl and/or neutrophils
<1500/mm3, and/or thrombocytes <100,000/mm3.
**Cocriteria of MDS: Colony forming cells and reticulocytes in circulation, abnormal immunophenotyping by flow
cytometry, monoclonality of myeloid cells detected by molecular markers or mutations, abnormal gene expression
profile by mRNA profiling assays.
†If one or more cocriteria are found, the disorder should be called ‘highly susceptive for a clonal myeloid disease/MDS’
[113].
Table 10. Diagnostic criteria for ICUS and IDUS [5, 58, 112–116].
On the other hand, recent reports demonstrated that ICUS had a broad spectrum including
patients with both nonclonal and clonal hematopoiesis, the latter being called as clonal
hematopoiesis of indeterminate potential (CHIP) [112]. Hence, 35% of ICUS patients were
found to carry a somatic mutation or chromosomal abnormality indicative of clonal hemato‐
poiesis [117] called clonal ICUS (CCUS).
Differentiation between MDS and ICUS may be challenging. In ICUS, FISH may reveal a very
small clone carrying MDS-related cytogenetic defect [113, 114]. Clonal expansion of such a
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significance (IDUS)
Constant marked cytopenia* Present [5, 58, 112–116] Absent [5, 58, 112–116]
Diagnostic criteria of MDS Absent [5, 58, 112–116] Absent [5, 58, 112–116]
Diagnostic cocriteria of MDS**,† Absent [113]; flow cytometric abnormalities:
not known [112]
–?
Dysplasia (>10% of cells) Absent [112–115] Present [112–116]
Karyotype typical for MDS Absent but FISH may reveal a very small
clone carrying MDS-related cytogenetic defect
[113, 114]
Present in a minority [112]
Clonality by HUMARA In a minority of patients [112] (CCUS) Not known [112]
Other diseases leading to
cytopenia
No [113] –
Other diseases leading to
dysplasia
– No [113]
Age Older [113] Younger [113]
Erythropoietin level Low [113] Adequate [113]
Marked reduction in BFU-E In a minority of patients [112] In a minority of patients [112]
Ring sideroblasts >15% Absent [114] In a majority of patients [114]
*Cytopenia in one or more of hematopoietic lineages lasting for at least 6 months, with Hb <11 g/dl and/or neutrophils
<1500/mm3, and/or thrombocytes <100,000/mm3.
**Cocriteria of MDS: Colony forming cells and reticulocytes in circulation, abnormal immunophenotyping by flow
cytometry, monoclonality of myeloid cells detected by molecular markers or mutations, abnormal gene expression
profile by mRNA profiling assays.
†If one or more cocriteria are found, the disorder should be called ‘highly susceptive for a clonal myeloid disease/MDS’
[113].
Table 10. Diagnostic criteria for ICUS and IDUS [5, 58, 112–116].
On the other hand, recent reports demonstrated that ICUS had a broad spectrum including
patients with both nonclonal and clonal hematopoiesis, the latter being called as clonal
hematopoiesis of indeterminate potential (CHIP) [112]. Hence, 35% of ICUS patients were
found to carry a somatic mutation or chromosomal abnormality indicative of clonal hemato‐
poiesis [117] called clonal ICUS (CCUS).
Differentiation between MDS and ICUS may be challenging. In ICUS, FISH may reveal a very
small clone carrying MDS-related cytogenetic defect [113, 114]. Clonal expansion of such a
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small clone in ICUS and occurrence of slight cytopenia in IDUS in the follow-up, points at an
imminent transformation to MDS [58, 113, 114].
These patients should be examined regularly, like in low-risk MDS, from the aspect of
hematological findings, karyotype, FISH, flow cytometry, and flow FISH, if available [114].
Reduced number of colony forming unit (CFU) progenitor cells like CFU-granulocyte-
macrophage (CFU-GM) and burst-forming unit-erythroid (BFU-E) show impaired bone
marrow function in MDS [58]. While BFU-E is markedly reduced in MDS, it is reduced only
in a minority of patients with ICUS and IDUS [114]. However, reduced numbers of CFU-GM
and BFU-E are also found in aplastic anemia, acute leukemia, and in post chemotherapy
conditions, but not in nonclonal cytopenias like vitamin B12 deficiency, autoimmune hemo‐
lytic anemia and chronic inflammation [58] (Table 10).
Screening for molecular lesions by exome sequencing and other “omics-based techniques” can
be used, in order to search clonality. However, these techniques are expensive and not practical
[58]. Human androgen receptor gene-based assay (HUMARA) which is promising has
restrictions, since it can be used only in females and it is positive in other clonal disorders also
[58, 116]. Application of flow cytometric tools are of considerable help [58] (see Section 10).
Patients with CCUS can be differentiated from low-risk MDS only by lack of dysplasia [112].
The data about patients with ICUS, CCUS, and IDUS are limited. Future studies will enlighten
the pathogenesis of ICUS and IDUS which is not well understood yet.
8. Autoimmune disorders
Patients with chronic immune stimulation and autoimmune disorders have a tendency to
develop malignant neoplasias and MDS.
On the other hand, MDS and AML can trigger paraneoplastic syndromes and manifestations
including inflammatory paraneoplasia, like seronegative rheumatoid arthritis, Sweets
syndrome, hemophagocytic lymphohistiocytosis, pyoderma gangraenosum, cutaneous
vasculitis, lupus-like symptoms [72, 73], polychondritis [73], Behçet syndrome, inflammatory
bowel disease, cryoglobulins, vitiligo, autoimmune hemolytic anemia, peripheral neuropathy,
by 12–19% in adults but in lower frequency in childhood [74].
Relevance of autoimmune disorders with prognosis of MDS is disputable. Their response to
immunosuppressive therapy is good [72].
In MDS, not only the stem cells but an inflammatory microenvironment is also involved.
Therefore, the inflammatory microenvironment aggravates ineffective hematopoiesis and
carcinogenesis/tumorigenesis [72].
The majority of acquired AA and some RCC cases can be considered as T-cell-mediated
autoimmune disease, resulting in bone marrow failure [74, 76]. Autoantibodies are detected
in both conditions. However, their significance and pathophysiological significance in MDS
and SAA is unclear [76].
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Relative lymphocytosis, oligoclonal T-cell expansion, elevated cytokine levels are common
features of AA and MDS, suggesting a common immune defect in the pathogenesis [72] of
adults with low-grade MDS.
Decreased CD4 + FOXP3 + Treg cells, increased NK cells/impaired activity of NK cells,
suppression of hematopoietic progenitors by cytotoxic CD8+ cells [72, 74], increased cytokines
secreted by bone marrow microenvironment, macrophages (IF-, TNF-α which are pro-
apoptotic), increased Th17 cells [interleukin ((IL)-17, IL-23, IL-1, and IL-6] which are cytotoxic
to bone marrow precursors, decreased dendritic cells, decreased B cells [72], polyclonal hypo-,
hypergammaglobulinemia, C3 hypocomplementemia, altered self-reactive antibody reper‐
toires [74] play role in the pathogenesis, some of which change as to the risk of MDS [72].
Some of these abnormalities overlap with those in autoimmune disorders themselves. The
dysmorphic features in autoimmune disorders were delineated previously. Patients with
autoimmune disorders should always be suspected for being MDS cases and should be
evaluated for pathologic and genetic abnormalities.
9. Common features in pathogenesis
9.1. Cytopenia
Inherited bone marrow failure syndromes, MDS and SAA share the same pathogenetic
features for involving a driver mutation, overproduction of cytokines and/or suppression of
hematopoiesis through cytokines and deregulation of stem cell niche [76].
MDS and severe aplastic anemia share the same pathogenesis, as to abnormalities in T cells,
especially in CD8+ cells; autoimmune manifestations and giving good response to immuno‐
suppressive therapy [76].
9.2. Myelodysplasia in relation to cell cycle and other factors
Myelodysplasia in blood cells arise due to any challenge during the course of normal differ‐
entiation in which cells exit the cell cycle and enter G0 phase permanently (Figure 10a)
Cell cycle control system depends on cyclically activated cyclin-dependent protein kinases
(Cdks) a number of enzymes and other proteins, the most important being cyclins and other
genes [118]. Stem cell differentiation is regulated by differentiation specific genes, homeotic
genes, tumor suppressor genes, abnormality of which result in restriction in further prolifer‐
ation giving rise to alteration in normal cell cycle, and dysdifferentiation [119].
Hence, disturbance of expression of iron dependent genes regulating cell cycle in differentia‐
tion of hematopoietic cells in iron deficiency (see Section 2.5.2), deletion in human cell division
cycle related gene (hCDCrel) in patients with del (22q11.2) are a few examples that lead to
aforementioned myelodysplastic findings through genetic abnormalities. That the severity
and spectrum of dysmorphic features in myelodysplasia differ according to the underlying
secondary or primary pathology like in dysmegakaryopoiesis and thrombocytosis in inv
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3(q21q26)/t(3;3)(q21;q26) and 5q-syndrome also reflect the various alterations playing role in
different levels of differentiation.
We previously detected various temporary or permanent cell cycle abnormalities in total
leukocytes, granulocytes and mononuclear cells from peripheral blood of ITP patients who
had received steroids and a child with congenital neutropenia and her non-neutropenic mother
all displaying myelodysplasia (Figure 10) [17, 45, 99].
The peripheral granulocytes (neutrophils and bands), monocytes, and lymphocytes are
expected to be in G0 phase of the cell cycle, since they are terminally differentiated (Fig‐
ure 10a). We interpreted these numerous abnormal cell cycle configurations instead of G0 [99],
as an alteration in differentiation, after a stimulus that was sensed as DNA damage, probably
through disruption of one or more of these aforementioned enzymes [118]. Increased trilineage
apoptosis, a type of cell death in some of these patients [45, 99], all having myelodysplasia are
also in accordance of this interpretation.
Overlapping of a number of myelodysplastic features (Tables 1–4) closely with those of
senescence-like phenotype (SLP) of rapid cell senescence (RCS), another type of cell death, led
us to search RCS both in congenital neutropenia [45, 99] and autoimmune disorders (JRA, SLE,
and ITP) all having myelodysplasia [17, 28, 30, 31, 79]. We detected that three children with
congenital neutropenia and their non-neutropenic mothers [45, 99] and all patients with
autoimmune disorders displayed RCS in their leukocytes shown by β-galactosidase (SA-β-gal)
positivity [79] (Figure 1). In several patients, cell cycle abnormalities accompanied [99]
(Figure 10I).
The RCS that was detected in autoimmune disorders and those with congenital neutropenia
[45] were attributed to increased proinflammatory cytokines and chemokines in autoimmune
disorders [79] and congenital neutropenia [45] through giving rise to loss of telomeres by
keeping the immune system in a state of low level of activation [79]. Absence of RCS (unpub‐
lished data) in iron deficient patients was thought to be due to absence of increase in proin‐
flammatory cytokines, confirming this hypothesis.
Differentiation is controlled not only by intracellular genetic factors but by extracellular factors
like extracellular matrix and soluble factors like fibroblast growth factor (FGF), transforming
growth factor beta (TGFB), colony stimulating factor-1 (CSF-1), GCSF, GM-CSF, stem cell factor
(SCF), Fms-like tyrosine kinase 3 ligand (Flt-3 ligand), ILs as well [119].
The reasons that we previously discussed in secondary myelodysplasia like immune destruc‐
tion of stromal and hematopoietic cells, inhibitory effects of cytokines and/or other intracel‐
lular/extracellular messengers/soluble factors, on the microenvironment and/or hematopoietic
cells; decreased differentiation, regeneration and increased clearance of stem cells, reflected
by alterations in cell cycle, impairment of heme synthesis and iron utilization also play role in
dysdifferentiation.
Therefore, myelodysplasia either primary or secondary is associated with cell death parame‐
ters, and cell cycle alterations. It reflects the viability of the cell and can be assumed as a tip of
a big iceberg that is an harbinger of a large spectrum of primary (clonal) and secondary
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(nonclonal) disorders. We think that the criteria of dysplasia should be revised in the definition
of MDS and attention should be exercised to find out practical laboratory means to detect
clonality.
10. Differential diagnosis
Discrimination between low-risk MDS and disorders mimicking MDS depends on determin‐
ing whether hematopoiesis is clonal or not.
To assess clonality and dysplasia, flow cytometric evaluation is promising [58, 120, 121]. The
minimal requirements to assess dysplasia by flow cytometry have been defined for adulthood
low-risk MDS as in the following [120]:
(a) For immature myeloid and monocytic progenitors: Increased percentage of cells in
nucleated cell fraction, lack of/decreased/increased expression of CD45, CD34, CD13 + CD33,
homogenous under/overexpression of CD117, lack of/increased expression of HLA-DR,
asynchronous expression of CD11b, CD15, expression of CD5, CD7, CD19, CD56 which are
lineage infidelity markers.
(b) For maturing neutrophils: Decreased percentage of cells as ratio to lymphocytes, sideward
light scatter (SSC) as ratio vs SSC of lymphocytes, altered pattern in relationship of CD13 with
CD11b and CD13 with CD16, CD15 with CD10 (like lack of CD10 on mature neutrophils).
(c) For monocytes: Decreased or increased percentage of cells, shift toward immature distri‐
bution, altered pattern in relationship of HLA-DR with CD11b and CD36 with CD14, homo‐
genous under or overexpression of CD13 and CD33, expression of CD56 as which is a lineage
infidelity marker.
(d) Progenitor B cells: Decreased or absent progenitor B cells when enumeration is performed
as fraction of total CD34+ based on CD45/CD34/SSC in combination with CD10 or CD19.
(e) Erythroid compartment: Increased percentage of nucleated erythroid cells, altered pattern
in relationship of CD71 with CD235a, decreased expression of CD71 and CD36, increased
percentage of CD117-positive precursors.
(f) For megakaryocytes: No standard application of flow cytometry has been described for
megakaryocytes yet.
World Health Organization recognized more than three flow cytometric aberrancies as
indicative of MDS [120]. It was also reported that two or more aberrancies in only the four
parameters as increased percentage of CD34+ progenitor cells in bone marrow, decreased
number of progenitor B cells within the CD34+ compartment, decreased or increased CD45
expression on myeloid progenitor cells and decreased SSC of neutrophils, CD10, CD15, CD11b,
CD56 being additional useful markers could identify 70% of low-risk MDS cases with 94%
specificity [120]. In children, for distinction between SAA and RCC, which generally present
with hypocellular bone marrow, a cutoff of 2 flow cytometric abnormalities was found to have
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60% sensitivity and 88% specificity which changed as 76% and 84% respectively, when
combined with other diagnostic parameters [121]. In nonclonal disorders either no or only one
flow cytometric abnormality was found. In low-risk MDS, in rare patients no flow-cytometric
abnormality was found [58].
However, abnormal flow patterns were encountered in AML, MPN, and natural aging also
[58]. Current knowledge on normal and abnormal patterns in the elderly and in normal
controls is still inadequate [120].
The flow cytometric analysis of children with RCC (low-risk MDS in childhood) showed no
difference in the relative SSC of granulocytes between those in RCC and healthy controls and
absence of lineage infidelity markers on myeloid blasts unlike commonly occurring in adult
low-risk MDS. The most frequent abnormality in RCC was reported to be heterogeneous
expression of CD71 and CD36 on erythrocytes and aberrant expression of CD56 on monocytes
(in 58 and 20%). All other abnormalities were observed in RCC in lower frequency than in
adulthood low-risk MDS [121].
However, although flow cytometric evaluation is promising in diagnosis of MDS cases which
lacked specific diagnostic markers like ring sideroblasts or karyotypic aberrations, it can only
be used as a part of a diagnostic work-up consisting of histopathology and cytogenetic analysis
[120, 121].
Flow cytometry can be used to rule out PNH; but minor PNH clones are present in 13–23% of
adult MDS, and 41% of children with RCC [121].
11. Future recommendations
We recommend that all the aforementioned disorders be considered in the differential
diagnosis of MDS. Patients who do not comply with none of a definite diagnosis should be
followed-up for a considerable time period in order to assure a spontaneous remission or
progression. Spontaneous remission in children and youngsters were reported as 2.2–30
months after the diagnosis [61–68]. In childhood, in the setting of hypocellular bone marrow
with absence of cytogenetic abnormality [4] or a bone marrow biopsy with topography and
cellularity of the local hematopoiesis [9], two bone marrow biopsies at least two weeks apart
are necessary [4]. For cases with refractory cytopenia and cases with less than 15% ring
sideroblasts all of which display unilineage dysplasia without excess blasts, repeated bone
marrow examination is recommended after a 6 months’ observation [5].
Since morphologic dysplasia can be encountered in both clonal and nonclonal disorders, the
criteria of dysplasia should be revised in the definition of MDS and attention should be
exercised to find out practical laboratory means to detect clonality. Flow cytometry is a
promising means to distinguish between clonal and nonclonal cytopenia when used together
with other diagnostic tools.
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Abstract
The myelodysplastic syndromes (MDSs) are characterized by ineffective erythropoie‐
sis and progressive cytopenia and ultimately affected patients develop acute myeloid
leukemia (AML) or die from advanced bone marrow (BM) failure.
Myelodysplastic syndrome (MDS) with isolated del (5q) is a common type of MDS with
specific  pathological  and  clinical  manifestations  including  refractory  anemia.  It  is
usually treated by (1) supportive measures including blood transfusions that may cause
iron overload that requires iron chelation therapy, (2) targeted therapies such as the
immunomodulatory drug lenalidomide, and (3) hematopoietic stem cell transplanta‐
tion  (HSCT)  in  transplant  eligible  individuals.  The  establishment  of  the  various
prognostic systems, the discovery of the new genetic mutations, and the identification
of new targets, in MDSs in general and in 5q-syndrome in particular, will hopefully
translate  into  more  pinpointed  targeted  therapies  that  will  further  improve  the
outcomes of patients having these disorders.
Keywords: myelodysplastic syndrome, 5q-syndrome, iron overload, lenalidomide,
hematopoietic stem cell transplantation
1. Introduction
The MDSs are a group of clonal stem cell disorders that are characterized by ineffective
erythropoiesis due to excessive apoptosis and progressive peripheral blood cytopenia
culminating into acute myeloid leukemia AML or death from progressive BM failure [1–4].
MDS is primarily a disease of the elderly with a median age of 70 years [3]. The MDSs have
been linked to several etiologies, risk factors, and environmental associations such as alcohol
intake, tobacco use, Sweet’s syndrome, vitamin deficiencies, cytotoxic chemotherapy, various
hereditary disorders, and BM failure syndromes [5–12].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. Pathogenesis of MDSs
The pathogenesis of MDS is poorly understood [5, 12]. However, several pathogenic mecha‐
nisms have been described and these include the following: (1) genetic mutations as the cell
of origin has acquired multiple mutations that result in dysplasia and ineffective erythropoi‐
esis; (2) MDS clonality: MDS is a clonal process thought to develop from a single-transformed
hematopoietic progenitor cell. The inciting mutation is unknown for the majority of cases.
However, recurrent genetic mutations involving RNA splicing machinery have been identi‐
fied; (3) haploinsufficiency of ribosomal proteins particularly ribosomal protein (RPS) 14 in
del (5q); (4) telomere dysfunction and aberrant or absent expression of micro-RNA species; (5)
epigenetic changes: MDS genomes are characterized by global DNA hypomethylation with
concomitant hypermethylation of gene-promoter regions relative to normal controls; (6)
factors extrinsic to hematopoietic cells such as stromal abnormalities and T-cell dysregulation
that may occur causally or secondary to the primary genetic defects; (7) accelerated apoptosis
and ineffective erythropoiesis; (8) altered immune responses such as polyclonal expansion of
helper T cells (CD4+) and oligoclonal expansion of cytotoxic T cells (CD8+) in the peripheral
blood and BM; (10) leukemic transformation in MDS; the estimated risk of leukemic transfor‐
mation is more than 50% and is more frequent in patients with high-risk MDS such as refractory
anemia with excess of blasts (RAEB) II, monosomy 7, deletion of short arm of chromosome 17,
deletion of long arm of chromosome 7, and trisomy 8 [5, 12].
3. Chromosome 5 abnormalities in MDS
Approximately, 15% of patients with MDS have abnormalities of chromosome 5 that include
insertional deletion of a segment of the long arm of the chromosome [del (5q) or 5q-syndrome],
monosomy 5, and unbalanced translocations [13].
3.1. Del (5q) type of MDS
The insertional deletion of the long arm of chromosome 5, del (5q), is the one of the most
common cytogenetic abnormality encountered in patients with MDSs as it has been reported
in 10–30% of patients with MDS [14–17]. The long arm of chromosome 5 has two distinct
commonly deleted regions (CDRs). The more distal CDR lies in 5q33.1 and contains 40 protein
coding genes and genes that code for microRNAs (miR-143 and miR-145) [13]. Many genes
related to hematopoiesis are located on the long arm of chromosome 5 [18]. In del (5q), one
allele is deleted and this accounts for the genetic haploinsufficiency [13]. The gene cluster at
5q31 includes interleukins (ILs) 3, 4, 5, 9, 13, and 17β in addition to granulocyte monocyte-
colony-stimulating factor (CSF). Several cytokine receptor genes are also located on the long
arm of chromosome 5 including: CSF-1 receptor and platelet-derived growth factor-β [18].
The world health organization (WHO) recognizes del (5q), which was first described by Van
den Berghe et al. in the year 1974, as a distinct form of MDS [15, 18–20]. The 5q-syndrome is
the most distinct type of all MDSs as it has clear genotype/phenotype relationship [18, 21]. If
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del (5q) occurs as the only cytogenetic abnormality, it is associated with favorable prognosis
but once it is encountered in association with other single or multiple chromosomal abnor‐
malities, particularly in the setting of complex cytogenetics, the clinical outcome is rendered
poor [14, 16, 20, 22, 23].
Patients with del (5q) have specific clinical and pathological features [15, 18, 20]. The 5 q-
syndrome is usually characterized by the following: (1) female predominance, (2) refractory
macrocytic anemia that is often severe, (3) normal or elevated platelet count, (4) BM findings
of erythroid hypoplasia, less than 5% blasts as well as abnormal, dysplastic or hypolobulated
megakaryocytes, (5) del (5q) chromosomal abnormality as the sole karyotypic abnormality,
and (6) a rather benign clinical course with approximately 10% of patients ultimately pro‐
gressing to AML [13, 14, 18–20].
Despite the remarkable progress that has been achieved recently, certain unclear issues related
to the pathogenesis of del (5q) need further evaluation [18, 20]. Del (5q) MDS is considered a
disorder of the hematopoietic stem cells with lympho-myeloid potential. Also, involvement
of B cells, rather than T cells, was documented by combining immunophenotyping and
fluorescence in situ hybridization (FISH) analysis [18]. Cytogenetic and FISH analysis in BM
progenitor cells have revealed that, in del (5q) MDS, the deletion was generally present in the
pluripotent hematopoietic stem cells (CD34+ and CD38+) with the persistence of the normal
progenitor cells in the BM [20]. Genomic stability in 5q-syndrome is related to the infrequency
of additional cytogenetic abnormalities [18]. The lack of mutations in the genes mapping the
CDR suggests that haploisufficiency is the basis of 5q-syndrome [13, 18, 20]. Candidate genes
that show haploinsufficiency in del (5q) include SPARC (secreted protein acidic and cysteine
rich), a tumor suppressor gene, and RPS14, which is a component of the 40s ribosomal subunit
[13]. Only in advanced forms of the disease, rare mutations involving p53, JAK2, and MPL
genes have been described [13, 18, 20].
The erythroid defect or failure in del (5q) appears to be multifactorial as it has been reported
to involve in the following: (1) the decreased expression or haploinsufficiency of the ribosomal
protein S14 [RPS14] gene, (2) the upregulation of the p53 pathway induced by ribosomal stress,
and (3) enhancement of the endogenous erythropoietin production that ultimately leads to red
cell transfusion dependence in most patients [13, 15, 18, 21]. On the other hand, loss of the
microRNA genes miR-145 and miR-146a has been associated with the thrombocytosis
observed in 5q-syndrome patients [21]. Also, the increased expression of Friend leukemia virus
integration 1(FLI1), which is one of the target genes of miR-145, maintains effective megakar‐
yopoiesis in del (5q) MDS resulting in normal or elevated platelet (PLT) counts [13].
Isolated del (5q) has been reported in in higher grade MDSs such as RAEB and RAEB-
thrombocytosis (RAEB-T), thus contributing to the heterogeneity of the disease [20, 22]. MDS
with del (5q) occurs not only in myelodysplastic disorders, but also in AML and it contributes
to the pathogenesis of both myeloid diseases by deleting one or more of the tumor suppressor
genes [22]. Once associated with additional cytogenetic abnormalities and once new genetic
mutations are acquired, such as TP53 mutation, MDS with del (5q) becomes an aggressive
disease with rapid evolution into AML [20, 22]. Therefore, isolated del (5q) MDS should be




cytogenetic abnormalities and an excess of BM blasts [20]. Other specific aspects of 5q-
syndrome will be discussed separately in the subsequent sections of the review manuscript.
3.2. Monosomy 5 type of MDS
Loss of the whole chromosome 5 has been described in about 3–8% MDS cases. Recent studies
have shown that many suspected monosomies 5 are in fact cryptic translocations or insertions,
undetectable by conventional G-banding [24]. The mechanism responsible for the fragmenta‐
tion of deleted chromosome 5 remains unclear. One of the possible explanations might be the
phenomenon called chromothripsis, whereby one or more chromosomes or chromosomal
regions shatter into pieces in a single catastrophic event. MDS patients with deleted chromo‐
some 5 involved in complex rearrangements should be considered as a unique entity with
extremely poor prognosis [24].
Monosomy 5 does exist but is rarely encountered and the presence of this chromosomal
abnormality is usually associated with complex karyotypes, conferring poor prognosis [25].
Studies have shown that, compared to 5q- syndrome, monosomy 5 is more frequently
associated with: advanced or higher risk MDS, other chromosomal abnormalities including
chromosome 7 abnormalities and inferior overall survival [26]. Monosomy 5 has been reported
in therapy-related MDS (t-MDS) with complex cytogenetics and rapid progression to death
[27].
4. Clinical manifestations and complications of MDS
MDS has nonspecific signs and symptoms at presentation. However, many patients are
asymptomatic at presentation. The main manifestations of MDS are those related to cytopenia.
Anemic manifestations include fatigue, weakness, dizziness, exercise intolerance, angina,
cognitive impairment, and altered sense of well-being [12, 28]. Patients having thrombocyto‐
penia present with bleeding from various sites such as skin and mucous membranes. Easy
bruising, epistaxis, petechiae, ecchymoses, and gum bleeding are the main manifestations [12,
28]. Patients with neutropenia may develop fever and infections may be due to viruses,
bacteria, fungi, and mycobacteria [12, 28, 29]. Physical examination in patients with MDS
usually reveals: pallor, petechiae or ecchymoses, hepatosplenomegaly, and lymphadenopathy
uncommonly, weight loss in advanced cases and skin manifestations in case of associated
Sweet’s syndrome [12, 28].
Autoimmune abnormalities may be present in MDS patients and they include cutaneous
vasculitis, monoarticular arthritis, pericarditis, pleural effusions, edema formation, skin
ulcerations, iritis, myositis, peripheral neuropathy, fever, and pulmonary infiltrates [12]. Other
abnormalities that may be encountered in patients with MDS include pure red cell aplasia,
acquired HbH disease, myeloid sarcomas, Sweet's syndrome, myocardial ischemia, and
thrombocytosis in patients with del (5q) and RARS-T [12, 28].
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cytogenetic abnormalities and an excess of BM blasts [20]. Other specific aspects of 5q-
syndrome will be discussed separately in the subsequent sections of the review manuscript.
3.2. Monosomy 5 type of MDS
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[27].
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5. Diagnosis and subtypes of MDS
Minimal morphological diagnostic criteria in MDS include the following: (1) BM findings: ≥
10% dysplastic cells in ≥ 1 myeloid lineages, (2) highly suggestive features: (a) granulocytic
series: agranular neutrophils and Pelger–Huet neutrophils, (b) megakaryocytes, small
binucleated megakaryocytes and small round separated nuclei in megakaryocytes, and (c)
erythroid series: multinuclear or asymmetrical nuclei, nuclear bridging, and ring sideroblasts
[6, 30, 31].
The minimal diagnostic criteria in MDS include the following: (1) prerequisite criteria that
include (a) constant cytopenia in ≥ 1 of the following lineages: erythroid: Hb < 11 g/dL,
neutrophilic; absolute neutrophil count (ANC) < 1.5 × 109/L or megakaryocytic, PLTs <
100 × 109/L. (b) exclusion of all other hematopoietic and nonhematopoietic disorders as primary
reasons for cytopenia or dysplasia; (2) MDS-related or decisive criteria: (a) dysplasia in at least
10% of all cells in one of the following lineages in the BM smear; erythroid, neutrophilic or
megakaryocytic or > 15% ring sideroblasts on iron staining, (b) 5–19% blasts on BM smears,
and (c) typical chromosomal abnormality by FISH or conventional karyotype. (3) cocriteria for
patients fulfilling (1) but not (2): (a) abnormal phenotype of BM cells clearly indicative of a
monoclonal population of erythroid and/ or myeloid cells determined by flow cytometry, (b)
clear molecular signs of a monoclonal cell population in human androgen receptor (HU‐
MARA) assay, gene chip profiling or point mutation analysis such as RAS mutation, (c)
markedly or persistently reduced colony formation of BM and/or circulating progenitor cells
by colony-forming unit assay [6, 30, 31]. The subtypes of MDS according to the WHO classi‐
fication are illustrated in Table 1 [6, 30, 31].
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MDS: myelodysplastic syndrome; PLT: platelet; ↑: increased.
Table 1. WHO classification of MDS.
5.1. Cytogenetics in MDS
Several cytogenetic abnormalities can be encountered in patients with MDSs, some of these
are balanced, while others are unbalanced as illustrated in Table 2 [6]. Cytogenetic abnormal‐
ities are major determinants in the pathogenesis of MDS. They are becoming increasingly
recognized as the basis of selecting drugs in individual patients with MDS and they play a
significant role in monitoring response to treatment [32]. Chromosomal abnormalities are
detected in approximately 50% of patients with de novo MDS and 80% of patients with t-MDS
[32]. Recently, our ability to define the prognosis of the individual patient with MDS has
improved significantly [6]. Cytogenetic abnormalities are becoming essential in determining
the prognosis of MDS because they constitute the basis of the new cytogenetic scoring system
as shown in Table 3 [31, 33, 34]. The values of the new prognostic systems will certainly become
higher as new genetic-based therapy move through trials and into clinical practice [6].
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Balanced chromosomal abnormalities Unbalanced chromosomal abnormalities
Abnormality Frequency Abnormality Frequency
t (11,16) (q23;p13.3) – +8 10%
t (3,21) (q26. 2; q22.1) – −7 or del (7q) 10%
t (1,3) (p36.3; q21.2) – −5 or del (5q) 5–8%
t(2,11) (p21; q23) 1% Del (20q) 5%
inv (3) (q21; q26.2) 1% −Y 3–5%
t (6,9) (p23; q34) 1% I (17q) or t (17p) 3%
−13 or del (13q) 3%
Del (11q) 10%
Del (12p) or t (12p) 3%
Del (9q) 1–2%
Idic (x) (q13) 1–2%
*MDS: myelodysplastic syndrome.
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inv (3); t(3q); del (3q)
Double including -7/del (7q)
Complex: 3 cytogenetic abnormalities
1.5 1.7
Very poor 4% Complex > 3 cytogenetic abnormalities0.7 0.7
MDS: myelodysplastic syndrome; AML: acute myeloid leukemia.




5.2. Impact of monosomal karyotype on the prognosis of MDS
A monosomal karyotype (MK) is defined by the presence of ≥ 2 distinct autosomal chromosome
monosomies or a single autosomal monosomy associated with ≥ 1 structural abnormality [1].
In AML, MK has been associated with a worse prognosis than an otherwise complex karyo‐
type, regardless the specific type of autosome involved [1].
Studies have shown that MK in MDS identifies a prognostically worse subgroup of patients
than a complex karyotype regardless of whether monosomy 7 or 5 is part of the MK component
[1]. Chromosomal abnormalities are present in 20–70% of patients with MDS, but complex
cytogenetics are universally considered unfavorable as they are associated with poor overall
survival (OS) and high rates of leukemic transformation [1, 32, 34].
5.3. Genetic mutations described in MDSs and 5q-syndrome
Several classes of genetic mutations have been described in patients with MDS as shown in
Tables 4–6 [34–40]. These mutations are essential in not only determining the prognosis but
also constituting a platform for the current and future novel and targeted therapies for various
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PTEN 10q 23 <1% –
CDKN2A 9q (12) <1% –
BRAF 7q 34 <1% –


















5% of RARS – T
MDS: myelodysplastic syndrome; CMML: chronic myelomonocytic leukemia; JMML: juvenile myelomonocytic
leukemia; AML: acute myeloid leukemia; RCMD: refractory cytopenia with multilineage dysplasia; RA: refractory
anemia; RAEB: refractory anemia with excess of blasts; RARS: refractory anemia with ring sideroblasts; RARS-T:
refractory anemia with ring sideroblasts thrombocytosis.
Table 4. Genetic mutations in MDS.
TP53 encodes a cytoplasmic protein p53 that regulates cell growth and death. TP53 mutations
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MDS: myelodysplastic syndrome; CMML: chronic myelomonocytic leukemia; JMML: juvenile myelomonocytic
leukemia; AML: acute myeloid leukemia; RCMD: refractory cytopenia with multilineage dysplasia; RA: refractory
anemia; RAEB: refractory anemia with excess of blasts; RARS: refractory anemia with ring sideroblasts; RARS-T:
refractory anemia with ring sideroblasts thrombocytosis.
Table 4. Genetic mutations in MDS.
TP53 encodes a cytoplasmic protein p53 that regulates cell growth and death. TP53 mutations
have been found mainly in intermediate to high-risk MDS patients [41]. Patients having TP53
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mutations often present with severe thrombocytopenia, complex cytogenetic abnormalities,
an increased risk of leukemic transformation, and a shorter survival [41, 42]. Patients with
mutant p53, compared to patients carrying wild-type p53, have the following features: older
age, anemia, and leucopenia at the time of diagnosis and shorter median survival. Molecular
identification of mutant p53 contributes to the risk stratification of patients with lower-risk
MDS that may alter the treatment approach [41]. TP53 mutations develop at an early disease
stage in almost 20% of patients with lower-risk MDS having del (5q) [42].
Biological process Genetic mutation
Transcriptional regulators – SF3 B1 nm – SRSF2 nm
– UZ AF1 – CUX1
– SETBP1
Epigenetic regulators – ASXL1 – TET2 nm
– DNMT3 A – EZH2
Cell cycle regulators – TP53
– NPM1
Apoptosis – BCL2
Translation – RPS14 nm –RPL 23
– RPS 4x – RPS 25
– RPA 19
Signaling or differentiation – RUNX1 – N-RAS
– ETV 6 – FMS
– FLT 3 – SET BP1
*MDS: myelodysplastic syndrome;
* nm: non-mutated
Table 5. Genetic mutations associated with poor prognosis in MDS.
Mouse models of the 5q-syndrome have indicated that a p53-dependent mechanism underlies
the pathophysiology of this disorder. Importantly, activation of p53 has been demonstrated in
the human 5q-syndrome [43]. Recurrent TP53 mutations have been associated with an
increased risk of AML disease evolution and with decreased response to lenalidomide therapy
in del (5q) MDS patients [43].
TP53 mutations are usually present years before disease progression. They are associated with
p53 overexpression but are not associated with specific clinical manifestations [42]. The
presence of TP53 mutations in low-risk MDS with del (5q) contributes to the heterogeneous
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DNA methylation – DNMT3A
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40–50% – DNA methyl transferase inhibitors
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Chromatin modification – ASXL1
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20–30% – Deacetylyase inhibitors
























Table 6. Point mutations in MDS.
In patients with 5q-syndrome, TP53 mutations are present in a small fraction of patients and
they cause p53 overexpression subsequently. These aberrant subclones remain quiescent
during treatment with lenalidomide and they expand at transformation into acute leukemia
[44]. Studies have confirmed that in patient with low-risk MDS having 5q-syndrome, TP53
mutations are associated with strong p53 expression and that p53 positivity is the strongest
independent predictor of transformation into AML [45]. Patients with MDS having del (5q)
may have mutations other than TP53 such as FOXP1, TP63, JAK2, and MPL mutations [19,
46]. FOXP1 and TP63 mutations may be involved not only in the pathogenesis of the disease,
but also they may play a role in the progression into AML [46]. JAK2 and MPL mutations may
be found in a small proportion of patients, but their presence does not seem to affect phenotype
or progression [19].
Potential new therapeutic agents for del (5q) MDS include the translation enhancer L-leucine,
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Table 6. Point mutations in MDS.
In patients with 5q-syndrome, TP53 mutations are present in a small fraction of patients and
they cause p53 overexpression subsequently. These aberrant subclones remain quiescent
during treatment with lenalidomide and they expand at transformation into acute leukemia
[44]. Studies have confirmed that in patient with low-risk MDS having 5q-syndrome, TP53
mutations are associated with strong p53 expression and that p53 positivity is the strongest
independent predictor of transformation into AML [45]. Patients with MDS having del (5q)
may have mutations other than TP53 such as FOXP1, TP63, JAK2, and MPL mutations [19,
46]. FOXP1 and TP63 mutations may be involved not only in the pathogenesis of the disease,
but also they may play a role in the progression into AML [46]. JAK2 and MPL mutations may
be found in a small proportion of patients, but their presence does not seem to affect phenotype
or progression [19].
Potential new therapeutic agents for del (5q) MDS include the translation enhancer L-leucine,
as it may have some efficacy in ribosomopathies. L-leucine has shown increased hemoglobi‐
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nization and red cell numbers and reduced developmental defects both in humans and in
mouse models [43].
6. Prognostic systems in MDSs
In MDS, there are several prognostic scoring systems and these include the following: (1) the
international prognostic scoring index (IPSS), (2) the revised IPSS (R-IPSS) (Table 7), (3) the
WHO prognostic scoring system (WPSS), (4) MD Anderson Cancer Center (MDACC) MDS
model that includes the global and the lower-risk scoring systems, and (5) the French prog‐
nostic scoring system (FPSS) [30, 31, 33, 47, 48]. The components of the prognostic stratification
systems of MDS are as follows: BM blast cells, age, comorbid medical conditions, serum lactic
dehydrogenase (LDH), cytogenetics, number of cytopenia, severity of anemia, and high white
blood cell (WBC) count [4].
Prognostic variable Points
0 0.5 1 1.5 2 3 4
Cytogenetics Very good – Good – Intermediate Poor Very poor
Bone marrow blasts % ≤2 – >2–5% – 5–10% >10% –
Hb (g/dL) ≥10 – 8– < 10 <8 – – –
PLT count
×109/L
≥100 50–100 <50 – – – –
ANC
×109/L
≥0.8 <0.8 – – – – –
MDS: myelodysplastic syndrome; Hb: hemoglobin; ANC: absolute neutrophil count – indicates not applicable; PLT:
platelet.
Table 7. (R-IPSS) Revised international prognostic scoring system for MDS.
The IPSS is composed of: blast percentage, karyotype or cytogenetics and the number of
cytopenia. The IPSS is classified into low, intemediate-1, intemediate-2, and high-risk score [6,
49]. The R-IPSS model incorporates: BM blasts, cytogenetics, hemoglobin (Hb) level, PLTs, and
ANC. The R-IPSS is divided into five risk categories: very low, low, intermediate, high, and
very high risks (Table 7) [30, 31, 33, 47]. The R-IPSS is an excellent predictor of MDS in the era
of disease modifying therapies. The early recognition of patients at high risk of progression to
aggressive disease may optimize the timing of treatment before worsening of comorbidities
[50]. The precise definition of a prognostic score, such as the R-IPSS, and the probability of
leukemia evolution are particularly important in patients with lower-risk MDS in which new





The WPSS incorporates the following variables: WHO classification of MDS, cytogenetics, and
the need for RBC transfusions [6, 47]. The MD Anderson prognostic model depends on the
following factors: age, performance status, prior blood transfusion, WBC and PLT counts, Hb
level, BM blasts, and karyotype [47, 49]. The scoring system is divided into four risk categories:
low, intermediate-1, intermediate-2, and high [47, 49]. The FPSS includes the following items:
the Eastern Cooperative Oncology Group (ECOG) performance status, IPSS cytogenetic risk,
the presence of circulating blasts, and packed red blood cell (RBC) transfusion dependency
[48]. The prognostic models of MDS are important, as they are used as tools in determining
the severity of the illness, the prognosis of MDS, and the best line of management to be
considered, that is, supportive care, hypomethylating agents, immunomodulatory drugs or
HSCT [49]. The proliferation index (PI) of specific compartments of BM cells is a dynamic
parameter that reflects the ongoing rate of production of hematopoietic cells in MDS. It is
directly related to the maturation-associated alteration of distinct subgroups of hematopoietic
cells in individual patients [4]. Assessment of the PI of nucleated RBCS and other components
of BM precursors, such as myeloid CD34+ hematopoietic progenitor cells, could significantly
contribute to a better management of MDS. The PI of nucleated RBCS is emerging as an
independent prognostic factor for both OS and progression-free survival (PFS) in MDS [4].
7. Anemia and iron overload in MDSs and 5q-syndrome
Anemia is a very common finding in MDS patients [51, 52]. Packed RBC transfusions are the
only therapeutic option in 40% of MDS patients [51, 52]. RBC transfusions are considered in
MDS patients when Hb level falls below 8 g/dL and may provide temporary relief of anemic
symptoms [51, 52]. Anemia contributes to cardiac dysfunction predominantly in elderly
individuals [51]. In MDS patients, anemia can be corrected by the following: (1) RBC transfu‐
sions, (2) administration of hematopoietic growth factors such as erythropoietin, (3) adminis‐
tration of certain drugs such as lenalidomide, cyclosporine-A, and antithymocyte globulin
(ATG), and (4) allogeneic HSCT that is the only curative therapeutic approach [51, 52].
Anemia and blood transfusions have significant impact on the quality of life (QOL) of MDS
patients [51]. Transfusion dependency is associated with shortened overall and leukemia-free
survival in MDS patients [51]. In these patients, transfusion dependency and iron overload
have been retrospectively associated with: (1) inferior survival, (2) worse clinical outcome
including cardiac, hepatic, and endocrine dysfunction and in some studies, (3) leukemic
transformation, and infectious complications [52].
The most serious side effects of regular blood transfusion are elevation of iron blood levels
and iron overload, that is, deposition of iron in body tissues [51–54]. Magnetic resonance
imaging (MRI) of the heart and liver is an excellent noninvasive diagnostic tool for (1) the
assessment of iron overload and (2) monitoring the response to iron chelation therapy [51, 55,
56]. MRI of the heart and liver is superior to the surrogate markers of iron overload such as
serum ferritin, liver iron, ventricular ejection fraction, and tissue-related parameter [51]. The
diagnostic parameters used for the evaluation of iron overload in MDS are shown in Table 8
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[55]. Serum erythropoietin is a predictive factor for response to therapy with subcutaneous
erythropoietin [57]. MDS patients with higher values of erythropoietin have poorer response
to the administration of erythropoietin therapy even at higher doses [57].
Method Normal level Mild to moderate iron overload Severe iron overload













* MDS: myelodysplastic syndrome. * MRI: magnetic resonance imaging.
Table 8. Diagnostic parameters used for evaluation of iron overload in MDS.
7.1. Iron overload in low-risk MDS
In patients with low-risk MDS, packed RBC transfusion are required to correct anemia.
Ultimately, these patients become transfusion dependent [55, 58, 59]. Also, more aggressive
disease is usually associated with a high transfusion rate and thus significant transfusion
dependency becomes a surrogate marker of aggressive disease [59]. On the long-term,
transfusion dependence leads to the development of iron overload, which becomes an
important clinical problem, that is associated with an increase in morbidity and mortality [59].
However, in some transfusion-independent low-risk MDS patients, an increased erythro‐
poietic activity results in the suppression of hepcidin and contributes to iron loading [55].
In patients with low-risk MDS who are chronically transfused, transfusion-related morbidity
is an emerging challenge [58]. Blood transfusion therapy may lead to organ toxicity due to the
formation of nontransferrin bound iron and resulting in oxidative stress. Therefore, in low-
risk MDS patients with longer life expectancy, preventing organ damage due to iron overload
is an important concern [59].
Recently, high serum ferritin level has been identified as a prognostic factor for short time to
progression to acute leukemia [59]. Transfusion-dependent patients with an isolated erythroid
dysplasia and a low risk of leukemic transformation are more likely to develop parenchymal
iron overload and its toxicity and hence benefit from iron chelation therapy [56]. In low-risk
MDS patients with relatively lower RBC transfusion requirements, T2-MRI is indicated every
10–20 units of packed RBCS in order to evaluate the need to: (1) initiate iron chelation therapy,




Currently, the initiation of iron chelation therapy is based on: (1) the total number of RBC
transfusions and (2) increased serum ferritin in transfusion-dependent patients [55]. Iron
chelation therapy is generally recommended for selected patients with low-risk MDS [52–54].
It is reasonable to offer iron chelation therapy to low-risk MDS patients who are at high risk
of developing iron overload [55, 59]. Data from multiple retrospective studies have demon‐
strated that iron chelation therapy results in marked survival benefit in patients with low-risk
MDS [52, 55].
8. Management of MDSs and 5q-syndrome
Most patients with MDS are treated with supportive measures due to their old age and
comorbid medical conditions [3]. However, there are various therapeutic options for patients
with low or intermediate-1 risk MDS and these include the following: (1) blood product
transfusions: packed RBCS and PLTs, (2) iron chelation therapy with: deferasirox, deferoxa‐
mine, and deferiprone, (3) erythropoietin with or without granulocyte-CSF, (4) ATG and
cyclosporine-A, (5) danazol, (6) pyridoxine, (7) valproic acid, (8) lenalidomide, (9) 5-azaciti‐
dine, (10) decitabine, and (11) low-dose cytarabine [60].
8.1. Iron chelation therapy
The role of iron chelation therapy in MDS patients with transfusion dependency and iron
overload remains a very controversial issue in the management of MDS, mainly due to lack of
solid prospective clinical trials [52, 59, 61]. However, case–control studies, retrospective
analyses, and phase-II clinical trials have indicated that iron chelation therapy reduces iron
overload as measured by serum ferritin and may even prolong overall survival [54].
Iron chelation therapy is indicated in the following categories of patients: (1) patients with
frank iron overload; stable or increasing serum ferritin > 1000 ng/mL without signs of active
inflammation or liver disease; who are transfusion-dependent at any frequency and have a life
expectancy of >1 year, (2) transfusion-dependent patient who receive > 2 units of packed RBCs
per month, at any serum ferritin level, and have a life expectancy of > 2 years, except for patients
with frank iron deficiency such as chronic gastrointestinal (GIT) bleeding, and (3) in selected
patients, iron chelation therapy is considered when life expectancy < 2 years. Examples include:
planned curative treatment such as HSCT, massive iron overload with consecutive organ
dysfunction or massive iron overload that is judged to significantly reduce QOL [51, 58].
Additional parameters that may influence decision to treat with iron-chelating agents in
selected MDS patients include the following: (1) old age, (2) social and mental circumstances,
(3) comorbidity and organ dysfunction, and (4) genetic status such as HFE gene mutations [51,
58]. The guidelines of the National Comprehensive Cancer Network (NCCN) and those of the
MDS Foundation for the treatment of iron overload in MDS are illustrated in Table 9 [52, 55].
The proposed response criteria for iron chelation therapy in MDS are shown in Table 10 [58].
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Currently, the initiation of iron chelation therapy is based on: (1) the total number of RBC
transfusions and (2) increased serum ferritin in transfusion-dependent patients [55]. Iron
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MDS [52, 55].
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cyclosporine-A, (5) danazol, (6) pyridoxine, (7) valproic acid, (8) lenalidomide, (9) 5-azaciti‐
dine, (10) decitabine, and (11) low-dose cytarabine [60].
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Source Transfusion status Serum ferritin
level
ng/mL or mg/L
MDS risk category Patient profile




– Continuing transfusion >1000 mg/L – IPSS: low or intermediate
– WHO: RA/RARS/5q-
– Candidate for allogeneic
HSCT – No erythroid response
to primary therapy
MDS: myelodysplastic syndrome; HSCT: hematopoietic stem cell transplantation; IPSS: international prognostic
scoring index; WHO: world health organization; RA: refractory anemia; RARS: refractory anemia with ring
sideroblasts.
Table 9. Guidelines for the treatment of iron overload in MDS.
Complete response (CR) Minor response (MR) Stable iron load No response
Decrease in serum ferritin to
<200 ng/mL or Decrease in
serum ferritin by 500 ng/mL
Decrease in serum ferritin to <
200 ng/mL or Decrease in serum





serum ferritin by at




Table 10. Proposed response criteria for iron chelation therapy in MDS.
There are three forms of iron-chelating agents, namely (1) oral deferasirox (exjade), (2) oral
deferiprone (feriprox), and (3) parenteral deferoxamine (desferal) [54, 58]. The availability of
two effective oral chelating agents, deferasirox and deferiprone, has renewed interest in the
evaluation of iron chelation therapy in MDS [52].
The beneficial effects of iron chelation therapy in MDS patients having iron overload include
significant reduction of: labile plasma iron, nontransferrin-bound iron and reactive oxygen
species (ROS) that mediate tissue damage observed in iron overload [52]. Adverse effects of
iron chelation therapy include cost and toxicity. Therefore, MDS patients should be initiated
on iron chelation therapy after weighing potential risks and benefits for each patient until more
definitive data are available [53]. Application of recent advances in the treatment of MDS can
reduce or eliminate the need for blood product transfusions thus minimizing the risk of iron
overload [54]. Careful attention to iron parameters with early initiation of iron chelation
therapy in patients with evidence of transfusion-related iron overload is an important





There are 40 genes in the CDR on the long arm of chromosome 5 in MDS with del (5q). Examples
of the CDR genes and the effects of lenalidomide on the haplodeficient genes are shown in
Table 11 [13, 62, 63].
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Table 11. Genes in the commonly deleted region and effects of lenalidomide on the haplodeficient genes.
Lenalidomide is a novel thalidomide analog that has enhanced immunomodulatory and
antiangiogenic effects and diminished thalidomide-related adverse events [60]. The approved
indications of lenalidomide treatment in MDS include the following: (1) patients with del (5q)
who have symptomatic transfusion-dependent anemia, (2) lower risk, according to IPSS, MDS
patients having 5q- syndrome, and (3) other low-risk and intermediate 1 risk types of MDSs
[60, 62].
The important clinical trials of lenalidomide in patients with MDS are shown in Table 12 [60,
62–66]. Lenalidomide has several mechanisms of action that include the following: (1)
promotion of erythropoiesis by inhibition of CD45 protein tyrosine phosphatase and activation
of EPO-R/STAT5-signaling pathway, (2) the stimulation of production of certain ILs such as
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The important clinical trials of lenalidomide in patients with MDS are shown in Table 12 [60,
62–66]. Lenalidomide has several mechanisms of action that include the following: (1)
promotion of erythropoiesis by inhibition of CD45 protein tyrosine phosphatase and activation
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IL-2, IL-10, and interferon (IFN) -δ, (3) inhibition of pro-inflammatory cytokines and chemo‐
kines such as tumor necrosis factor (TNF)-α, IL-12, IL-1B, IL-6, monocyte chemotactic pro‐
tein-1, and macrophage anti-inflammatory protein-1α, (4) anti-angiogenic effects of
lenalidomide-mediated through endothelial cell migration inhibition, that is, inhibition of
bFGF-, VEGF-, and TNF-α-induced endothelial cell migration, (5) immunomodulatory effects,
(6) anti-inflammatory properties, (7) direct antineoplastic activity by the inhibition of malig‐
nant clone and upregulation of SPARC gene, (8) direct cytotoxic effect on abnormal del (5q)
clones by targeting haploinsufficient genes and their pathways, (9) T-cell activation or
stimulation of T-cell proliferation including natural killer (NK) cells number and function and
production of multiple cytokines, and (10) inhibition of haplodeficient phosphatases and
release of progenitors from p53 arrest [14, 21, 60, 62, 63, 67]. The adverse effects of lenalidomide
include the following: (1) myelosuppression: neutropenia, anemia and thrombocytopenia, (2)
venous thromboembolism such as deep venous thrombosis in 3.4% of treated patients, (3)
infectious complications such as pneumonia, fever and febrile neutropenia, (4) skin rashes,
pruritis, and urticaria, (5) GIT upset including nausea and diarrhea, (6) fatigue, muscle cramps,
and bone pains, (7) bleeding diathesis, (8) hypokalemia, (9) autoimmune hemolytic anemia,
(10) edema formation, and (11) rarely, hypothyroidism and hypogonadism [15, 17, 60, 62, 64,
68]. The mechanisms of resistance to lenalidomide include the following: (1) over expression
of PP2A and (2) restoration of p53 expression leading to accumulation of p53 [62].
Cereblon, an E3 ligase protein, was first described to be the molecular target of lenalidomide
in a seminal paper, published in the year 2010, that linked its role to the teratogenic effects of
thalidomide in zebrafish and chicks [69, 70]. In 2011, cereblon was found to play a key role in
mediating the antiproliferative and immunomodulatory activities of lenalidomide and
pomalidomide in multiple myeloma (MM) and T cells, respectively [69, 70]. Thalidomide has
been shown to bind and inhibit cereblon and cereblon loss had been found to cause birth defects
[71]. Studies on MM cell lines have shown lack of correlation between cereblon expression and
sensitivity to lenalidomide. However, in MM cell lines, made resistant to lenalidomide and
pomalidomide, cereblon protein was greatly reduced [69–71].
The central role of cereblon as a target of lenalidomide and pomalidomide suggests its potential
utility as a predictive biomarker of response or resistance to immunomodulatory drug therapy
[69]. The currently available commercial assays that are used in measuring cereblon levels have
their own limitations. Therefore, standardization and validation of the techniques used are
needed to accurately assess the role of cerebron as a predictive biomarker of the response to
immunomodulatory drugs [69].
The serine-thionine kinase, casein kinase 1α (CK1α), is encoded by casein kinase 1 A1
(CSNK1A1) gene [72, 73]. CK1α has been implicated in the biology of del (5q) MDS and has
been shown to be a therapeutic target in myeloid malignancies and is therefore an attractive
candidate for mediating the effects of lenalidomide in del (5q) MDS [73]. CSNK1A1 gene is a
putative tumor suppressor gene located in the CDR at 5q 32 for del (5q) MDS and is expressed
at haploinsufficiency levels in MDS with del(5q) [72–74]. Haploinsufficiency of CSNK1A1
leads to hematopoietic stem-cell expansion in mice and may play a role in the initial clonal




or pathogenesis of del (5q) MDS and is a promising therapeutic target [74]. Lenalidomide
induces the ubiquitination of CSNK1A1 by the E3 ubiquitin ligase [CRL4 CRBN] resulting in
CSNK1A1 degradation. Lenalidomide significantly alters the protein abundance of three out
of five differentiated ubiquitinated proteins [73].
The development of CK1α inhibitors may provide a new therapeutic opportunity in MDS
patients with del (5q) and CSNK1A1 mutations [72]. In MDS patients with del (5q), CSNK1A1
mutations have been found in 7.2% of patients and are associated with older age [72].
CSNK1A1 mutations may coexist with ASKL1 but not with p53 mutations. They are usually
responsive to lenalidomide and have no independent prognostic impact on overall survival
[72].
In del (5q) MDS, lenalidomide-induced degradation of CSNK1A1 below the haploinsufficiency
levels induces p53 activity, that is, CSNK1A1 is a negative regulator of p53 [73]. The deletion
of genes on chromosome 5q, such as RPS-14, may further sensitize del (5q) cells to p53
activation. This mechanism of activity is consistent with the acquisition of TP53 mutations in
del (5q) MDS patients who develop resistance to lenalidomide [73].
Lenalidomide is a potent therapy for low-risk MDS with del (5q) that causes transfusion
independency in 67% of patients and complete cytogenetic remission in 45% of patients [44].
However, 50% of patients responding to lenalidomide relapse within 2 years, and 15% of
patients achieving cytogenetic response, and 67% of patients not achieving cytogenetic
response are at risk of leukemic transformation within 10 years [44].
8.3. The role of HSCT in MDSs
Allogeneic HSCT is the only known curative therapeutic option for MDS [2, 3, 75–84]. Not only
the rates of allogeneic HSCT to treat MDS are continuously increasing, but also survival rates
are steadily improving [76, 85]. In patients with MDS, the indications of HSCT are as follows:
(1) higher-risk MDS, (2) intermediate-2 MDS, (3) MDS in blast cell crisis, (4) younger patients
with MDS having good performance status, and (5) patients with low-risk MDS with poor
prognostic features such as: old age, refractory cytopenias and transfusion-dependence [3, 75,
76, 81, 82]. Both blast percentage and percentage of cytogenetically abnormal cells reflect MDS
disease burden and predict the outcome of HSCT [86]. Therefore, accurate assessment of MDS
disease burden and MDS disease biology based on cytogenetic and molecular profiles is critical
to determine the optimal HSCT timing and improve the outcome of HSCT [86]. Incorporation
of novel diagnostic techniques such as flow cytometry, molecular cytogenetics and microarray
gene expression profiling in the diagnostic algorithms and risk stratification may further
optimize therapeutic decisions including the timing of allogeneic HSCT [85].
In patients with MDS undergoing HSCT, predictors of the outcome of HSCT include the
following: (1) age, (2) performance status, (3) transfusion dependence, (4) serum erythropoietin
level, (5) HSCT-comorbidity index, (6) MK, (7) MDS risk score such as R-IPSS category, and
(8) severity of cytopenias [75, 76, 79, 82]. Novel classification schemes for MDS allow for more
accurate prognostication and consequently recommendations for HSCT or non-HSCT
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therapies [78]. MDS disease classification by IPSS, R-IPSS, and WPSS as well as patient
characteristics as assessed by HSCT-comorbidity index provide guidance for optimal patient
management [81].
  Median duration of complete hematological response: 11 months




The age of MDS patients undergoing HSCT has increased significantly over the last 30 years.
While HSCT is being carried out in older patients with MDS, this enthusiasm has been over
shadowed by the impact of the procedure and its complications, namely graft versus host
disease (GVHD) on the QOL and socioeconomic status [78]. Comorbid medical conditions are
the major patient characteristics impacting transplantation success. Validation of comorbidity
scoring systems has provided the basis for risk assignment to a given patient [78]. HSCT
comorbidity index allows estimation of the probability of non-relapse mortality after HSCT
[81].
Pre-HSCT serum ferritin > 100 mg/L has been shown to have an adverse impact on OS
following HSCT [75]. Adverse consequences of iron overload on the outcome of HSCT include
increased risk of septicemia, invasive fungal infections, and sinusoidal obstruction syndrome
[75]. BM blast percentage < 5% at the time of HSCT is the major predictor of improved disease-
free survival (DFS) and disease relapse [80]. Prior treatment to decrease blast percentage < 5%
prior to allogeneic HSCT is recommended as it has been shown to improve DFS particularly
in patients undergoing nonmyeloablative (NMA)-conditioning therapy [80].
The major factors that have a negative effect on relapse-free survival in MDS patients subjected
to HSCT are pretransplant karyotype and pre-HSCT BM blast count [76, 81]. Patients with very
poor cytogenetics, including MK, have a 10% or less probability of long-term survival [81].
Studies have also shown that a patient with MDS having MK has lower survival rates, higher
relapse rates, and higher overall mortality following allogeneic HSCT [76]. The presence of
p53, DNMT3A, and TET2 genetic mutations in the pre-HSCT period decreases the probability
of post-transplant survival by a factor of 3–4 [76, 81]. On the other hand, SF3B1 mutations are
associated with superior leukemia-free survival and OS in MDS patients subjected to alloge‐
neic HSCT [81].
In MDS patients receiving allogeneic HSCT, the stem cell sources are the following: peripheral
blood, BM, and umbilical cord blood (UCB) have yielded similar outcomes [80, 83]. Peripheral
blood progenitor cells are currently the preferred source of stem cells due to faster engraftment
and higher risk of GVHD giving rise to more potent graft versus tumor (GVT) effect [81, 83].
Cord blood cells are typically associated with slow engraftment and hence higher risk of
infections and bleeding complications [81]. UCB-derived hematopoietic grafts provide the
advantage of transplanting rather immature cells that allows successful HSCT in some patients
even in the presence of HLA mismatches [87]. The following forms of allografts are available
for MDS patients who are eligible for transplantation: HLA-matched sibling grafts, matched
unrelated donor (MUD) allografts, UCB grafts, and HLA-haploidentical donor allografts [78,
83]. The availability of: HLA matched related and unrelated donors, HLA-haploidentical
relatives and UCB helps to identify donors for the vast majority of MDS patients [81]. Tradi‐
tionally, transplantation of HLA-haploidentical cells carries an increased risk of graft rejection
and an increased risk of GVHD. However, the recently introduced conditioning regimens have
reduced the risk of graft rejection and the administration of cyclophosphamide in the early
post-transplant period has minimized the risk of GVHD to similar or even lower rates than
observed following HLA-matched donor cell [81].
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An increased use of unrelated donors and the establishment of protocols for cord blood HSCT
and HLA-haploidentical HSCT have made HSCT available for a rapidly growing number of
patients [78]. Haploidentical HSCT performed using T-cell replete allografts and post-
transplant cyclophosphamide can achieve outcomes equivalent to those of conventional HSCT
using HLA-matched related or unrelated donors [87]. The preferred donor for MDS patients
undergoing allogeneic HSCT is an HLA-matched sibling or alternatively a fully matched
unrelated donor as both have comparable survival rates. However, MUD form of HSCT is
associated with higher treatment-related mortality (TRM) [82].
Development of a broad range of conditioning regimens has allowed clinicians to offer HSCT
taking into consideration: stage of the disease and patient characteristics [78]. Conventional
myeloablative conditioning (MAC) protocols include the following: total body irradiation
(TBI), cyclophosphamide, busulfan, and fludarabine, while reduced intensity conditioning
(RIC) regimens incorporate low-dose TBI, fludarabine, cyclophosphamide, ATG, and alem‐
tuzumab in various doses and schedules [75]. MAC therapy is associated with lower relapse
rate particularly in patients in complete remission or with < 5% blasts. MAC therapy is also
associated with increased toxicity and nonrelapse mortality [78, 80]. Long-term survival results
in remission following allogeneic HSCT from HLA-matched related or unrelated donor and
high-intensity conditioning treatment are as follows: lower-risk MDS: 75%, intermediate-1
MDS: 60%, intermediate-2 MDS: 45% and high-risk MDS: 30% [81]. NMA or RIC conditioning
regimens may be considered for MDS patients who are not candidates for MAC regimens due
to comorbidities or old age, but such regimens should ideally be used within the context of a
clinical trial [82]. Since approximately 75% of MDS patients are > 60 years of age at diagnosis,
MAC-allogeneic HSCT can only be offered to a subset of individuals [82]. In patients unfit for
MAC therapy, NMA conditioning yields equivalent: TRM, DFS, and OS [80]. For patients with
de novo MDS aged 60–70 years, the favored therapy varies according to the IPSS risk for patients
with low risk and intermediate-1 IPSS risk, nontransplantation approaches are preferred and
for patients with intermediate-2 and high-IPSS risk, RIC-allogeneic HSCT offers overall and
quality-adjusted survival benefit [88]. In patients with MDS, emphasis should be shifted from
high-dose chemotherapy aimed at maximum tumor-cell kill to RIC allogeneic HSCT relying
on the donor cell-mediated GVT effect that is most prominent in patients having chronic
GVHD in particular in order to eradicate the disease [81]. RIC regimens for allogeneic HSCT
have the capacity to result in long-term remissions in MDS patients who are ineligible for
conventional allogeneic HSCT [89]. The role of RIC-allogeneic HSCT in MDS patients is to
induce chronic GVHD which in turn reduces relapse rate and improves DFS and OS [82, 89].
Autologous HSCT is applicable only to a minority of younger patients with MDS because of
difficulty in harvesting adequate numbers of CD34+ cells even in low-risk MDS patients and
lack of graft versus leukemia or GVT effect thus resulting in high risk of MDS relapse [3].
8.4. HSCT in lower risk MDS patients
In patients with low- or intermediate-1-risk MDS, aged 60–79 years, life expectancy following
RIC-allogeneic HSCT is about 38 months compared to 77 months in patients not subjected to




with low or very low-risk MDS should ideally be treated with supportive measures and low
intensity therapies, such as lenalidomide, erythropoiesis stimulating agents, hypomethylating
agents or immunosuppressive therapies rather than allogeneic HSCT [81, 84].
8.5. Road blocks and other unresolved issues related to HSCT in MDSs
The major road blocks to a universally successful HSCT are relapse of MDS and NRM, often
related to GVHD [75, 78, 83]. Allogeneic HSCT in MDS patients can lead to considerable
mortality and morbidity mostly as a consequence of toxicity to organs, infectious complications
and GVHD [87]. Acute and chronic GVHD are frequent causes of morbidity after HSCT in
MDS patients [78]. Additional research is required to prevent GVHD while maintaining the
GVT effect [81]. The graft versus dysplasia resulting from allogeneic HSCT and the infusion
of donor leukocytes has led to a great understanding of the immunological mechanisms that
govern the outcome of HSCT in MDS patients [3]. Post-transplant relapse is a major hurdle to
greater success, particularly in patients with high-risk cytogenetics [78]. Pretransplant
cytogenetics and BM blasts are the strongest risk factors for post-HSCT relapse [81]. The time
interval from allogeneic HSCT until relapse represents a crucial factor to predict response to
salvage therapy and survival in patients with high-risk MDS relapsing after allogeneic HSCT
[90]. Strategies to reduce relapse and TRM and improve outcome of HSCT include the
following: (1) modification of the intensity of conditioning therapy taking into consideration:
age, organ function and comorbid medical conditions, (2) pretransplantation strategies that
include (A) improvement of remission: (a) hypomethylating agents and/or histone deacetylase
inhibitors (HDACs), (b) induction therapy followed by RIC (FLAMSA), and (c) clofarabine
and/or cytosine arabinoside. (B) induction of cytogenetic remission by lenalidomide for 5q-
syndrome and hypomethylating agents for monosomy 7, and (3) post-transplantation strat‐
egies that include (a) boosting GVL effect by immune enhancers such as lenalidomide, CTLA4
(cytotoxic T-lymphocyte-associated protein 4), anti-PDL1 (programmed death-ligand 1) and
adoptive transfer of tumor-reactive T cells and natural killer cells, (b) maintenance with
HDACs and/or donor lymphocyte infusion (DLI), and (c) maintenance with lenalidomide and/
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The following represent the unresolved issues related to HSCT in MDS: (1) timing of the
transplant; standard conditioning for younger patients and RIC for older patient with comor‐
bidities, (2) disease status at transplant, (3) pre-HSCT therapy or pretransplant tumor debulk‐
ing with traditional chemotherapeutic agents or the novel DNA hypomethylating drugs, (4)
the intensity of the conditioning therapies, (5) stem cell source and alternative donors, (6)
optimal therapy for intermediate-risk MDS, and (7) the combination of HSCT with novel
therapies such as hypomethylating agents and immunomodulatory drugs [3, 79, 80, 84, 92].
As MDS patients are usually on the old side, QOL is a top priority for most patients, so
discussion regarding transplantation in older patients must include not only the acute effects
of transplantation but also the delayed effects [81]. Incorporation or integration of novel non-
HSCT therapeutic modalities in the overall management of MDS patients undergoing
allogeneic HSCT is needed [78].
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with low or very low-risk MDS should ideally be treated with supportive measures and low
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9. Prognosis in low-risk MDS
There are several poor prognostic factors in patients with MDS. The poor prognostic factors
in MDS in general are listed in Table 13 [47]. However, in low-risk disease, the following factors
have been found to correlate with poor prognosis: (1) severe anemia, (2) transfusion depend‐
ence, (3) poor performance status, (4) older age, (5) number and severity of medical comor‐
bidities, (6) leukocytosis, and (7) elevated level of serum LDH [4].
1. Old age
2. Poor performance status
3. Presence of comorbid medical conditions
4. WBC count > 20 × 109/L
5. Severe anemia
6. Severe or refractory thrombocytopenia; PLTs <30 × 109/L
7. Eosinophilia: > 350/microliter (μL) and basophilia: > 250/μL
8. Absolute lymphocytic count < 1200/mL
9. Reduced platelet mass
10. Transfusion dependence
11. Presence of bone marrow fibrosis
12. CD34 positivity of nucleated BM cells
13. RBC-MCV (mean corpuscular volume) < 100 FL
14. Increased expression of WT1 (Wilm's tumor gene)
15. Monsomy 5 or del (5q) associated with other chromosomal abnormalities
16. Specific genetic mutations: TP53/TET2/DNMT3A/FLT3/EZH2/ETV6/BCOR
17. Reduced circulating endothelial cells
18. Increased levels of: TNF-α, single-nucleotide polymorphism in TNF gene
19. Increased serum B2 microglobulin concentration
20. Downregulation of granulopoiesis regulator lymphoid enhancer-binding factor 1 (LEF1)
21. Abnormal localization of immature precursors (ALIP)
22. Increased DNA methylation
23. Failure of decitabine therapy
Table 13. Adverse prognostic factors in MDS.
In patients with del (5q), the following factors have been found to be independent predictors




10. Conclusions and future perspectives
MDSs including 5q-syndrome are often complicated by BM suppression reflected by cytope‐
nias, infectious complications, iron overload and transformation into AML. Management of
these disorders includes the following: (1) supportive care that comprises transfusion of blood
products, antimicrobials, growth factors, and iron chelation therapy; (2) targeted therapies,
such as lenalidomide, and (3) various forms of HSCT. The role of allogeneic HSCT in MDSs is
surging as the recently introduced conditioning therapies have allowed application of this
curative therapy to older patients and those with comorbid medical conditions. The recent
developments in the science of MDSs will allow more advanced targeted therapies to be
integrated into the therapeutic algorithms of these disorders.
The role of cereblon as a molecular target for lenalidomide and pomalidomide and that of
CK1α in mediating the effects of lenalidomide will ultimately translate into more refined
targeted therapies for patients with del (5q) MDS. Also, early incorporation of more pinpointed
targeting of clones harboring TP53 mutations and utilization of the translation enhancer, L-
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Abstract
Myelodysplastic  syndromes  (MDSs)  are  heterogeneous  hematopoietic  disorders
associated with various degrees of myelosuppression and transformation into acute
leukemia.  Chromosome  7  abnormalities  occur  at  any  age,  have  several  disease
associations,  and  are  generally  associated  with  poor  outcome.  Treatment  of  the
associated disease conditions may have a positive impact on the outcome of certain
types of MDSs. For patients eligible for hematopoietic stem cell transplantation (HSCT),
allografts are the standard of care, while supportive measures and the use of hypome‐
thylating  agents,  such  as  5-azacytidine  and  decitabine,  constitute  the  mainstay  of
management in individuals who are not fit for allogeneic HSCT. However, the use of
hypomethylating agents in conjunction with allogeneic HSCT using nonmyeloabla‐
tive conditioning therapies may be an appealing therapeutic option for older patients
with comorbid medical conditions.
Keywords: myelodysplastic syndrome, monosomy 7, 5-azacytidine, decitabine, hema‐
topoietic stem cell transplantation
1. Introduction
MDSs are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by
ineffective hematopoiesis, dysplastic changes in the peripheral blood and bone marrow (BM),
and a variable risk of progression into acute myeloid leukemia (AML) [1–4]. Primary MDS has
a bimodal age incidence. It is usually a disease of old age as more than 50% of patients are ≥70
years of age [5]. Primary MDS is less common in the pediatric population and it includes specific
pediatric syndromes such as juvenile chronic myeloid leukemia (JCML) and infantile monos‐
omy 7 syndrome [5].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
The clinical, pathologic, and cytogenetic features of primary MDS in younger patients appear
to be different from those in elderly individuals suggesting that this may represent a biologi‐
cally different disease [5]. In patients with MDS, with or without abnormal chromosomal
karyotype, the type and the quantity of the abnormal karyotype have clinical values in
predicting transformation to acute leukemia [6]. The use of granulocyte-monocyte colony
stimulating factor (GM-CSF) in congenital BM failure syndromes may induce or accelerate the
onset of leukemic transformation [7].
2. Pathogenetic mechanisms in MDSs
Several mechanisms are involved in the pathogenesis of MDSs and these include: (1) enhance‐
ment of a self-renewal of a hematopoietic stem cell or acquisition of self-renewal in a progenitor
cell, (2) enhancement of proliferative capacity in the disease-sustaining clone and/or in its more
differentiated progeny, (3) impairment or blockade of differentiation, (4) genetic or epigenetic
instability, (5) antiapoptotic mechanisms in the disease-sustaining cells, (6) evasion of the
immune system, and (7) suppression of normal hematopoiesis leading ultimately to BM failure
[8].
3. Epigenetics in MDSs
Epigenetics is the heritable alteration in gene expression without DNA sequence change. The
primary epigenetic modifiers are DNA methylation and histone modifications, both of which
are potentially reversible [9]. DNA methylation plays a major role in tissue- and stage-specific
gene regulation and it increases with age. Aberrant methylation of certain promoter regions
can occur in diseases particularly cancers and correlates with gene silencing [9]. Epigenetic
changes in the form of modification of the transcriptional capacity of the cell via processes such
as DNA methylation and histone deacetylation can also alter gene expression impacting
disease biology [10].
Advances in the science of epigenetics have led to better understanding of the specific
pathogenetic mechanisms underlying MDSs. DNA methylation provides a major epigenetic
code of lineage and development-specific genes that control expression of normal cells [8]. The
most relevant molecular mediators of the epigenetic state in MDS are gene expression patterns
maintained by methylation of cytosine residues in DNA and covalent modification of histones.
TET2 status may be a genetic predictor of response to azacytidine, independently of karyotype
and holds promise as one of the tools available to help in better selection of patients for
treatment [8].
Cancer is characterized by global DNA hypomethylation and regional promoter hyperme‐
thylation of genes [9, 10]. Promoter methylation of CDKN2B [encoding p15INK4b] has been
shown to be restricted to the malignant hematological disorders [9, 10]. Several tumor
suppressor genes (TSGs) are inactivated by promoter hypermethylation. Potentially reversible
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silencing of genes, such as CDKN2B, by promoter methylation has been shown to occur in
MDS and it increases with disease progression [9, 10].
1. Unknown etiology.





7. Vitamin deficiency: B12 and folate
8. Infections: - Human immunodeficiency virus - Epstein-barr virus




- Systemic lupus erythromatosis
10. Exposure to: - Solvents - Lead
- Benzene - Arsenic
- Herbicides - Hair dyes
- Pesticides - Agricultural chemicals
11. Cytotoxic chemotherapy: - Alkylating agents - Topoisomerase Π inhibitors
12. Radiotherapy
13. Bone marrow failure syndromes: - Aplastic anemia - Fanconi anemia
- Dyskeratosis congenita - Diamond Blackfan syndrome
- Paroxysmal nocturnal hemoglobinuria
- Congenital neutropenia (Kostmann's syndrome)
14. Genetic, familial and hereditary
disorders:
- Ataxia telangiectasia - Trisomy 8 mosaicism
- Xeroderma pigmentosa - Down syndrome
- Bloom's syndrome - Neurofibromatosis
15. Miscellaneous:
- Polycythemia rubra vera
- Familial myelodysplastic syndromes;
monosomy 7
- Germ cell tumors (embryonal dysgenesis)
- Mutagen detoxification [ GSTq1 - null ]
- Family history of hematopoietic cancer
Table 1. .Etiology, risk factors and epidemiological associations of myelodysplastic syndromes.
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4. Etiology and associations of MDSs
MDSs have several etiologies, risk factors, and epidemiological associations as shown in
Table 1 [11–43]. Also, several hereditary diseases predispose to familial forms of MDS/AML
as shown in Table 2 [11, 16, 18, 23, 25, 27, 44–48].
4.1. Familial MDSs
Familial MDSs are rare diseases. The most common form of familial MDSs is familial platelet
disorder, caused by heterozygous germline RUNX1 mutations, which has the propensity to
evolve into myeloid malignancy. Many patients lack history of bleeding or thrombocytopenia
[44, 46, 47]. Several cases of T-acute lymphoblastic leukemia (ALL) have been reported in
patients with inherited RUNX1 mutations [44]. Novel causative mechanisms such as RUNX1
deficiency result in constitutional microdeletions of 21q22 and myelodysplasia associated with
telomerase deficiency [44]. Treatment of familial MDS is allogeneic hematopoietic stem cell
transplantation (HSCT) but donors have to be screened for deficiency of RUNX1 and deficiency
of telomerase [44].
The following genetic mutations have been described in familial MDS/AML: TERC, TERT,
CEBPA, GATA2, and RUNX1 [16, 44, 46–48].
4.2. MonoMac syndrome
MonoMac syndrome is a familial disorder associated with GATA2 deficiency, inherited as
autosomal dominant and causes early onset of MDS/AML [47, 48]. Additional acquisitions
include: monosomy 7 and ASXL1 mutations. Genetic mutations are detected in dendritic cells,
monocytes, natural killer (NK) cells and B-lymphocytes. Many carriers are asymptomatic. The
syndrome is associated with severe infectious complications and familial predisposition to
cancer. Aggressive therapeutic strategies are needed as the disease has poor outcome [47, 48].
GATA2 mutations have also been described in familial MDS/AML and Emberger syndrome
[46–48].
5. Cytogenetic abnormalities in MDSs
Chromosomal abnormalities are detectable in 40–60% of patients with de novo MDS and
approximately 90% of patients with secondary therapy-related MDSs (t-MDSs) [1]. The most
frequent cytogenetic abnormalities are del(5q), monosomy 7, del(7q), trisomy 8, complex
karyotype, and -Y [1]. Chromosome 5 and 7 abnormalities are considered to be the most
frequent recurrent genetic abnormalities in myeloid malignancies (MDS and AML) as they
occur in 10–20% of myeloid neoplasms [49].
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Pure familial MDS Familial MDS/AML
1. Familial monosomy 7
2. Chromosome 21q22 deletions
3. Telomere deficiency-associated familial MDS
[occult dyskeratosis congenita]
4. Familial platelet disorder with propensity to myeloid
malignancy
- Bone marrow failure syndromes:
1. Diamond-Blackfan syndrome
2. Severe congenital neutropenia
3. Congenital amegakaryocytic thrombocytopenia
4. Dyskeratosis congenita
5. Schwachman-Diamond syndrome







- Numerical chromosomal abnormalities:
1. Trisomy 21
Abbreviations: MDS, myelodysplastic syndrome; AML, acute myeloid leukemia.
Table 2. Familial MDS/AML.
6. Chromosome 7 abnormalities
Abnormalities involving chromosome 7 occur in approximately 20% of patients with MDS
having clonal cytogenetic abnormalities. Abnormalities of chromosome 7 include: (1) total loss
of chromosome 7 [monosomy 7], (2) deletion of a segment of the long arm of chromosome 7
[del(7q)], and (3) translocations involving chromosome 7 [2]. However, these cytogenetic
anomalies have different prognostic significance [1, 2, 50, 51]. MDS with monosomy 7 has poor
prognosis, while isolated del (7q) has a better outcome compared to isolated monosomy 7 [2].
Del(7q) which has distinct clinical and pathological characteristics should no longer be
considered in the same prognostic category as monosomy 7 [2]. Also, the prognostic impact
of der(7) t(1,7) (q10 or p10) is less adverse once compared to monosomy 7 or del (7q) [1]. In a
series of 246 patients with myeloid disorders: monosomy 7 or -7 was the most frequent
chromosomal abnormality as it was reported in 51% of patients with secondary myeloid
disorders, del(7q) was found in 7% of cases, and partial monosomy was found in 8% of
secondary myeloid diseases, while in de novo myeloid disorders, monosomy 7 and del(7q) were
reported in only 10% of patients [52].
6.1. Disease associations
Chromosome 7 abnormalities are associated with: (1) de novo and t-MDS, (2) de novo and
therapy related AML (t-AML), (3) JCML, (4) juvenile myelomonocytic leukemia [JMML], (5)
familial monosomy 7, (6) primary myelofibrosis, (7) Down's syndrome, (8) Fanconi anemia,
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and (9) lymphoma [50, 51, 53]. Monosomy 7 is the commonest chromosomal abnormality in
all of the above conditions except in primary myelofibrosis, where del(7q) is the commonest
chromosome 7 anomaly [53]. In adults, chromosome 7 abnormalities are associated with: (1)
advanced age, (2) antecedent MDS, and (3) resistance to current therapies [54]. In patients with
MDS and AML, chromosome 7 abnormalities usually carry poor prognosis [54].
6.2. Genes on chromosome 7 and their detection
Genes that have been reported to have microdeletions involving chromosome 7q21.2-q21.3
include: SAMD9, SAMD9L, and HEPACAM2 [55]. The following acquired somatic deletions
have also been reported at chromosome 7q36.1: EZH2, CUL1, and TET2 [56, 57]. Examples of
additional genetic mutations that have been reported in monosomy 7 and del(7q) include:
ASXL1, RUNX1, CBL, ETV6, FAM40B, FAM115A, SEMA3A, LUC7L2, SSPO, NRCAM, GRM8,
HYAL4, RABL5, TRIM24, FISI, and CUX1 [51, 57, 58]. Chromosome 7 abnormalities can be
detected by conventional cytogenetics or interphase fluorescence in situ hybridization (FISH)
[59]. Interphase FISH is a very useful method in detecting -7/7q- in patients with MDS. Also,
it is more sensitive in detecting chromosome 7 abnormalities than conventional cytogenetics
[59]. Refined chromosomal analysis has emerged as a tool that has considerable impact on
decision making and development of treatment protocols in patients with MDS and AML [60].
6.3. The commonly deleted segments (CDSs)
Several studies on MDS and AML specimens with interstitial deletions on chromosome 7 have
implicated three putative CDSs at the following chromosome bands: 7q22, 7q34, and 7q35-36.
However, 7q22 is the most frequently deleted band in patients with MDS/AML having del(7q)
[3]. The following genes in monosomy 7/del(7q) MDS/AML have been reported to be inacti‐
vated or to harbor recurrent genetic mutations such as EZH2, LUC7L2, and CUX1 [3].
The CDS on the long arm of chromosome 7 between 7q22 and 7q36 has been identified to
harbor a number of haploinsufficient myeloid TSGs [49, 50, 54]. Loss of function of at least one
TSG contributes to disease progression and leukemogenesis or leukemic transformation [50,
54]. It is feasible to somatically delete a large chromosomal segment that is implicated in tumor
suppression in hematopoietic cell population in vitro [54]. The CDSs that occur at chromosomal
bands7q22, 7q34, and 7q35-q36 contain the following genes: TRIM24, SVOPL, ATP6V0A4,
TMEM213, KIAA1549, LUC7L2, KLRG2, CLEK2L, HIPK2, TBXAS1, ZC34AV1L, ZC3HAV1,
TTC26, UBN2, C7orf55, TPK1, CNTNAP2, MIR548F3, C7orf33, CUL1, and EZH2 [49].
Loss of TP53 is more frequently associated with del5q rather than del7q, while loss of ETV6 is
particularly associated with concurrent del(5q) and del(7q) [49]. CUX1, a gene encoding a
homeodomain-containing transcription factor, has been identified within the CDS on chro‐
mosome 7 (7q22.1) [61]. CUX1 is expressed at haploinsufficient levels in leukemias with
chromosome 7 abnormalities. Haploinsufficiency of CUX1 gave human hematopoietic cells a
significant engraftment advantage on transplantation in immunodeficient mice [61].
Monosomy 7 and del(7q) are highly recurrent chromosomal abnormalities in myeloid malig‐
nancies including: AML, de novo MDS, and t-MDS/AML [51, 54, 61]. Also, monosomy 7 and
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del(7q) are common findings in children and adults who develop MDS as a second malignant
neoplasm [27]. In t-MDS/AML with chromosome 7 abnormalities, the peak incidence is
between 3 and 7 years after cessation of cytotoxic chemotherapy such as alkylating agents [27].
Under such circumstances, monosomy 7 and del(7q) are not equivalent in prognosis and
spectrum of disease phenotype [51].
Monosomy 7 and del(7q) are highly prevalent in acquired cytogenetic abnormalities in de
novo MDS/AML and t-MDS/AML [3]. The proportion of -7/del (7q) cells is markedly increased
in hematopoietic stem cell (HSC) and progenitor cell compartments of MDS patients relative
to T and B lymphocytes [3]. Recent studies demonstrating quantitative changes in the fre‐
quencies of phenotypic primitive long-term HSCs, common myeloid progenitors, and
granulocyte-monocyte progenitors in MDS patients with -7/del(7q) further support the diverse
effects on hematopoiesis [3].
After many attempts, mice with 5A3 deletions in the CDS of chromosome band 7q22 have been
successfully generated [54]. The 5A3 deleted mice have shown normal hematologic parameters
but have not developed myeloid malignancies spontaneously [54]. Animal studies have also
shown that heterozygous 5A3 deletion does not accelerate the evolution of leukemia or
modulate the responsiveness to antileukemic drugs, while homozygous 5A3 deletions are
embryonically lethal [54].
The following 7q genes have been implicated in contributing to leukemogenesis by haploin‐
sufficiency or epigenetic transcriptional repression: SAMD9L, RASA4, dedicator of cytokinesis
4 (DOCK4), and MLL3 [3]. Animal studies have shown that the long-term HSC compartment
is expanded in 5A3+/del mice and that the 5A3 deletion partially rescues defective repopulation
in GATA2 mutant mice [3]. Studies have also shown that 7q22 deletions are implicated in
playing a strong haploinsufficiency role in leukemogenesis [3]. Mutations in DOCK4 gene
which is a putative 7q gene have been identified in prostate and ovarian cancers and studies
have demonstrated that DOCK4 gene acts as a tumor suppressor [62]. Depletion of DOCK4
levels in MDS stem and progenitor cells leads to erythroid dysplasia by disrupting the action
of cytoskeleton in developing red blood cells (RBCs) ultimately leading to dysplastic mor‐
phology of erythroid cells both in vivo and in vitro [62].
7. Monosomy 7 MDS
Monosomy 7 is characterized by (1) lower median age of affected patients than that of 5q-
syndrome, (2) severe refractory cytopenias, (3) rapid disease progression, (4) resistance to
therapy, and (5) increased susceptibility to infectious complications [52, 63]. Infections
encountered in monosomy 7 may be life-threatening and they include (1) bacterial infections:
these are the most common types of infections and may be complicated by sepsis, and (2)
invasive aspergillosis [63, 64]. Infectious complications in monosomy 7 are caused by neutro‐
penia, dysfunctional neutrophils, and chemotherapy or targeted therapy given to control the
disease [64].
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In patients having monosomy 7, isolated monosomy 7 occurs in 36% of the cases, monosomy
7 and one additional chromosomal abnormality are encountered in 14% of patients, and
monosomy 7 associated with complex cytogenetics in seen in approximately 50% of the cases
[63]. Monosomy 7 can be associated with the following chromosomal abnormalities: trisomy
8, chromosome 5 abnormalities, and t(1,7) [63]. Chromosomal microarray analysis is a clinically
useful tool in the diagnosis and follow-up of MDS patients with monosomy 7 [65]. In monos‐
omy 7, there is an association between DNA loss and functional impairment or defect of
granulocytes [66]. Monosomy 7 is not rare in acute lymphoblastic leukemia as it has been
reported in 3–6% of the cases of ALL and in 16% of Philadelphia chromosome positive ALL
as it occurs as a secondary anomaly to t(9,22) [52]. Monosomy 7 carries poor prognosis as
studies have shown that (1) relapse rate of monosomy 7 at 1 year to be 81%, and (2) event-free
survival at 7 years to be 6% [52]. Monosomy 7 does not usually affect lymphoid subpopulations
but it is restricted to committed progenitor cells with the capacity to differentiate into mature
myeloid cells [67].
Analysis of expression profiles in CD34+ cells from MDS patients with monosomy 7 has shown
a malignant phenotype with highly proliferative potential expressing HOX9A, PRAME,
BMI-1, PLAB, and BRCA2 (DNA repair gene) [63]. Gene therapy for chronic granulomatous
disease has been reported to cause activation of ectopic viral integration site 1 (EVI1) which in
turn induces development of genomic instability that ultimately results in clonal progression
toward myelodysplasia and monosomy 7 [68].
Conventional chemotherapy in monosomy 7 carries a high risk of early death and poor
response. Even if complete remissions are obtained, they are usually short-lived [63]. Targeted
therapies such as 5-azacytidine and lenalidomide are more effective than cytotoxic chemo‐
therapy in patients with monosomy 7 MDS. However, lenalidomide is more effective in
patients having monosomy 7 and 5q- syndrome. Complete hematological and even cytogenetic
responses have been documented in patients with monosomy 7 MDS treated with lenalido‐
mide [63].
In transplant-eligible patients, allogeneic HSCT is the treatment of choice in patients with
monosomy 7 [25, 63, 69]. Following allogeneic HSCT, presence of monosomy 7 is a predictor
of unfavorable outcome [52].
Masked monosomy 7 refers to monosomy 7 that is detected by FISH but not by conventional
cytogenetics. It has been reported in varying frequencies in patients with MDS [70]. Masked
monosomy 7 is less common than has been thought and does not seem to carry the same
prognostic weight as monosomy 7 diagnosed by metaphase cytogenetics [70].
7.1. Monosomy 7 in children
MDS is uncommon in children as it accounts for less than 5% of all hematopoietic neoplasms
[33, 71]. Viral infections including Epstein-Barr virus (EBV) may contribute to the pathogenesis
of MDS by stimulating a preexisting clone and may induce certain genetic mutations [33].
Chromosome 7 abnormalities, monosomy 7 and del (7q), are common cytogenetic abnormal‐
ities in MDS and they are found in 31% of children with myeloid neoplasms [22, 71]. They are
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characterized by ineffective erythropoiesis, BM dysplasia, and increased risk of leukemic
transformation [22]. Monosomy 7 is the most common chromosomal abnormality in children
with MDS [33, 71]. In children, monosomy 7 implies poor prognosis because it is associated
with high risk of transformation into acute leukemia including ALL [33, 71].
Treatment of children with MDS/AML associated with monosomy 7 with allogeneic HSCT,
using a variety of donor types such as sibling donor, unrelated donor, and umbilical cord
blood, as well as different sources such as BM and peripheral blood, is an effective therapeutic
modality [69]. In patients with more advanced disease, optimization of conditioning therapies
may further improve disease-free survival [69]. Graft versus leukemia effect appears to play
a major role in leukemia control for some patients and quality of life (QOL) in patients
surviving allogeneic HSCT is usually very good [69].
7.2. Familial monosomy 7 syndrome
Familial monosomy 7 syndrome is a rare familial disorder [44, 45]. It is inherited as autosomal
dominant with incomplete penetrance [45]. Familial monosomy 7 can be partial or complete
monosomy and it is associated with the following chromosomal abnormalities: trisomy 8, 5q-,
and t(1;7) [45]. It has even sex distribution and often presents before the age of 18 years and
the median age at diagnosis in 8 years [45]. Allogeneic HSCT in this category of MDS is
problematic due to familial predisposition to cancer, hence the prognosis is usually poor [44,
45]. Familial monosomy 7 has several associations including: (1) inherited BM failure syn‐
dromes, (2) secondary MDS/AML, (3) occupational exposure to chemical toxins, (4) exposure
to cytotoxic chemotherapy, particularly alkylating agents, (5) Noonan syndrome, (6) Fanconi
anemia, and (7) cerebellar ataxia [44, 45]. The cell origin or phenotype is multipotential
progenitor cell [45]. The clinical manifestations of familial monosomy 7 syndrome include
complications of cytopenias, dysplasia, and acute leukemic transformation in addition to
features of the associated disease conditions [44, 45].
7.3. JMML
JMML is a rare clonal MDS/myeloproliferative neoplasm (MPN) of young children [44, 45, 72,
73]. It has also been described as juvenile CML and was formerly grouped in the French-
American-British (FAB) classification of MDS [74]. Without treatment, the 10-year overall
survival (OS) of patients with JMML is 6% [74]. Allogeneic HSCT is the only curative therapy
for children with JMML [72, 74]. Studies have also shown that event-free survival is 52% at 5
years post-HSCT [72]. Also, relapse is expected to occur in 50% of transplanted patients [72,
73]. Treatment options of relapsed JMML after the first HSCT include: (1) withdrawal of
immunosuppressive therapy and/or donor lymphocyte infusion, and (2) second allogeneic
HSCT, which may be the treatment of choice in such situations [72]. The major causes of HSCT
failure in patients with JMML are treatment-related mortality and relapse [74].
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8. Anemia in MDS
Severe anemia should be considered a major criterion for deciding not only the type but also
the timing of therapeutic interventions in patients with MDS [75]. Once anemia is symptomatic,
transfusion of packed RBCs is the mainstay of therapy in MDS [76]. The redistribution of
transfusion iron from reticuloendothelial cells to parenchymal cells is modulated by hepcidin.
Ineffective erythropoiesis has a suppressive effect on hepcidin production and hence increases
iron redistribution [76].
9. Iron overload in high-risk MDS
Transfusion history should be considered in transplantation decision making in patients with
MDS because pre-HSCT transfusion history and serum ferritin levels have been shown to have
significant prognostic value in patients with MDS undergoing allogeneic HSCT [77]. Elevated
serum ferritin and elevated liver iron content in patients with MDS and acute leukemia prior
to HSCT are associated with inferior post-HSCT survival [78]. Studies have shown that
transfusion dependency is independently associated with (1) reduced overall survival, (2)
increased nonrelapse mortality (NRM), and (3) increased risk of acute graft versus host disease
(GVHD) in patients with MDS undergoing allogeneic HSCT [77].
In patients with high-risk MDS, iron overload has adverse consequences on the outcome of
HSCT as it has been associated with (1) increased transfusion-related mortality, (2) infectious
complications, and (3) AML progression [79]. Iron chelation therapy in patients with higher
risk MDS should be considered to possibly (1) reduce infectious complications, (2) delay
leukemic transformation, and (3) improve the outcome of HSCT [80].
Nuclear factor-kappaB (NF-kB) is key regulator of many cellular processes and its impaired
activity has been described in different myeloid malignancies including MDS [81]. NF-kB
inhibition by deferasirox could prove to be an important therapeutic option in higher risk MDS
patients by targeting blast cells in which increased NF-kB activity has been extensively
demonstrated thus acting as a possible enhancer of chemosensitivity of the malignant clone
[81].
10. Management of MDS
The following therapeutic modalities are available for patients with MDS: (1) supportive
measures: packed RBCs and platelet (PLT) transfusions, antimicrobial therapy, and hemato‐
poietic growth factors, (2) drug therapies including novel agents such as lenalidomide,
azacytidine, and decitabine, and (3) various forms of HSCT [82].
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azacytidine, and decitabine, and (3) various forms of HSCT [82].
Myelodysplastic Syndromes140
10.1. Epigenetic therapies of MDS
Epigenetic therapies cause potentially reversible epigenetic changes that can alter gene
expression patterns [83]. Epigenetic therapies in MDS include (1) histone deacetylase inhibi‐
tors, and (2) hypomethylating agents, such as azacytidine and decitabine, that inhibit the DNA
methyltransferase enzymes (DNMT) [83].
Epigenetic silencing is a universal mechanism of gene inactivation in malignant cells, probably
exceeding mutational events. Recent therapeutic approaches targeting the aberrant epigenome
of cancer has been developed [84]. The hypomethylating agents, azacytidine and decitabine,
have shown remarkable activity in older individuals with higher risk MDSs including patients
with poor-risk cytogenetic profiles. Translational studies performed on BM biopsies obtained
from MDS patients with both azanucleoside demethylating agents have indicated that both
azanucleosides can revert the aberrant hypermethylation state in vivo [84].
10.2. Hypomethylating agents
The azanucleosides, 5-azacytidine and decitabine, were originally synthesized more than 50
years ago in order to be used as classical cytotoxic agents [85–88]. Azacytidine was first
described by Sorm in 1964 as a cancerostatic agent [89]. Both hypomethylating agents, 5-
azacytidine and decitabine, had demonstrated activity against lymphoid leukemic cells as well
as hemopoietic tissues in experimental leukemia mice models [90–93].
10.2.1. 5-Azacytidine
Azacytidine is a pyrimidine nucleoside analog that differs from cytosine by the presence of
nitrogen, rather than ring carbon, at position 5 [8, 9]. It was first manufactured in Europe in
the 1960s [8, 9]. Azacytidine is a DNA methyltransferase inhibitor (DMTI) that has in vitro and
in vivo demethylating effects [9]. The hypomethylating effects of azacytidine appear to
primarily depend on the structural alternations at position 5 [8]. Azacytidine was the first
hypomethylating agent to be approved by the Food and Drug Administration (FDA) in United
States of America for the treatment of all subtypes of MDS in May 2009 [8, 10, 94]. In patients
with high-risk MDS, the benefits of azacytidine therapy on survival compared to conventional
chemotherapy have not been established outside clinical trials [95, 96]. Despite the wide spread
use of azacytidine in the treatment of high-risk MDSs, there is lack of improvement in long-
term survival. Therefore, identification of predicting factors of response and survival is
mandatory [95, 96].
Hypomethylating agents or azanucleosides are becoming the standard therapy for patients
with higher-risk MDSs [97]. Patients with high-risk MDSs treated with azanucleosides have a
median overall survival of 11–16 months, so they should be strongly considered for upfront
allogeneic HSCT or experimental therapies [97]. In patients with high-risk MDSs planned for
allogeneic HSCT, azacytidine treatment may be valuable in stabilizing the disease and
preventing relapse [98]. Additionally, pretransplant administration of azacytidine does not
adversely affect transplant outcome [98]. Preemptive azacytidine therapy has an acceptable
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safety profile and can substantially prevent or at least delay relapse in patients with MDS or
AML with minimal residual disease after allogeneic HSCT [99].
Name of trial CALG-B/8421 trial CALG-B/8921 trial
Phase Phase I Phase II
Azacytidine therapy IV administration
Initial dose: 75 mg/m2 continuous IV infusion over 7 days
every 28 daysdose escalated to 150 mg/m2
SC administration
100 mg/m2
Number of patients evaluated 43 68
Complete response 5 patients (12%) 8 patients (12%)
Partial response 11 patients (25%) 10 patients (15%)
Improvement 5 patients (12%) 18 patients (27%)
Total response 21 Patients (49%) 36 patients (53%)
Abbreviations: MDS, myelodysplastic syndrome; IV, intravenous; CALG-B, cancer and leukemia group B; SC,
subcutaneous.
Table 3. Phase I and phase II CALG-B clinical trials on azacytidine in MDS.
The outcome of patients with high-risk MDSs after failure of azacytidine treatment is generally
poor [100]. After failure of azacytidine treatment, the options are rather limited to (1) best
supportive care in patients unfit for allogeneic HSCT, and (2) allogeneic HSCT and investiga‐
tional agents in patients who are eligible for such therapies [100]. Mechanisms of action of 5-
azacytidine are multifactorial and they include (1) demethylation of several key genes, that is,
reduction of DNA methylation by inhibition of methyltransferase enzymes, (2) cytotoxic action
by inhibition of protein translation, and (3) enhancement of apoptosis [8–10]. In patients with
MDSs, 5-azacytodine is indicated in (1) high-risk MDSs, and (2) intermediate 2 risk MDSs [8,
10, 95, 97, 100–102]. The side effects of azacytidine therapy include myelosuppression (leuco‐
penia, anemia, and thrombocytopenia); gastrointestinal (GIT) upset (nausea, vomiting,
diarrhea, and constipation); injection site reactions and erythema; serum sickness-like illness;
abnormal liver function tests; fatigue; weakness; lethargy; anorexia; headache; arthralgias;
febrile neutropenia; cytomegalovirus infection; and pneumonia [9, 10, 99, 101, 103].
The effects of azacytidine in patients with MDSs include (1) prolongation of survival, (2)
improvement in QOL, and (3) delayed leukemic transformation [8, 10, 95, 101, 102]. Responses
to azacytidine according to karyotypes are as follows: (1) excellent responses are expected in
patients with normal cytogenetics, (2) durable remission and 80% response rate are expected
in patients having chromosome 7 abnormalities as the sole karyotypic abnormalities, and (3)
good early responses but early relapses in patients with trisomy 8 [9]. Predictors of positive
responses to DMTIs is include (1) doubling of PLT count, (2) mutated TET2, (3) mutated EZH2,
(4) Phosphoinositide-phospholipase C beta hypomethylation, and (5) low serum level of
micro-RNA-21 [96, 104, 105]. Predictors of poor response to DMTIs include (1) BM blasts >15%,
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(2) previous therapy, (3) transfusion dependency, (4) grade 3 marrow fibrosis, (5) mutated p53,
(6) abnormal karyotype of complex cytogenetics, (7) high serum level of micro-RNA-21, and
(8) increased cytidine deaminase expression of activity in males [96, 104, 106].
Trial AZA-001 trial CALG-B 9221 trial
Phase Phase III randomized controlled multicenter
international study
Phase III randomized controlled study




Number of patients 179 179 – 99 92 –
IPSS class
intermediate
2 and high risk
158 patients (89%) 155 patients (87%) – 20% 26% –
Median survival
(months)
24.5 months 15 months ≤0.0001 18 months 11 months 0.03
2 year overall
survival




Median time to AML
transformation
17.8 months 11.5 months ≤0.0001 21 months 13 months 0.007
Complete response 30 patients (17%) 14 patients (4%) 0.015 7% 0% 0.01
Partial response 21 patients (12%) 7 patients (4%) 0.0094 16% 0% <0.0001




0.33 37% 5% <0.0001
Overall response HI in 87 patients
(49%)
HI in 51 patients
(29%)
60% 5% -
Abbreviations: MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; IPSS, International Prognostic Scoring
System; CALG-B, cancer and leukemia group B; AZA, azacytidine HI: hematological improvement.
Table 4. Phase III randomized controlled clinical trials on azacytidine.
In patients with high-risk MDSs and AML, the combination of 5-azacytidine, valproic acid,
and all-trans retinoic acid (ATRA) are safe and they are active and associated with induc‐
tion of global DNA hypomethylation and histone acetylation [107, 108]. Lessons learned from
clinical experience with hypomethylating agents include (1) in the majority of treated
patients, the beneficial effects are only noted after approximately four cycles of therapy, (2)
the achievement of hematological improvement is sufficient to ensure prolonged OS, (3) in
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almost all patients, interruption of treatment induces relapse, (4) patients who relapse after
treatment or who are refractory to therapy have extremely limited survival, and (5) pa‐
tients with complex karyotype involving monosomy 7 or monosomy 5 have negligible
survival advantage from hypomethylating agents despite achievement of response [96].
Clinical phase I, II, and III trials on the use of azacytidine in patients with MDSs are shown
in Tables 3 and 4 [9, 10, 101, 103, 109]. Investigational agents that can be used in the treatment
of MDSs in case of failure of hypomethylating agents include (1) rigosertib, (2) sapacita‐
bine, (3) clofarabine, and (4) BCL2 inhibitors (proapoptotic drug therapy) including ABT-737
and ABT-199 [96, 110].
Conclusion that can be drawn from phase III trials on azacytidine include: (1) in CALG-B 9221
trial: compared to best supportive care (BSC), azacytidine therapy resulted in (a) significantly
higher response rates, (b) improved QOL, (c) improved survival, and (d) reduced risk of
leukemic transformation; and (2) in AZA-001 trial: compared to conventional therapy, that
Included BSC, low dose cytarabine ± intensive chemotherapy, azacytidine increased OS in
patients with high-risk MDS [101, 109]. In patients with chromosome 7 abnormalities [mon‐
osomy 7 and del(7q)], the median survival was 13.1 months in patients treated with azacytidine
compared to 4.6 months in patients who received conventional therapies [101].
10.2.2. Decitabine
Decitabine (5-aza-2-deoxycytidine) inhibits DNMT. It was approved by the FDA in the United
States for the treatment of MDS in the year 2006 [83, 111, 112]. It is postulated that initially the
drug and the DNMT enzymes become attached, then the outcome will be: (1) enzyme degra‐
dation resulting in low DNMT levels, and (2) ultimately achievement of hypomethylation [83].
Although decitabine antitumor activity is not fully understood, there are several possible
mechanisms of action that include (1) induction of hypomethylation or reversal of cancer-
associated hypermethylation effects, (2) reactivation of genes responsible for cellular differ‐
entiation, (3) stimulation or induction of immune responses, (4) induction of DNA damage
pathways or apoptotic response pathways, that is, induction of changes in the rates of
apoptosis, and (5) augmentation of stem cell renewal [83, 105]. Various doses, schedules, and
even routes of administration have been used: 10, 15, or 20 mg/m2 intravenously (IV) or
subcutaneously (SC) for 3–5 days, each cycle for at least four cycles that are given at 4- to 6-
week intervals [83, 111, 112].
Although it has been used in the treatment of all FAB subtypes of MDS, the specific indications
are as follows: (1) intermediate 1, intermediate 2, and high-risk MDS, (2) de novo and secondary
MDS, including t-MDS, (3) MDS transforming into AML, in individuals unfit for intensive
cytotoxic chemotherapy, as upfront therapy, (4) treatment of MDS refractory to lenalidomide,
(5) debulking treatment prior to HSCT in high-risk patients, and (6) patients with chronic
myelomonocytic leukemia (CMML) [83, 105, 111]. The adverse effects of decitabine therapy
include (1) myelosuppression leading to febrile neutropenia, sepsis, pneumonia, and fungal
infections, (2) gastrointestinal effects including nausea, vomiting, diarrhea, and mucositis, (3)
hair loss, skin rashes, fatigue, and bleeding, (4) renal failure, (5) cardiovascular complications
are uncommon, and (6) pleural effusions and acute lung injury [83, 112, 113]. Encountering
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myelosuppression that requires decitabine dose modification may truly indicate response to
therapy [112].
Despite the efficacy of dectiabine therapy, there are no known definitive predictors of response.
However, in patients with high-risk MDS treated with decitabine, high expression of human
equilibrative nucleoside transporter-1 (hENT-1) gene appears to predict a good response to
decitabine therapy and is associated with prolonged survival [114]. Patients with chromosome
7 abnormalities usually respond more favorably to continuous IV infusion of low-dose
decitabine than to conventional chemotherapy with low-dose cytarabine [115]. Results of
clinical trials on decitabine are shown in Table 5 [83, 84, 111, 113]. Unfortunately, there is no
head-to-head comparison with 5-azacytidine. Also, decitabine has not shown a statistically
significant evidence of prolonged survival benefit in prospective studies. In addition, the role
of decitabine after HSCT needs further evaluation [83].
10.2.3. Rigosertib (ON01910.Na)
Rigosertib is a multikinase inhibitor that inhibits both the phosphoinositide 3 kinase and the
polo-like kinase pathways [116–120]. It inhibits the cell-cycle progression by selectively
inducing a mitotic arrest and apoptosis in cancer cells [116, 118–120]. Recently, it has been
highlighted as a novel anticancer agent for the treatment of MDS. Rigosertib has shown activity
in the following malignancies: (1) mantle cell lymphoma, (2) chronic lymphocytic leukemia,
and (3) MDS [118]. In MDS, rigosertib has several mechanisms of action that include: (a)
upregulation of genes related to microtubule kinetics, (b) downregulation of the mRNA
degradation system, that is, suppression of nonsense mRNA decay (NMD) gene, (c) suppres‐
sion of cyclin-D1 in BM CD34+ cells in MDS patients with trisomy 8 and monosomy 7, and (d)
induction of cell death by inhibition of PI3kinase/Akt pathway and DNA damage-induced G2/
M arrest, that is, induction of mitotic arrest and apoptosis in myeloblasts while sparing normal
cells [118–120].
Rigosetib has shown efficacy in all morphologic, prognostic risk and cytogenetic subgroups
of MDS and has produced complete responses in some patients [121]. It has shown activity in
high-risk MDS patients and in those having monosomy 7 and trisomy 8. It has produced the
following beneficial effects: (1) decrease in BM blasts, (2) improvement in hematopoiesis, (3)
inhibition of cyclin D1 accumulation, and (4) decrease in trisomy 8 and monosomy 7 aneu‐
ploidy [116, 119, 121]. However, a randomized controlled, phase 3, clinical trial that had been
performed in 74 institutions in Europe and the United States on the use of rigosertib in patients
with high-risk MDS after failure of hypomethylating agents did not show significant OS
compared to best supportive care [117]. The drug is available in oral and injectable formula‐
tions [120, 121]. Although rigosertib has exhibited a favorable safety profile, the following
adverse effects have been reported: syncope, fatigue, nausea, vomiting, abdominal pain,
hypotension, anemia, thrombocytopenia, neutropenia, febrile neuropenia, pneumonia,
dysuria, and hematuria [116, 117, 120].
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Abbreviations: MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; OR, overall response; CR, complete
response; PR, partial response; HI, hematological improvement; BSC, best supportive care; vs., versus; 20, secondary;
OS, overall survival.
Table 5. Decitabine trials in MDS patients.
11. The role of HSCT in high-risk MDSs including monosomy 7
11.1. HSCT in adults with MDSs
Allogeneic HSCT is the only potentially curative therapy for MDS patients [4, 82, 122–124].
Recently, HSCT is being used with increasing frequency in patients with MDS, partly due to
the development of novel conditioning therapies, such as nonmyeloablative conditioning, that
allow HSCT to be offered to older patients [4, 122]. Also, the use of immunomodulatory drugs
and hypomethylating agents prior to HSCT has shown efficacy in (1) controlling disease, that
is, a bridging approach to HSCT, and (2) tumor debulking before HSCT [4, 122]. The indications
of allogeneic HSCT in adults with MDS are shown in Table 6 [4, 82, 122–125].
MDS patients with monosomy 7 or complex cytogenetics and preserved BM are considered
indications for immediate rather than delayed HSCT. Secondary MDS is another special
indication for HSCT [82, 125]. Currently, patients with therapy-related MDS (t-MDS) are being
treated using the same paradigm as in de novo MDS [82]. Despite its curative potential, the role
of allogeneic HSCT in the treatment of elderly patients with MDS is less well defined than in
younger individuals [4]. The following issues related to HSCT remain an area of intense
investigations: (1) pretransplant disease burden, (2) optimal conditioning therapies, (3)
optimal donor selection, (4) optimal stem cell source, (5) GVHD prophylaxis, and (6) post‐
transplant relapse [122]. The following complications of allogeneic HSCT: GVHD, infections,
and non-relapse mortality may offset the benefits of allogeneic HSCT over medical therapies
[82]. Despite the remarkable improvement in both efficacy and safety of HSCT over the past
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two decades, therapy-related morbidity and mortality as well as disease relapse still pose
significant risks to transplanted patients [82, 122, 123]. Methods employed to prevent and treat
relapse of MDS following HSCT include (1) donor lymphocyte infusion (DLI), (2) hypome‐
thylating agents, (3) novel cellular therapies including vaccination, and (4) use of alloreactive
natural killer cells [4, 122].
In children In adults
1- Refractory anemia with excess of blasts
(RAEB)
2- Refractory anemia with excess of blasts in
transformation (RAEB-t)
3- Chemotherapy or radiotherapy related MDS
(t-MDS)
4- Juvenile myelomonocytic leukemia




1- Intermediate 2 IPSS
2- High-risk IPSS
(B) Probable indications:
1- t-MDS or secondary MDS
2- Packed Red blood cell transfusions refractory to:
- Hematopoietic growth factors
- Immunomodulatory drugs
- Hypomethylating agents
3- Severe neutropenia or thrombocytopenia
4- At least one line of cytopenia with multilineage dysplasia
5- High risk chromosomal abnormalities: monosomy 7 and complex
cytogenetics
6- High percentage of blasts [≥10%]
Abbreviations: MDS, myelodysplastic syndrome; t-MDS, therapy-related myelodysplastic syndrome; RAEB, refractory
anemia with excess of blasts; RAEB-t, refractory anemia with excess of blasts in transformation; SCT, hematopoietic
stem cell transplantation.
Table 6. Indications for allogeneic HSCT in patients with MDS.
Predictors of outcome of allogeneic HSCT in MDS patients include: (1) disease stage including
blast count, (2) transfusion dependence, and (3) karyotype, cytogenetic abnormalities and
molecular aberrations or genetic mutations such as: monosomal karyotype, complex cytoge‐
netic and TP53 mutation [82, 122, 125].
11.2. HSCT in children with MDSs
Allogeneic HSCT is the only potentially curative therapy for children with MDSs, particularly
those having JMML [73, 126]. The indications of allogeneic HSCT in children with MDSs are
shown in Table 6 [73, 126–128]. Relapse rate following allogeneic HSCT performed for JMML
may reach 50% or more [73]. Children with MDS and JMML should be referred for allogeneic
HSCT soon after making the diagnosis in order to prevent disease progression as pretransplant
chemotherapy does not appear to improve outcome [127, 128]. Predictors of poor outcome of
allogeneic HSCT in children with MDS include (1) monosomy 7, (2) age more than 4 years at
transplant, (3) relapse after HSCT, (4) female gender, and (5) human leukocyte antigen (HLA)-
mismatched allografts [73].
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11.3. HSCT in higher risk MDS patients
Patients with higher risk MDS who have an HLA-matched donor should be transplanted early
before progression of their disease or acquisition of a nonhematological contraindication to
HSCT [129]. In patients with intermediate-2 or high-risk MDS, aged 60–79 years, subjected to
reduced intensity conditioning allogeneic HSCT, life expectancy is about 36 months compared
to 28 months in patients not subjected to HSCT, that is, HSCT in this group of patients has a
survival advantage [130]. Patients with higher risk MDS should be treated with either
hypomethylating agents or HSCT [131]. It is justified to offer patients with higher risk MDS
who have an HLA identical donor an allograft [129]. Retrospective studies have concluded
that patients with higher risk MDS have a survival advantage over demethylating agents if
they can be offered an early allogeneic HSCT [129]. Transplant-related mortality remains high
in HSCT, it ranges between 10% and 40% particularly after myeloablative conditioning therapy
in elderly individuals [129]. Long-term survival ranges between 30% and 60% depending on
patient characteristics, disease risk, type of donor, source of stem cells, and complications that
evolve following HSCT [129].
12. Conclusions and future directions
In children and adults, high-risk MDSs including monosomy 7 are often complicated by
various degrees of BM suppression, infectious complications, severe iron overload, and
transformation into AML. Management of these disorders includes (1) supportive care that
comprises transfusion of blood products, antimicrobials, and iron chelation therapy, (2)
epigenetic therapies including histone deacetylase inhibitors and hypomethylating agents
such as azacytidine and decitabine, and (3) various types of allogeneic HSCT. Recently, the
role of allogeneic HSCT in high-risk MDSs is increasing due to the introduction of the new
conditioning therapies that have allowed the application of this curative modality of therapy
not only to older patients, but also to individuals with medical comorbidities. However, in
patients with familial causes of their MDSs of BM failure planned for allogeneic HSCT using
a sibling donor, great caution should be exercised and enough investigations should be
performed before clearing the sibling for donation. The role of certain growth factors in the
management of patients with high-risk MDS is controversial as G-CSF has been reported to
accelerate the progression into acute leukemia.
The recent developments in the diagnostics of MDSs and the recently introduced therapeutic
agents such as rigosertib, clofarabine, sapacitabine, and BCL2 inhibitors as well as the evolving
modalities of HSCT are likely to improve the outcome of patients with higher risk MDSs
significantly.





Address all correspondence to: kaa_alanazi@yahoo.com
Department of Adult Hematology and Hematopoietic Stem Cell Transplantation, Oncology
Center, King Fahad Specialist Hospital, Dammam, Saudi Arabia
References
[1] Bacher U, Schanz J, Braulke F, Haase D. Rare cytogenetic abnormalities in myelodys‐
plastic syndromes. Mediterr J Hematol Infect Dis 2015; 7 (1): e2015034. doi: 10.4084/
MJHID.2015.034. eCollection 2015.
[2] Cordoba I, González-Porras JR, Nomdedeu B, Luño E, de Paz R, Such E, et al. Spanish
Myelodysplastic Syndrome Registry. Better prognosis for patients with del(7q) than for
patients with monosomy 7 in myelodysplastic syndrome. Cancer 2012; 118 (1): 127–
133. doi: 10.1002/cncr.26279. Epub 2011 Jun 29.
[3] Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, et al.
Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodys‐
plastic syndrome pathogenesis. eLife 2015; 4: e07839. doi: 10.7554/eLife.07839
[4] Kröger N. Allogeneic stem cell transplantation for elderly patients with myelodysplas‐
tic syndrome. Blood 2012; 119 (24): 5632–5639. doi: 10.1182/blood-2011-12-380162. Epub
2012 Apr 13.
[5] Chang KL, O'Donnell MR, Slovak ML, Dagis AC, Arber DA, Niland JC, et al. Primary
myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52
patients. Leukemia 2002; 16 (4): 623–631. doi: 10.1038/sj.leu.2402392
[6] Li Y, Li WW, Wang XM, An L, Liu H, Wang ZS, et al. The relevance between quantitative
and type of chromosomal abnormality and leukemia transformation in myelodysplas‐
tic syndrome. Zhonghua Xue Ye Xue Za Zhi 2013; 34 (3): 221–224. doi: 10.3760/
cma.j.issn.0253-2727. 2013. 03.009.
[7] Weinblatt ME, Scimeca P, James-Herry A, Sahdev I, Kochen J. Transformation of
congenital neutropenia into monosomy 7 and acute nonlymphoblastic leukemia in a
child treated with granulocyte colony-stimulating factor. J Pediatr 1995; 126 (2): 263–
265.
[8] Khan C, Pathe N, Fazal S, Lister J, Rossetti JM. Azacitidine in the management of





Address all correspondence to: kaa_alanazi@yahoo.com
Department of Adult Hematology and Hematopoietic Stem Cell Transplantation, Oncology
Center, King Fahad Specialist Hospital, Dammam, Saudi Arabia
References
[1] Bacher U, Schanz J, Braulke F, Haase D. Rare cytogenetic abnormalities in myelodys‐
plastic syndromes. Mediterr J Hematol Infect Dis 2015; 7 (1): e2015034. doi: 10.4084/
MJHID.2015.034. eCollection 2015.
[2] Cordoba I, González-Porras JR, Nomdedeu B, Luño E, de Paz R, Such E, et al. Spanish
Myelodysplastic Syndrome Registry. Better prognosis for patients with del(7q) than for
patients with monosomy 7 in myelodysplastic syndrome. Cancer 2012; 118 (1): 127–
133. doi: 10.1002/cncr.26279. Epub 2011 Jun 29.
[3] Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, et al.
Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodys‐
plastic syndrome pathogenesis. eLife 2015; 4: e07839. doi: 10.7554/eLife.07839
[4] Kröger N. Allogeneic stem cell transplantation for elderly patients with myelodysplas‐
tic syndrome. Blood 2012; 119 (24): 5632–5639. doi: 10.1182/blood-2011-12-380162. Epub
2012 Apr 13.
[5] Chang KL, O'Donnell MR, Slovak ML, Dagis AC, Arber DA, Niland JC, et al. Primary
myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52
patients. Leukemia 2002; 16 (4): 623–631. doi: 10.1038/sj.leu.2402392
[6] Li Y, Li WW, Wang XM, An L, Liu H, Wang ZS, et al. The relevance between quantitative
and type of chromosomal abnormality and leukemia transformation in myelodysplas‐
tic syndrome. Zhonghua Xue Ye Xue Za Zhi 2013; 34 (3): 221–224. doi: 10.3760/
cma.j.issn.0253-2727. 2013. 03.009.
[7] Weinblatt ME, Scimeca P, James-Herry A, Sahdev I, Kochen J. Transformation of
congenital neutropenia into monosomy 7 and acute nonlymphoblastic leukemia in a
child treated with granulocyte colony-stimulating factor. J Pediatr 1995; 126 (2): 263–
265.
[8] Khan C, Pathe N, Fazal S, Lister J, Rossetti JM. Azacitidine in the management of
patients with myelodysplastic syndromes. Ther Adv Hematol 2012; 3 (6): 355–373. doi:
10.1177/2040620712464882.
Myelodysplastic Syndromes150
[9] Raj K, Mufti GJ. Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes.
Ther Clin Risk Manag 2006; 2 (4): 377–388.
[10] McCormack SE, Warlick ED. Epigenetic approaches in the treatment of myelodysplas‐
tic syndromes: clinical utility of azacitidine. Onco Targets Ther 2010; 3: 157–165.
[11] Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872–
1885. doi: 10.1056/NEJMra0902908
[12] Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic
syndromes: a case-control study. Leukemia 2005; 19 (11): 1912–1918. doi: 10.1038/sj.leu.
2403945
[13] Pagano L, Caira M, Fianchi L, Leone G. Environmental risk factors for MDS/AML.
Haematologica Rep 2006; 2 (15): 42–45.
[14] Lv L, Lin G, Gao X, Wu C, Dai J, Yang Y, et al. Case–control study of risk factors of
myelodysplastic syndromes according to World Health Organization classification in
a Chinese population. Am J Hematol 2011; 86 (2): 163–169. doi: 10.1002/ajh.21941
[15] Jin J, Yu M, Hu C, Ye L, Xie L, Chen F, et al. Alcohol consumption and risk of myelo‐
dysplastic syndromes: a meta-analysis of epidemiological studies. Mol Clin Oncol 2014;
2 (6): 1115–1120. Epub 2014 Aug 7. doi: 10.3892/mco.2014.376
[16] Aster JC, Stone RM. Clinical manifestations and diagnosis of the myelodysplastic
syndromes. Topic 4492, version 33.0 Edited by Larson RA, Connor RF. UpToDate 2016.
Topic last updated: Dec 1, 2015.
[17] Invernizzi R, Filocco A. Myelodysplastic syndrome: classification and prognostic
systems. Oncol Rev 2010; 4 (1): 25–33. doi: 10.1007/s12156-009-0033-4
[18] Shekhter-Levin S, Penchansky L, Wollman MR, Sherer ME, Wald N, Gollin SM. An
abnormal clone with monosomy 7 and trisomy 21 in the bone marrow of a child with
congenital agranulocytosis (Kostmann disease) treated with granulocyte colony-
stimulating factor. Evolution towards myelodysplastic syndrome and acute basophilic
leukemia. Cancer Genet Cytogenet 1995; 84 (2): 99–104.
[19] Bakanay SM, Topcuoglu P, Bilgin AU, Yararbas K, Karauzum SB, Ozcan M, et al. Clonal
evolution of monosomy 7 in acquired severe aplastic anemia: two cases treated with
allogeneic hematopoietic stem cell transplantation. Turk J Hematol 2008; 25: 94–97.
[20] Tsuzuki M, Okamoto M, Yamaguchi T, Ino T, Ezaki K, Hirano M. Myelodysplastic
syndrome with monosomy 7 following combination therapy with granulocyte colony-
stimulating factor, cyclosporin A and danazole in an adult patient with severe aplastic
anemia. Rinsho Ketsueki 1997; 38 (9): 745–751.
[21] Nishimura M, Yamada T, Andoh T, Tao T, Emoto M, Ohji T, et al. Granulocyte colony-
stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient
Myelodysplastic Disorders, Monosomy 7
http://dx.doi.org/10.5772/64549
151
with severe aplastic anemia after ATG/CsA/G-CSF combined therapy. Int J Hematol
1998; 68 (2): 203–211.
[22] McDonald S, Wilson DB, Pumbo E, Kulkarni S, Mason PJ, Else T, et al. Acquired
monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of
dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer 2010; 54 (1): 154–
157. doi: 10.1002/pbc.22283.
[23] Dror Y, Squire J, Durie P, Freedman MH. Malignant myeloid transformation with
isochromosome 7q in Shwachman-Diamond syndrome. Leukemia 1998; 12 (10): 1591–
1595.
[24] Mellink CH, Alders M, van der Lelie H, Hennekam RH, Kuijpers TW. SBDS mutations
and isochromosome 7q in a patient with Shwachman-Diamond syndrome: no predis‐
position to malignant transformation? Cancer Genet Cytogenet 2004; 154 (2): 144–149.
[25] Cunningham J, Sales M, Pearce A, Howard J, Stallings R, Telford N, et al. Does
isochromosome 7q mandate bone marrow transplant in children with Shwachman-
Diamond syndrome? Br J Haematol 2002; 119 (4): 1062–1069.
[26] Nifosì G, Sbolli G, Ferrari B, Berte' R, Vallisa D, Civardi G, et al. Sweet's syndrome
associated with monosomy 7 myelodysplastic syndrome. Eur J Intern Med 2001; 12 (4):
380–383. doi: http://dx.doi.org/10.1016/S0953-6205(01)00137-6
[27] Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, et al.
Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in
children with neurofibromatosis type 1. Cancer 1997; 79 (7): 1438–1446.
[28] Karimata K, Masuko M, Ushiki T, Kozakai T, Shibasaki Y, Yano T, et al. Myelodysplastic
syndrome with Ph negative monosomy 7 chromosome following transient bone
marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Internal
Med 2011; 50 (5): 481–485. doi: 10.2169/internalmedicine.50.4481
[29] [29] Marques-Salles TJ, Soares-Ventura EM, de Oliveira NL, Silva M, Assis R, de Morais
VLL, et al. Myeloproliferative syndrome of monosomy 7: a brief report. Gene Mol Biol
2008; 31, 1, 36–38.
[30] Endo M, Sekikawa A, Tsumura T, Maruo T, Osaki Y. A case of myelodysplastic
syndrome with intestinal Behçet's disease-like symptoms treated by prednisolone and
azacitidine. Am J Case Rep. 2015; 16: 827–831. doi: 10.12659/AJCR.895431
[31] Özbek N, Yazal Erdem A, Arman Bilir Ö, Karaca Kara F, Yüksek M, Yaralı N, et al. A
child with psoriasis, hypogammaglobulinemia and monosomy 7-positive myelodys‐
plastic syndrome. Turk J Haematol 2015; 32 (1): 87–88. doi: 10.4274/tjh.2014.0308.
[32] Neas K, Peters G, Jackson J, Tembe M, Wu ZH, Brohede J, et al. Chromosome 7
aberrations in a young girl with myelodysplasia and hepatoblastoma: an unusual
association. Clin Dysmorphol 2006; 15 (1): 1–8.
Myelodysplastic Syndromes152
with severe aplastic anemia after ATG/CsA/G-CSF combined therapy. Int J Hematol
1998; 68 (2): 203–211.
[22] McDonald S, Wilson DB, Pumbo E, Kulkarni S, Mason PJ, Else T, et al. Acquired
monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of
dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer 2010; 54 (1): 154–
157. doi: 10.1002/pbc.22283.
[23] Dror Y, Squire J, Durie P, Freedman MH. Malignant myeloid transformation with
isochromosome 7q in Shwachman-Diamond syndrome. Leukemia 1998; 12 (10): 1591–
1595.
[24] Mellink CH, Alders M, van der Lelie H, Hennekam RH, Kuijpers TW. SBDS mutations
and isochromosome 7q in a patient with Shwachman-Diamond syndrome: no predis‐
position to malignant transformation? Cancer Genet Cytogenet 2004; 154 (2): 144–149.
[25] Cunningham J, Sales M, Pearce A, Howard J, Stallings R, Telford N, et al. Does
isochromosome 7q mandate bone marrow transplant in children with Shwachman-
Diamond syndrome? Br J Haematol 2002; 119 (4): 1062–1069.
[26] Nifosì G, Sbolli G, Ferrari B, Berte' R, Vallisa D, Civardi G, et al. Sweet's syndrome
associated with monosomy 7 myelodysplastic syndrome. Eur J Intern Med 2001; 12 (4):
380–383. doi: http://dx.doi.org/10.1016/S0953-6205(01)00137-6
[27] Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, et al.
Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in
children with neurofibromatosis type 1. Cancer 1997; 79 (7): 1438–1446.
[28] Karimata K, Masuko M, Ushiki T, Kozakai T, Shibasaki Y, Yano T, et al. Myelodysplastic
syndrome with Ph negative monosomy 7 chromosome following transient bone
marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Internal
Med 2011; 50 (5): 481–485. doi: 10.2169/internalmedicine.50.4481
[29] [29] Marques-Salles TJ, Soares-Ventura EM, de Oliveira NL, Silva M, Assis R, de Morais
VLL, et al. Myeloproliferative syndrome of monosomy 7: a brief report. Gene Mol Biol
2008; 31, 1, 36–38.
[30] Endo M, Sekikawa A, Tsumura T, Maruo T, Osaki Y. A case of myelodysplastic
syndrome with intestinal Behçet's disease-like symptoms treated by prednisolone and
azacitidine. Am J Case Rep. 2015; 16: 827–831. doi: 10.12659/AJCR.895431
[31] Özbek N, Yazal Erdem A, Arman Bilir Ö, Karaca Kara F, Yüksek M, Yaralı N, et al. A
child with psoriasis, hypogammaglobulinemia and monosomy 7-positive myelodys‐
plastic syndrome. Turk J Haematol 2015; 32 (1): 87–88. doi: 10.4274/tjh.2014.0308.
[32] Neas K, Peters G, Jackson J, Tembe M, Wu ZH, Brohede J, et al. Chromosome 7
aberrations in a young girl with myelodysplasia and hepatoblastoma: an unusual
association. Clin Dysmorphol 2006; 15 (1): 1–8.
Myelodysplastic Syndromes152
[33] Manor E, Shemer-Avni Y, Boriakovski S, Kafka M, Bodner L, Kapelushnik J. Myelo‐
dysplastic syndrome (MDS) associated with EBV infection in a pediatric patient. Open
J Pediatr 2013; 3 (1): 28–34. doi: http://dx.doi.org/10.4236/ojped.2013.31006
[34] Maserati E, Minelli A, Olivieri C, Bonvini L, Marchi A, Bozzola M, et al. Isochromosome
(7) (q10) in Shwachman syndrome without MDS/AML and role of chromosome 7
anomalies in myeloproliferative disorders. Cancer Genet Cytogenet 2000; 121 (2): 167–
171.
[35] Kalra R, Dale D, Freedman M, Bonilla MA, Weinblatt M, Ganser A, et al. Monosomy 7
and activating RAS mutations accompany malignant transformation in patients with
congenital neutropenia. Blood 1995; 86 (12): 4579–4586.
[36] Hu J, Shekhter-Levin S, Shaw PH, Bay C, Kochmar S, Surti U. A case of myelodysplastic
syndrome with acquired monosomy 7 in a child with a constitutional t(1;19) and a
mosaicism for trisomy 21. Cancer Genet Cytogenet 2005; 156 (1): 62–67.
[37] Williamson BT, Leitch HA. Higher risk myelodysplastic syndromes in patients with
well-controlled HIV infection: clinical features, treatment, and outcome. Case Rep
Hematol 2016; 2016: 8502641. doi: 10.1155/2016/8502641. Epub 2016 Jan 20.
[38] Arathi CA, Puttaraj KR, Shobha SN. An association between hypoplastic myelodys‐
plastic syndrome and T-prolymphocytic leukaemia. J Lab Physicians 2011; 3(1): 49–51.
doi: 10.4103/0974-2727.78568.
[39] Al-Anazi KA, Al-Jasser AM. Brucella bacteremia in patients with acute leukemia: a case
series. J Med Case Rep 2007; 1: 144. doi: 10.1186/1752-1947-1-144
[40] Li JJ, Sheng ZK, Tu S, Bi S, Shen XM, Sheng JF. Acute brucellosis with myelodysplastic
syndrome presenting as pancytopenia and fever of unknown origin. Med Princ Pract
2012; 21 (2): 183–185. doi: 10.1159/000333698. Epub 2011 Dec 1.
[41] Shaharir SS, Tumian NR, Yu Lin AB, Abdul Wahid SF. Disseminated tuberculosis
masquerading primary myelodysplastic syndrome. J Infect Dev Ctries 2013; 7 (3): 286–
288. doi: 10.3855/jidc.2691.
[42] Neonakis IK, Alexandrakis MG, Gitti Z, Tsirakis G, Krambovitis E, Spandidos DA.
Miliary tuberculosis with no pulmonary involvement in myelodysplastic syndromes:
a curable, yet rarely diagnosed, disease: case report and review of the literature. Ann
Clin Microbiol Antimicrob 2008; 7: 8. doi: 10.1186/1476-0711-7-8.
[43] Sultana T, Chowdhury AA, Yunus ABM, Ahmed ANN. Myelodysplastic syndrome
with tuberculosis which developed to AML—a case report. Bangladesh J Pathol 2009;
24 (1): 25–27.
[44] Liew E, Owen C. Familial myelodysplastic syndromes: a review of the literature.
Haematologica 2011; 96 (10): 1536–1542. doi: 10.3324/haematol.2011.043422. Epub 2011
May 23.
Myelodysplastic Disorders, Monosomy 7
http://dx.doi.org/10.5772/64549
153
[45] Hess JL. Familial monosomy 7 syndrome. Atlas Genet Cytogenet Oncol Hematol. 2001;
5(3): 220–221. doi: 10.4267/2024/37769.
[46] West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia
syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 2014;
1310: 111–118. doi: 10.1111/nyas.12346. Epub 2014 Jan 27.
[47] Bödör C, Renneville A, Smith M, Charazac A, Iqbal S, Etancelin P, et al. Germ-line
GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired
monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.
Haematologica 2012; 97 (6): 890–894. doi: 10.3324/haematol.2011.054361. Epub 2012 Jan
22.
[48] Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, et al.
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and
acute myeloid leukemia. Nat Genet 2011; 43 (10): 1012–1017. doi: 10.1038/ng.913.
[49] Zhang R, Kim YM, Wang X, Li Y, Lu X, Sternenberger AR, et al. Genomic copy number
variations in the myelodysplastic syndrome and acute myeloid leukemia patients with
del(5q) and/or -7/del(7q). Int J Mol Sci 2015; 12 (9): 719–726. doi: 10.7150/ijms.12612
[50] Abdelrazik HN, Farawila HM, Sherif MA, AlAnsary M. Molecular characterization of
chromosome 7 in AML and MDs patients. Afr J Health Sci 2006; 13: 33–42.
[51] Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychondzen B, et al.
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic
pathogenesis. Blood 2012; 119: 6109–6117. doi: 10.1182/blood-2011-12-397620
[52] Desangles F. -7/del(7q) in adults. Atlas Genet Cytogenet Oncol Hematol 1999; 3 (3):
139–140. doi: 10.4267/2042/37535
[53] Hussain FTN, Nguyen EP, Raza S, Knudson R, Pardanani A, Hanson CA, et al. Sole
abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic
correlates and prognostic implications. Am J Hematol 2012; 87: 684–686. doi: 10.1002/
ajh.23230
[54] Wong JC, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, et al. Use of chro‐
mosome engineering to model a segmental deletion of chromosome band 7q22 found
in myeloid malignancies. Blood 2010; 115 (22): 4524–4532. doi: 10.1182/
blood-2009-07-232504. Epub 2010 Mar 16.
[55] Asou H, Matsu H, Ozaki Y, Nagamachi A, Nakamura M, Aki D, et al. Identification of
a common microdeletion cluster in7q21.3 subband among patients with myeloid
leukemia and myelodysplastic syndrome. Biochem Biophys Res Commun 2009; 383:
245–251. doi: 10.1016/j.bbrc.2009.04.004. Epub 2009 Apr 7.
[56] Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, Tonnissen ERLTM,
et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic
syndromes. Nat Genet 2010; 42: 665–667.
Myelodysplastic Syndromes154
[45] Hess JL. Familial monosomy 7 syndrome. Atlas Genet Cytogenet Oncol Hematol. 2001;
5(3): 220–221. doi: 10.4267/2024/37769.
[46] West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia
syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 2014;
1310: 111–118. doi: 10.1111/nyas.12346. Epub 2014 Jan 27.
[47] Bödör C, Renneville A, Smith M, Charazac A, Iqbal S, Etancelin P, et al. Germ-line
GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired
monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.
Haematologica 2012; 97 (6): 890–894. doi: 10.3324/haematol.2011.054361. Epub 2012 Jan
22.
[48] Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, et al.
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and
acute myeloid leukemia. Nat Genet 2011; 43 (10): 1012–1017. doi: 10.1038/ng.913.
[49] Zhang R, Kim YM, Wang X, Li Y, Lu X, Sternenberger AR, et al. Genomic copy number
variations in the myelodysplastic syndrome and acute myeloid leukemia patients with
del(5q) and/or -7/del(7q). Int J Mol Sci 2015; 12 (9): 719–726. doi: 10.7150/ijms.12612
[50] Abdelrazik HN, Farawila HM, Sherif MA, AlAnsary M. Molecular characterization of
chromosome 7 in AML and MDs patients. Afr J Health Sci 2006; 13: 33–42.
[51] Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychondzen B, et al.
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic
pathogenesis. Blood 2012; 119: 6109–6117. doi: 10.1182/blood-2011-12-397620
[52] Desangles F. -7/del(7q) in adults. Atlas Genet Cytogenet Oncol Hematol 1999; 3 (3):
139–140. doi: 10.4267/2042/37535
[53] Hussain FTN, Nguyen EP, Raza S, Knudson R, Pardanani A, Hanson CA, et al. Sole
abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic
correlates and prognostic implications. Am J Hematol 2012; 87: 684–686. doi: 10.1002/
ajh.23230
[54] Wong JC, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, et al. Use of chro‐
mosome engineering to model a segmental deletion of chromosome band 7q22 found
in myeloid malignancies. Blood 2010; 115 (22): 4524–4532. doi: 10.1182/
blood-2009-07-232504. Epub 2010 Mar 16.
[55] Asou H, Matsu H, Ozaki Y, Nagamachi A, Nakamura M, Aki D, et al. Identification of
a common microdeletion cluster in7q21.3 subband among patients with myeloid
leukemia and myelodysplastic syndrome. Biochem Biophys Res Commun 2009; 383:
245–251. doi: 10.1016/j.bbrc.2009.04.004. Epub 2009 Apr 7.
[56] Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, Tonnissen ERLTM,
et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic
syndromes. Nat Genet 2010; 42: 665–667.
Myelodysplastic Syndromes154
[57] Makishima H, Traina F, Jankowska AM, Sugimoto Y, Guinta KM, Sakaguchi H, et al.
Pathogenesis of monosomy 7 in bone marrow failure syndromes. Poster 11, 53rd ASH
Annual Meeting and Exposition 2011.
[58] Wall M, Rayeroux KC, Mackinnon RN, Zordan A, Campbell LJ. ETV6 deletion is a
common additional abnormality in patients with myelodysplastic syndromes or acute
myeloid leukemia. Haematologica 2012; 97 (12): 1933–1936. doi: 10.3324/haematol.
2012.069716
[59] Shen Y, Xue Y, Li J, Guo Y, Pan J, Wu Y. Detection of monosomy 7 or 7q- in cases of
myelodysplastic syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001; 18 (4): 255–
258.
[60] Yunis JJ, Lobell M, Arnesen MA, Oken MM, Mayer MG, Rydell RE, et al. Refined
chromosome study helps define prognostic subgroups in most patients with primary
myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 1988; 68
(2): 189–194. doi: 10.1111/j.1365-2141.1988.tb06188.x
[61] McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, et al.
CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently
inactivated in acute myeloid leukemia. Blood 2013; 121 (6): 975–983. doi:10.1182/
blood-2012-04-426965. Epub 2012 Dec 3.
[62] Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, et al. Reduced DOCK4
expression leads to erythroid dysplasia in myelodysplastic syndromes. Proc Natl Acad
Sci USA 2015; 112 (46): E6359-E6368. doi: 10.1073/pnas.1516394112. Epub 2015 Nov 2.
[63] Geelani S, Manzoor F, Bashir N, Bhat S, Rasool J, Qadri SM, et al. Myelodysplastic
syndrome with monosomy 7—a rare case of morphological and cytogenetic remission
with lenalidomide. Case Study Case Rep 2015; 5 (1): 1–4.
[64] Tan NC, Lee KH, Liu TC. Myelodysplastic syndrome with monosomy 7 and pulmonary
aspergillosis. Singapore Med J 2000; 41(6): 290–291.
[65] Dwivedi AC, Lyons MJ, Kwiatkowski K, Bartel FO, Friez MJ, Holden KR, et al. Clinical
utility of chromosomal microarray analysis in the diagnosis and management of
monosomy 7 mosaicism. Mol Cytogenet 2014; 7 (1): 93. doi: 10.1186/s13039-014-0093-4.
eCollection 2014.
[66] Kere J, Ruutu T, de La Chapelle A. Monosomy 7 in granulocytes and monocytes in
myelodysplastic syndrome. New Engl J Med 1987; 316: 499–503.
[67] Gerritsen WR, Donohue J, Bauman J, Jhanwar SC, Kernan NA, Castro-Malaspina H, et
al. Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the
myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ
hybridization. Blood 1992; 80: 217–224.
[68] Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic
instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after
Myelodysplastic Disorders, Monosomy 7
http://dx.doi.org/10.5772/64549
155
gene therapy for chronic granulomatous disease. Nat Med 2010; 16 (2):198–204. doi:
10.1038/nm.2088. Epub 2010 Jan 24.
[69] Trobaugh-Lotrario AD, Kletzel M, Quinones RR, McGavran L, Proytcheva MA, Hunger
SP, et al. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS): successful management by allogeneic hematopoiet‐
ic stem cell transplant (HSCT). Bone Marrow Transplant 2005; 35 (2): 143–149. doi:
10.1038/sj.bmt.1704753
[70] Jakovleva K, Ogard I, Arvidsson I, Jacobsson B, Swolin B, Hast R. Masked monosomy
7 in myelodysplastic syndromes is uncommon and of undetermined clinical signifi‐
cance. Leuk Res 2001; 25 (3): 197–203.
[71] Aktas D, Tuncbilek E. Myelodysplastic syndrome associated with monosomy 7 in
childhood: a retrospective study. Cancer Genet Cytogenet 2006; 171 (1): 72–75.
[72] Yoshimi A, Mohamed M, Bierings M, Urban C, Korthof E, Zecca M, et al. Second
allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar
to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia
2007; 21 (3): 556–560. doi: 10.1038/sj.leu.2404537. Epub 2007 Feb 1.
[73] Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, et al; European Working
Group on Childhood MDS; European Blood and Marrow Transplantation Group.
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomo‐
nocytic leukemia (JMML): results of the EWOG–MDS/EBMT trial. Blood 2005; 105 (1):
410–419. Epub 2004 Sep 7. doi:10.1182/blood-2004-05-1944
[74] Korthof ET, Snijder PP, de Graaff AA, Lankester AC, Bredius RG, Ball LM, et al.
Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a
single center experience of 23 patients. Bone Marrow Transplant 2005; 35 (5): 455–461.
doi: 10.1038/sj.bmt.1704778
[75] Malcovati L. Red blood cell transfusion therapy and iron chelation in patients with
myelodysplastic syndromes. Clin Lymphoma Myeloma 2009; 9 (Suppl 3): S305–S311.
doi: 10.3816/CLM.2009.s.029
[76] Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion
iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ
Program 2008; 1: 166–175 doi: 10.1182/asheducation-2008.1.166
[77] Alessandrino EP, Angelucci E, Cazzola M, Della Porta MG, Di Bartolomeo P, Gozzini
A, et al. Iron overload and iron chelation therapy in patients with myelodysplastic
syndrome treated by allogeneic stem-cell transplantation: report from the working
conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo. Am J
Hematol 2011; 86: 897–902. doi: 10.1002/ajh.22104
[78] Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of
elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell
Myelodysplastic Syndromes156
gene therapy for chronic granulomatous disease. Nat Med 2010; 16 (2):198–204. doi:
10.1038/nm.2088. Epub 2010 Jan 24.
[69] Trobaugh-Lotrario AD, Kletzel M, Quinones RR, McGavran L, Proytcheva MA, Hunger
SP, et al. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS): successful management by allogeneic hematopoiet‐
ic stem cell transplant (HSCT). Bone Marrow Transplant 2005; 35 (2): 143–149. doi:
10.1038/sj.bmt.1704753
[70] Jakovleva K, Ogard I, Arvidsson I, Jacobsson B, Swolin B, Hast R. Masked monosomy
7 in myelodysplastic syndromes is uncommon and of undetermined clinical signifi‐
cance. Leuk Res 2001; 25 (3): 197–203.
[71] Aktas D, Tuncbilek E. Myelodysplastic syndrome associated with monosomy 7 in
childhood: a retrospective study. Cancer Genet Cytogenet 2006; 171 (1): 72–75.
[72] Yoshimi A, Mohamed M, Bierings M, Urban C, Korthof E, Zecca M, et al. Second
allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar
to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia
2007; 21 (3): 556–560. doi: 10.1038/sj.leu.2404537. Epub 2007 Feb 1.
[73] Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, et al; European Working
Group on Childhood MDS; European Blood and Marrow Transplantation Group.
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomo‐
nocytic leukemia (JMML): results of the EWOG–MDS/EBMT trial. Blood 2005; 105 (1):
410–419. Epub 2004 Sep 7. doi:10.1182/blood-2004-05-1944
[74] Korthof ET, Snijder PP, de Graaff AA, Lankester AC, Bredius RG, Ball LM, et al.
Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a
single center experience of 23 patients. Bone Marrow Transplant 2005; 35 (5): 455–461.
doi: 10.1038/sj.bmt.1704778
[75] Malcovati L. Red blood cell transfusion therapy and iron chelation in patients with
myelodysplastic syndromes. Clin Lymphoma Myeloma 2009; 9 (Suppl 3): S305–S311.
doi: 10.3816/CLM.2009.s.029
[76] Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion
iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ
Program 2008; 1: 166–175 doi: 10.1182/asheducation-2008.1.166
[77] Alessandrino EP, Angelucci E, Cazzola M, Della Porta MG, Di Bartolomeo P, Gozzini
A, et al. Iron overload and iron chelation therapy in patients with myelodysplastic
syndrome treated by allogeneic stem-cell transplantation: report from the working
conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo. Am J
Hematol 2011; 86: 897–902. doi: 10.1002/ajh.22104
[78] Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of
elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell
Myelodysplastic Syndromes156
transplantation. Blood. 2007; 109(10): 4586–4588. doi: 10.1182/blood-2006-10-054924.
Prepublished online January 18, 2007.
[79] Leitch HA. Optimizing therapy for iron overload in the myelodysplastic syndromes:
recent developments. Drugs 2011; 71 (2): 155–177. doi:
10.2165/11585280-000000000-00000.
[80] Mitchell M, Gore SD, Zeidan AM. Iron chelation therapy in myelodysplastic syn‐
dromes: where do we stand? Expert Rev Hematol 2013; 6 (4): 397–410. doi:
10.1586/17474086.2013.814456
[81] Messa E, Cilloni D, Saglio G. Iron chelation therapy in myelodysplastic syndromes.
Adv Hematol 2010; 2010: 756289. doi: 10.1155/2010/756289. Epub 2010 Jun 20.
[82] Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic
syndrome. Bone Marrow Transplant 2009; 43 (8): 597–609. doi: 10.1038/bmt.2009.28.
Epub 2009 Mar 2.
[83] Garcia JS, Jain N, Godley LA. An update on the safety and efficacy of decitabine in the
treatment of myelodysplastic syndromes. OncoTarget Ther 2010; 3: 1–13.
[84] Lubbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagonidis A, et al. Low-dose
decitabine versus best supportive care in elderly patients with intermediate-or high-
risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final
results of the randomized phase III study of the European Organization for Research
and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin
Oncol 2011; 29 (15): 1987–1996. doi: 10.1200/JCO.2010.30.9245.
[85] Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. Preferential
response of cancer cells to zebularine. Cancer Cell 2004; 6(2):151–158.
[86] Amatori S, Bagaloni I, Donati B, Fanelli M. DNA demethylating antineoplastic strat‐
egies: a comparative point of view. Genes Cancer 2010; 1 (3): 197–209. doi:
10.1177/1947601910365081.
[87] Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, et al. p53-
independent, normal stem cell sparing epigenetic differentiation therapy for myeloid
and other malignancies. Semin Oncol 2012; 39 (1): 97–108. doi: 10.1053/j.seminoncol.
2011.11.011.
[88] Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, et al. p53 independent
epigenetic-differentiation treatment in xenotransplant models of acute myeloid
leukemia. Leukemia 2011; 25 (11): 1739–1750. doi: 10.1038/leu.2011.159. Epub 2011 Jun
24.
[89] Šorm F, Piskala A, Čihák A, Veselý J. 5-Azacytidine, a new, highly effective cancero‐
static. Experientia 1964; 20 (4): 202–203.
Myelodysplastic Disorders, Monosomy 7
http://dx.doi.org/10.5772/64549
157
[90] Šorm F, Veselý J. The activity of the new antimetabolite, 5-azacytidine, against lym‐
phoid leukemia in AK mice. Neoplasma 1964; 11: 123–130.
[91] Šorm F, Veselý J. The effect of 5-aza-2-deoxycytidine against leukemic and hemopoietic
tissues in AKR mice. Neoplasma 1968; 15: 339–343.
[92] Veselý J, Čihák A, Šorm F. Association of decreased uridine and deoxycytidine kinase
with enhanced RNA and DNA polymerase in mouse leukemic cells resistant to 5-
azacytidine and 5-aza-2′-deoxycytidine. Cancer Res 1970; 30; 2180–2186.
[93] Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-
aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.
Clin Epigenetics 2013; 5 (1): 3. doi: 10.1186/1868-7083-5-3.
[94] Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval
summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist
2005; 10 (3): 176–182.
[95] Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, et al.
Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish
Society of Hematology. Effectiveness of azacitidine in unselected high-risk myelodys‐
plastic syndromes: results from the Spanish registry. Leukemia 2015; 29 (9): 1875–1881.
doi: 10.1038/leu.2015.115. Epub 2015 May 6.
[96] Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hema‐
tology Am Soc Hematol Educ Program. 2012; 2012: 65–73.
[97] Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, et al.
Comparison of risk stratification tools in predicting outcomes of patients with higher-
risk myelodysplastic syndromes treated with azanucleosides. Leukemia 2016; 30 (3):
649–657. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.
[98] Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, et al. 5-Azacitidine
for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow
Transplant 2010; 45 (2): 255–260. doi: 10.1038/bmt.2009.134. Epub 2009 Jun 22.
[99] Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al.
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic
HSCT: results of the RELAZA trial. Leukemia 2012; 26 (3): 381–389. doi: 10.1038/leu.
2011.234. Epub 2011 Sep 2.
[100] Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-
risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;
29 (24): 3322–3327. doi: 10.1200/JCO.2011.35.8135. Epub 2011 Jul 25.
[101] Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al.
International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine
compared with that of conventional care regimens in the treatment of higher-risk
Myelodysplastic Syndromes158
[90] Šorm F, Veselý J. The activity of the new antimetabolite, 5-azacytidine, against lym‐
phoid leukemia in AK mice. Neoplasma 1964; 11: 123–130.
[91] Šorm F, Veselý J. The effect of 5-aza-2-deoxycytidine against leukemic and hemopoietic
tissues in AKR mice. Neoplasma 1968; 15: 339–343.
[92] Veselý J, Čihák A, Šorm F. Association of decreased uridine and deoxycytidine kinase
with enhanced RNA and DNA polymerase in mouse leukemic cells resistant to 5-
azacytidine and 5-aza-2′-deoxycytidine. Cancer Res 1970; 30; 2180–2186.
[93] Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-
aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.
Clin Epigenetics 2013; 5 (1): 3. doi: 10.1186/1868-7083-5-3.
[94] Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval
summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist
2005; 10 (3): 176–182.
[95] Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, et al.
Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish
Society of Hematology. Effectiveness of azacitidine in unselected high-risk myelodys‐
plastic syndromes: results from the Spanish registry. Leukemia 2015; 29 (9): 1875–1881.
doi: 10.1038/leu.2015.115. Epub 2015 May 6.
[96] Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hema‐
tology Am Soc Hematol Educ Program. 2012; 2012: 65–73.
[97] Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, et al.
Comparison of risk stratification tools in predicting outcomes of patients with higher-
risk myelodysplastic syndromes treated with azanucleosides. Leukemia 2016; 30 (3):
649–657. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.
[98] Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, et al. 5-Azacitidine
for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow
Transplant 2010; 45 (2): 255–260. doi: 10.1038/bmt.2009.134. Epub 2009 Jun 22.
[99] Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al.
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic
HSCT: results of the RELAZA trial. Leukemia 2012; 26 (3): 381–389. doi: 10.1038/leu.
2011.234. Epub 2011 Sep 2.
[100] Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-
risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;
29 (24): 3322–3327. doi: 10.1200/JCO.2011.35.8135. Epub 2011 Jul 25.
[101] Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al.
International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine
compared with that of conventional care regimens in the treatment of higher-risk
Myelodysplastic Syndromes158
myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol
2009; 10 (3): 223–232. doi: 10.1016/S1470-2045(09) 70003-8. Epub 2009 Feb 21.
[102] Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, et al. 5-azacitidine
prolongs overall survival in patients with myelodysplastic syndrome--a systematic
review and meta-analysis. Haematologica 2010; 95 (2): 303–310. doi: 10.3324/haematol.
2009.010611. Epub 2009 Sep 22.
[103] Vigil CE, Martin-Santos T, Garcia-Manero G. Safety and efficacy of azacitidine in
myelodysplastic syndromes. Drug Des Devel Ther 2010; 4: 221–229.
[104] Kim Y, Cheong JW, Kim YK, Eom JI, Jeung HK, Kim SJ, et al. Serum microRNA-21 as
a potential biomarker for response to hypomethylating agents in myelodysplastic
syndromes. PLoS ONE 2014; 9 (2): e86933. doi: 10.1371/journal.pone.0086933
[105] Pleyer L, Greil R. Digging deep into dirty drugs-modulation of the methylation
machinery. Drug Metab Rev 2015; 47 (2): 252–279. doi: 10.3109/03602532.2014.995379
[106] Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, et al. Increased
CDA expression/activity in males contribute to decreased cytidine analogue half-life
and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin
Cancer Res 2013; 19 (4): 938–948. doi: 10.1158/1078-0432.CCR-12-1722
[107] Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Safety and clinical
activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in
acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 2302–2308.
doi: 10.1182/blood-2007-03-078576
[108] Raffoux E, Cras A, Recher C, Boëlle PY, de Labathe A, Turlure P, et al. Phase 2 clinical
trial of 5-azacytidine, valproic acid and all-trans retinoic acid in patients with high-risk
acute myeloid leukemia or myelodysplastic syndrome. OncoTarget 2010; 1(1): 34–42.
[109] Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig
R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic
syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20 (10): 2429–
2440. doi: 10.1200/JCO.2002.04.117
[110] Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, et al.
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-
risk myelodysplastic syndromes patients. Leukemia 2016; 30: 112–123. doi: 10.1038/leu.
2015.179
[111] Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, et al. Retrospective
analysis of prognostic factors associated with response and overall survival by baseline
marrow blast oercentage in patients with myelodysplastic syndromes treated with
decitabine. Clin Lymphoma Myeloma Leuk 2013; 13 (5): 592–596. doi: 10.1016/j.clml.
2013.05.004
[112] Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, et al. The
effect of decitabine doser modification and myelosuppression on response and survival
Myelodysplastic Disorders, Monosomy 7
http://dx.doi.org/10.5772/64549
159
in patients with myelodysplastic syndromes. Leuk Lymphoma 2015; 56 (2): 390–394.
doi: 10.3109/10428194.2014.914192
[113] Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, cortes J, et al. Results of a
randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic
syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57. doi: 10.1182/
blood-2006-05-021162
[114] Wu L, Shi W, Li X, Chang C, Xu F, He Q, et al. High expression of the human equili‐
brative nucleoside transporter 1 gene predicts a good response to decitabine in patients
with myelodysplastic syndrome. J Transl Med 2016; 14: 66. doi: 10.1186/
s12967-016-0817-9
[115] Rüter B, Wijermans P, claus R, Kunzmann R, Lübbert M. Preferential cytogenetic
response to continuous intravenous low-dose decitabine administration in myelodys‐
plastic syndrome with monosomy 7. Blood 2007; 110: 1080–1082. doi: 10.1182/
blood-2007-03-080630
[116] Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, et al. Clinical
activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodys‐
plastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol
2015; 33 (2): 57–66. doi: 10.1002/hon.2137. Epub 2014 Apr 29.
[117] Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, et al. ONTIME
Study Investigators. Rigosertib versus best supportive care for patients with high-risk
myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a
randomised, controlled, phase 3 trial. Lancet Oncol 2016 Mar 8. pii:
S1470-2045(16)00009-7. doi: 10.1016/S1470-2045(16)00009-7. [Epub ahead of print]
[118] Hyoda T, Tsujioka T, Nakahara T, Suemori Si, Okamoto S, Kataoka M, et al. Rigosertib
induces cell death of a myelodsplastic syndrome-derived cell line by DNA damage-
induced G2/M arrest. Cancer Sci 2015; 106 (3): 287–293. doi: 10.1111/cas.12605
[119] Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, et al. Directed
therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin
D1 with ON01910.Na. Leuk Res 2012; 36 (8): 982–989. doi: 10.1016/j.leukres.2012.04.002
[120] Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, et al. Phase I clinical trial of
oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol 2013; 162
(4): 517–524. doi: 10.1111/bjh. 12436
[121] Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, et al. Treatment of
higher risk myelodysplastic syndrome patients unresponsive to hypomethylating
agents withON01910.Na. Leuk Res 2012; 36 (1): 98–103. doi: 10.1016/j.leukres.
2011.08.022
[122] Vaughn JE, Scott BL, Deeg HJ. Transplantation for myelodysplastic syndromes 2013.
Curr Opin Hematol 2013; 20 (6): 494–500. doi:10.1097/MOH.0b013e328364f547.
Myelodysplastic Syndromes160
in patients with myelodysplastic syndromes. Leuk Lymphoma 2015; 56 (2): 390–394.
doi: 10.3109/10428194.2014.914192
[113] Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, cortes J, et al. Results of a
randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic
syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57. doi: 10.1182/
blood-2006-05-021162
[114] Wu L, Shi W, Li X, Chang C, Xu F, He Q, et al. High expression of the human equili‐
brative nucleoside transporter 1 gene predicts a good response to decitabine in patients
with myelodysplastic syndrome. J Transl Med 2016; 14: 66. doi: 10.1186/
s12967-016-0817-9
[115] Rüter B, Wijermans P, claus R, Kunzmann R, Lübbert M. Preferential cytogenetic
response to continuous intravenous low-dose decitabine administration in myelodys‐
plastic syndrome with monosomy 7. Blood 2007; 110: 1080–1082. doi: 10.1182/
blood-2007-03-080630
[116] Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, et al. Clinical
activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodys‐
plastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol
2015; 33 (2): 57–66. doi: 10.1002/hon.2137. Epub 2014 Apr 29.
[117] Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, et al. ONTIME
Study Investigators. Rigosertib versus best supportive care for patients with high-risk
myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a
randomised, controlled, phase 3 trial. Lancet Oncol 2016 Mar 8. pii:
S1470-2045(16)00009-7. doi: 10.1016/S1470-2045(16)00009-7. [Epub ahead of print]
[118] Hyoda T, Tsujioka T, Nakahara T, Suemori Si, Okamoto S, Kataoka M, et al. Rigosertib
induces cell death of a myelodsplastic syndrome-derived cell line by DNA damage-
induced G2/M arrest. Cancer Sci 2015; 106 (3): 287–293. doi: 10.1111/cas.12605
[119] Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, et al. Directed
therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin
D1 with ON01910.Na. Leuk Res 2012; 36 (8): 982–989. doi: 10.1016/j.leukres.2012.04.002
[120] Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, et al. Phase I clinical trial of
oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol 2013; 162
(4): 517–524. doi: 10.1111/bjh. 12436
[121] Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, et al. Treatment of
higher risk myelodysplastic syndrome patients unresponsive to hypomethylating
agents withON01910.Na. Leuk Res 2012; 36 (1): 98–103. doi: 10.1016/j.leukres.
2011.08.022
[122] Vaughn JE, Scott BL, Deeg HJ. Transplantation for myelodysplastic syndromes 2013.
Curr Opin Hematol 2013; 20 (6): 494–500. doi:10.1097/MOH.0b013e328364f547.
Myelodysplastic Syndromes160
[123] Mori T, Aisa Y, Yokoyama A, Nakazato T, Yamazaki R, Shimizu T, et al. Total body
irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine
as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for
advanced myelodysplastic syndrome: a single-institute experience. Bone Marrow
Transplant 2007; 39 (4): 217–221. doi:10.1038/sj.bmt.1705578. Epub 2007 Jan 15.
[124] Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, et al. Reduced-intensity
conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine
and melphalan is associated with durable disease control in myelodysplastic syn‐
drome. Bone Marrow Transplant 2007; 40 (9): 843–850. doi:10.1038/sj.bmt.1705801.
Epub 2007 Aug 27.
[125] Armand P, Deeg HJ, Kim HT, Lee H, Armistead P, de Lima M, et al. Multicenter
validation study of a transplantation-specific cytogenetics grouping scheme for
patients with myelodysplastic syndromes. Bone Marrow Transplant 2010; 45 (5): 877–
885. doi: 10.1038/bmt.2009.253. Epub 2009 Sep 28.
[126] Jan S. Stem cell transplantation for a myelodysplastic syndrome in children. Rep Pract
Oncol Radiother 2000; 5 (2): 43–47.
[127] Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, et al. Early
hematopoietic stem cell transplant is associated with favorable outcomes in children
with MDS. Pediatr Blood Cancer 2013; 60 (4): 705–710. doi: 10.1002/pbc.24390. Epub
2012 Nov 14.
[128] Yusuf U, Frangoul HA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG, et al.
Allogeneic bone marrow transplantation in children with myelodysplastic syndrome
or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant
2004; 33 (8): 805–814. doi:10.1038/sj.bmt.1704438. Epub 2004 Feb 2.
[129] Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, et al. HLA-matched
allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic
syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia 2015; 29
(7):1496–1501. doi: 10.1038/leu.2015.37. Epub 2015 Feb 13.
[130] Deeg HJ. Hematopoietic cell transplantation for myelodysplastic syndrome. Am Soc
Clin Oncol Educ Book 2015; asco.org/edbook: e375-e380. doi: 10.14694/EdBook_AM.
2015.35.e375
[131] Sekeres MA. Bone marrow transplantation (BMT) in myelodysplastic syndromes. To
BMT or not to BMT—that is the question. J Clin Oncol 2013; 31 (21): 2643–2644. doi:
10.1200/JCO.2013.48.9146. Epub 2013 Jun 24.







Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/63193
Abstract
The classification, pathobiology and clinical management of chronic myelomonocytic
leukaemia (CMML) are reviewed. Three important issues are identified: (1) CMML should
be recognised as a unique clinical entity and as distinct from myelodysplastic syn‐
dromes (MDSs). Somatic mutations of a restricted set of genes are frequent in CMML. (2)
Risk stratification for CMML patients should utilise new CMML‐specific prognostic
scoring systems. (3) Until randomised clinical trials have defined the role of new drugs
(especially of the hypomethylating agents), treatment must focus on the main symp‐
toms and aim at quality‐of‐life improvement.
Keywords: chronic myelomonocytic leukaemia, myelodysplastic/myeloproliferative
syndrome, somatic mutations, prognosis, therapy
1. Introduction
Chronic myelomonocytic leukaemia (CMML) is a rare haematological neoplasm character‐
ised by a persistent peripheral blood monocytosis and both myelodysplastic and myeloproli‐
ferative features. Our understanding of this disease has undergone profound changes in recent
years. Initially it was classified as a subtype of myelodysplastic syndromes (MDSs), and it is
now recognised as a unique disease. This reclassification has been substantiated by recent
advances in the genetic and molecular pathogenesis of CMML, which have confirmed that
CMML is biologically distinct from MDS with a different pattern of somatic mutations and a
different molecular ontogeny [1].  In addition, CMML‐specific prognostic scoring systems
(CPSSs) have been established by various groups. These differ from those commonly used in
MDS and, for the first time, also include molecular markers. Hopefully, these efforts will
culminate in CMML‐specific treatments in the near future. The following chapter will summa‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
rise these developments starting with a discussion of CMML classification and ending with an
outlook on new treatment approaches.
2. Diagnosis and classification
The first reports comprising significant numbers of patients with CMML were published
around 40 years ago [2, 3]. These early series already noted a considerable clinical diversity,
describing myelodysplasia and cytopenia accompanied by leukocytosis and other myelopro‐
liferative symptoms such as splenomegaly. Nevertheless, the first French–American–British
(FAB) Cooperative Group classification of MDS in 1982 included CMML as a MDS subtype,
emphasising its dysplastic features but not its diversity [4]. The diagnostic criteria proposed
included more than 1 × 109/L blood monocytes, bone marrow blasts of 20% or less, peripheral
blasts <5%, and bone marrow dysplastic features in at least one haematopoietic lineage
(Table 1). To account for the clinical diversity mentioned earlier, the FAB group later intro‐
duced a subclassification by dividing patients into two groups based on the leukocyte count
at diagnosis [5]. Patients with a leukocyte count above 13 × 109/L were considered to have a
myeloproliferative form (MPD‐CMML), those with a leukocyte count below 13 × 109/L a
myelodysplastic form (MDS‐CMML). This arbitrary threshold has been controversial, and its
clinical relevance was tested in several cohorts of patients with CMML. In a retrospective
analysis of 158 patients (81 patients with MDS‐CMML and 77 patients with MPD‐CMML),
Germing et al. found no significant difference in 2‐year overall survival (OS) between these
subgroups. The likelihood of transformation to AML was higher in the MDS‐CMML group,
but this difference was not statistically significant [6]. Voglova et al. [7] described the frequent
transition of MDS‐CMML to MPD‐CMML, suggesting that the two subgroups might represent
different stages of the same disease rather than two different entities. Onida et al. analysed a
cohort of 213 patients with CMML (35% with MDS‐CMML and 65% with MPD‐CMML) and
could also not find a statistically significant difference in survival after 12 months. There was,
however, a trend for a better survival of patients with MPD‐CMML after 16 months [8]. To
resolve these diagnostic inconsistencies, the WHO (2001) classification of myeloid neoplasms
defined a new group of overlap syndromes called myelodysplastic/myeloproliferative
diseases (MDS/MPS). Besides CMML, atypical (bcr‐abl negative) CML (aCML), juvenile
myelomonocytic leukaemia (JMML) and myelodysplastic/myeloproliferative disease, unclas‐
sifiable (MDS/MPS‐U) were placed in this group [9]. The details of the diagnostic criteria for
CMML are listed in Table 1. Further, two CMML subtypes were recognised: CMML‐1 with
PB blast <5% and <10% BM blasts and CMML‐2 with 5–19% PB blasts and 10–19% BM blasts.
The prognostic significance of these subgroups was confirmed in a reanalysis of the Düsseldorf
registry of 300 CMML patients. The 5‐year risk of transformation to AML was 63% for patients
with CMML‐2 compared to only 18% for patients with CMML‐1 [10]. More recently, the same
group found that further subclassification of CMML based on medullary blast count could
provide additional prognostic information [11]. Patients with the new subtype of CMML‐0
(defined as <5% medullary blasts) had a better prognosis than those with CMML‐1 (OS 31 vs.
19 months). These results have not yet been reproduced in an independent cohort.
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The 2008 revision of the WHO classification has maintained the main diagnostic criteria for
CMML, with one additional feature [12]. In particular, the recognition of an associated
eosinophilia is an important clue to an underlying rearrangement of the platelet‐derived
growth factor receptor, alpha or beta polypeptide (PDGFRA/B) gene. If this molecular lesion
is found, the case should be classified as a myeloid neoplasm with eosinophilia associated with
PDGFRA/B rearrangement. These patients often respond exquisitely to imatinib [13].
Diagnostic difficulties most commonly arise in the distinction between CMML and aCML,
because a monocytosis can be present in the latter. In difficult cases, the pattern of somatic
mutations might be exploited in the future [14, 15]. For example, the co‐existence of a serine/
arginine‐rich splicing factor 2 (SRSF2) and a ten–eleven translocation‐2 (TET2) mutation
suggests CMML, a SET nuclear proto‐oncogene binding protein1 (SETBP1) mutation points
towards aCML.
The presence of a peripheral blood monocytosis is a diagnostic prerequisite for the diagnosis
of CMML but can also be caused by a number of reactive conditions. In patients with clinical
or laboratory signs of inflammation, such as fever, arthritis, increased C‐reactive protein or
elevated erythrocyte sedimentation rate, the diagnosis of CMML should be made with caution.
Often, re‐evaluation is necessary once the signs of inflammation have subsided. A recent study
suggests that the distinction between reactive monocytosis and CMML might be possible by
immunophenotyping, but this finding needs further confirmation in independent studies [16].
FAB classification WHO classification
Myelodysplastic syndrome MDS/MPD overlap syndrome
PB Monocytosis >1 × 109/L
Myeloblasts <5% in PB, <20% in BM
Dysplasia in one or more haematopoietic lineage
PB Monocytosis >1 × 109/L
Myeloblasts <20% in BM
No BCR‐ABL1 fusion gene
No PDGFRA/PDGFRB rearrangement
Dysplasia in one or more myeloid lineage





CMML‐1: Blasts PB < 5%, BM < 10%
CMML‐2: Blasts PB 5–19%, BM 10–19%
FAB, French‐American‐British; PB, peripheral blood; BM, bone marrow.
Table 1. Comparison of the FAB and WHO classifications of CMML.
3. Epidemiology and clinical features
CMML is a rare disease of the elderly. Two recent population‐based studies found a similar




age was 70–75 years, and there was a slight male predominance. The study from the Nether‐
lands found that the diagnosis was made in a non‐university setting in 78%, indicating that
many patients are managed by practising haematologists. This observation emphasises the
need to perform clinical studies also in a community‐based setting to include as many patients
as possible. The 5‐year relative survival was poor (16–20%) in this study and did not improve
over time. Therapy‐related CMML (t‐CMML), defined as occurring after chemotherapy,
radiotherapy or both, is considered rare but was found in 10% in a recent MD Anderson Cancer
Centre (MDACC) series. Patients with t‐CMML had a significantly worse median OS com‐
pared to patients with de novo disease (13 vs. 20 months), most likely due to a higher rate of
intermediate‐ or high‐risk cytogenetic abnormalities [19]. Similar results were reported in a
series from the Mayo Clinic (median OS 11 vs. 20 months) [20].
3.1. Clinical features
Monocytosis can be an incidental finding in an otherwise asymptomatic patient. In other cases,
it is accompanied by anaemia (in about 50% of patients at diagnosis) and/or thrombocytopenia.
Frequently, a haematological prodrome, for example an unclear thrombocytopenia, can be
observed. In about 30–60% of patients, leukocyte counts >13 × 109/L are found, often with
clinical signs of myeloproliferation such as splenomegaly in around 30% [8]. Hepatospleno‐
megaly is more frequent (25–50% of patients) in the myeloproliferative variant [21]. Many
patients experience constitutional symptoms, fatigue, night sweats and occasionally bone pain.
In contrast to MDS, involvement of various organ systems has been described in CMML
patients. Skin lesions can be an indicator of leukemic transformation [22]. Serosal infiltration
causing pleural or pericardial effusion is quite frequent and can be difficult to treat [23]. Local
instillation of mitoxantrone, in combination with systemic chemotherapy, has been used with
some success in such cases. A case of widespread gastric involvement mimicking metastatic
gastric carcinoma was recently seen in our practice (own unpublished observation). Cases of
uncontrollable haematuria caused by CMML involvement of the urogenital tract have also
been described [24, 25].
An association with autoimmune‐mediated disorders is frequently seen in CMML. For
example, in a study of 123 CMML patients, 20% had at least one associated disorder, most
commonly immune thrombocytopenia (ITP), gout or psoriasis [26]. Importantly, ITP seems to
respond well to standard treatment used in primary ITP, such as steroids and splenectomy [27].
Over time transformation into acute myeloid leukaemia occurs in approximately 30% of
patients. The rate of transformation varies according to the risk profile at diagnosis. A sudden
rise in the leukocyte count does not necessarily indicate leukemic transformation but can be
an expression of increased myeloproliferation. A careful evaluation of the blast count is
important in this situation.
3.2. Laboratory and pathologic findings
In the peripheral blood, monocytes can be normal or display atypical features such as fine
nuclear chromatin or abnormal nuclear lobulations. In the myeloproliferative variant, median
Myelodysplastic Syndromes166
age was 70–75 years, and there was a slight male predominance. The study from the Nether‐
lands found that the diagnosis was made in a non‐university setting in 78%, indicating that
many patients are managed by practising haematologists. This observation emphasises the
need to perform clinical studies also in a community‐based setting to include as many patients
as possible. The 5‐year relative survival was poor (16–20%) in this study and did not improve
over time. Therapy‐related CMML (t‐CMML), defined as occurring after chemotherapy,
radiotherapy or both, is considered rare but was found in 10% in a recent MD Anderson Cancer
Centre (MDACC) series. Patients with t‐CMML had a significantly worse median OS com‐
pared to patients with de novo disease (13 vs. 20 months), most likely due to a higher rate of
intermediate‐ or high‐risk cytogenetic abnormalities [19]. Similar results were reported in a
series from the Mayo Clinic (median OS 11 vs. 20 months) [20].
3.1. Clinical features
Monocytosis can be an incidental finding in an otherwise asymptomatic patient. In other cases,
it is accompanied by anaemia (in about 50% of patients at diagnosis) and/or thrombocytopenia.
Frequently, a haematological prodrome, for example an unclear thrombocytopenia, can be
observed. In about 30–60% of patients, leukocyte counts >13 × 109/L are found, often with
clinical signs of myeloproliferation such as splenomegaly in around 30% [8]. Hepatospleno‐
megaly is more frequent (25–50% of patients) in the myeloproliferative variant [21]. Many
patients experience constitutional symptoms, fatigue, night sweats and occasionally bone pain.
In contrast to MDS, involvement of various organ systems has been described in CMML
patients. Skin lesions can be an indicator of leukemic transformation [22]. Serosal infiltration
causing pleural or pericardial effusion is quite frequent and can be difficult to treat [23]. Local
instillation of mitoxantrone, in combination with systemic chemotherapy, has been used with
some success in such cases. A case of widespread gastric involvement mimicking metastatic
gastric carcinoma was recently seen in our practice (own unpublished observation). Cases of
uncontrollable haematuria caused by CMML involvement of the urogenital tract have also
been described [24, 25].
An association with autoimmune‐mediated disorders is frequently seen in CMML. For
example, in a study of 123 CMML patients, 20% had at least one associated disorder, most
commonly immune thrombocytopenia (ITP), gout or psoriasis [26]. Importantly, ITP seems to
respond well to standard treatment used in primary ITP, such as steroids and splenectomy [27].
Over time transformation into acute myeloid leukaemia occurs in approximately 30% of
patients. The rate of transformation varies according to the risk profile at diagnosis. A sudden
rise in the leukocyte count does not necessarily indicate leukemic transformation but can be
an expression of increased myeloproliferation. A careful evaluation of the blast count is
important in this situation.
3.2. Laboratory and pathologic findings
In the peripheral blood, monocytes can be normal or display atypical features such as fine
nuclear chromatin or abnormal nuclear lobulations. In the myeloproliferative variant, median
Myelodysplastic Syndromes166
absolute monocyte counts ranging from 4.2 × 109 to 7.7 × 109/L have been reported [21]; in
general, the median monocyte count is around 2 × 109–3 × 109/L. Morphologic evidence of
dysgranulopoesis is often seen in CMML, while dysmegakaryopoiesis and dyserythropoiesis
are less frequent. The bone marrow is usually hypercellular with an elevated myelopoiesis‐to‐
erythropoiesis ratio. By definition, the blast count is <20%. When enumerating blasts, mono‐
blasts and promonocytes should be included. A helpful morphological classification of
monocytic precursors, particularly defining promonocytes in CMML, is available [28].
Monocytic precursors including monoblasts are frequently CD34 negative. Therefore, there is
a risk of underestimating the blast number by relying only on CD34 staining in bone marrow
biopsies or flow cytometry. The medullary blast count should be determined in good quality
bone marrow aspirates that have also been stained for esterase.
4. Cytogenetics
Clonal chromosomal abnormalities occur in approximately 30% of patients with CMML [29,
30]. The most frequent abnormalities are +8 (20–25%), -Y (20%), monosomy 7 and deletion 7q
(14%), deletion 20q (8%). A complex karyotype was found in 11%. In contrast to MDS, del5q
is very rare. Patients with an abnormal karyotype tended to be older, more anaemic and had
a higher peripheral blood and bone marrow blast count [30]. Additional sex combs like 1
(ASXL1) mutations were associated with an abnormal karyotype, SRSF2 mutations with a
normal karyotype [31]. Cytogenetic abnormalities were also found to be of prognostic
relevance (see Section 6).
5. Molecular findings
Large‐scale sequencing studies in myeloid malignancies have lead to important insights into
disease biology. These studies have shown one of the highest rates of acquired somatic
mutations in CMML patients. For example, in a study by Meggendorfer et al. [31], at least one
mutation in 9 recurrently mutated genes was found in 93% of 275 CMML patients. This study
and several others also identified clear differences in frequency of mutations in key cellular
pathways between CMML and MDS. In addition, the genomic landscape in CMML demon‐
strates a much smaller molecular heterogeneity compared to a more diffuse mutation profile
in MDS [32].
Table 2 summarises the frequency of mutations sorted by the cellular pathway affected [33].
In contrast to MDS, genes serving in different signalling pathways are frequently mutated in
CMML. As a biological correlate, an increased sensitivity to GM‐CSF has been found in vitro.
It appears to be mediated by the STAT pathway, since inhibition of proliferation was observed
by the JAK2 inhibitor ruxolitinib [34], indicating the therapeutic potential of these agents or










RNA splicing SRSF2 46%
ZRR2 10%
U2AF35 10%




Numbers based on Refs. [1, 33].
Table 2. Frequency of somatic mutations in CMML.
Significant differences were also found in the frequency of mutations affecting RNA splicing.
While mutations in SRSF2 are very common in CMML (40–45%), they are found in <10% of
MDS patients, with an enrichment in subtypes with blast excess [31, 32]. Similarly, mutations
in epigenetic regulators, among them TET2 and ASXL1, occur much more frequently in CMML
than in MDS. For example, using next generation sequencing, TET2 mutations were found in
only 39 of 320 patients with MDS (12%) but in 16 of 35 patients with CMML (46%) [35].
TET2 belongs to the ten–eleven translocations family of proteins and participates in the
conversion of 5‐methylcytosine to 5‐hydroxymethylcytosine. TET2 function depends on the
presence of alpha‐ketoglutarate, which is produced by isocitrate dehydrogenase 1 and 2
(IDH1/2). TET2 and IDH1/2 mutations are mutually exclusive and lead to promoter
hypermethylation [36], providing a potential explanation for the mode of action of the hypo‐
methylating agents (HMAs). TET2 mutations appear to be particularly important for CMML
pathophysiology and development of its characteristic phenotype. In a series of elegant
experiments with samples from CMML patients, Itzykson et al. [37] have shown that early
clonal dominance, particularly in a TET2‐mutated clone, promotes granulomonocytic differ‐
entiation. Knockdown experiments of TET2 in human cord blood CD34+ cells have also found
perturbation of myeloid development with promotion of the granulomonocytic lineage [38].
Furthermore, the early occurrence of TET2 mutations could predetermine the acquisition of
secondary mutations, for example in SRSF2, leading to characteristic mutational combinations.
Besides its role in understanding disease biology and classification, mutational analysis is
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likely to impact on various clinical aspects, for example prognostication (discussed below) and
prediction of treatment response.
6. Prognosis
6.1. Individual parameters
The importance of the medullary blast count as a prognostic variable was discussed before
and forms the basis of the subclassification of CMML into CMML‐1 and CMML‐2. The
prognostic significance of cytogenetic abnormalities was first described by the Spanish MDS
group in a cohort of 414 CMML patients. Three risk cytogenetic categories were identified in
that study: low risk (normal karyotype and loss of chromosome Y as single abnormality),
intermediate (all other single or double abnormalities) and high risk (trisomy 8, abnormalities
of chromosome 7 and complex karyotype). The OS at 5 years for these risk groups was 35, 24
and 4%, respectively [29]. In a recent large collaborative analysis of 409 patients with CMML,
slightly different cytogenetic risk groups were defined: low risk [normal, sole -Y, sole der(3q)],
intermediate (all karyotypes not belonging to high or low risk group) and high risk (complex
and monosomal karyotype). In contrast to the Spanish study, trisomy 8 was placed in the
intermediate risk group. The median OS was 41, 20 and 3 months, respectively [30]. The
mutational status of several genes has also shown to be of prognostic relevance, although
conflicting results were found in different cohorts. For example, mutations in TET2 were
associated with no effect on outcome in one study [35] and with an adverse outcome in another
study [39]. In a large series of 312 patients tested for a number of genes, only ASXL1 mutations
had a negative prognostic value in multivariate analysis [40]. This finding was confirmed in a
larger cohort of 466 patients (including the 312 patients from the original series) [41]. In another
large study of 275 CMML patients, no effect of SRSF2 mutations on survival was observed [31].
In summary, ASXL1 mutational status has emerged as a robust prognostic variable and has
thus been incorporated into CPSSs, as discussed below.
6.2. Prognostic scoring systems
A number of prognostic scoring systems for CMML patients have been developed in the past,
none of which however was universally used [42]. This is in contrast to MDS where the
International Prognostic Scoring System (IPSS) and its recently revised version (IPSS‐R) form
the basis of treatment decisions in studies as well as in clinical practice. More recently, novel
CMML‐specific scoring systems have been described that incorporate cytogenetic or molecular
information. These scores appear to be more precise and will be discussed further. First, the
CPSS has been developed by the Spanish MDS group in a cohort of 558 patients [43]. It uses
WHO/FAB subtype, a CMML‐specific cytogenetic risk categorisation and transfusion depend‐
ence to divide patients into four risk groups (low, intermediate‐1 or intermediate‐2, and high)
with a median OS of 72, 31, 13 and 5 months, respectively). This model demonstrated for the
first time that cytogenetic abnormalities are of prognostic relevance in CMML. Notably, it




CMML and MDS. For example, trisomy 8 carries an adverse prognosis in CMML but not in
MDS. The CPPS has been externally validated in a cohort of 274 patients. Second, the French
cooperative MDS group (GFM) developed a prognostic model that included the presence of
ASXL1 mutations, age (>65 years being an adverse prognostic factor), and haematological
parameters (WBC > 15 × 109/L, platelet count <100 × 109/L and haemoglobin <11 g/dl being
adverse factors). It stratifies patients into 3 risk categories with a median OS of not reached,
38.5 and 14.4 months, respectively, and has also been externally validated [40]. Lastly, the
group from the Mayo Clinic has improved on their original prognostic model by incorporating
ASXL1 mutational status. This new score has been termed Mayo Molecular Model (MMM)
and was developed in corporation with the GFM [41]. Five risk factors affected median survival
in multivariate analysis: ASXL1 mutation status, absolute monocyte count >10 × 109/L,
haemoglobin levels <10 g/dl, platelet count <100 × 109/L, and circulating immature myeloid
cells. It divides patients into four risk categories with median survival of 97, 59, 37 and 16 
months, respectively. Importantly, this new score can identify low risk patients (by the original
Mayo Clinic score) with a high risk of progression (without or with ASXL1 mutation: median
survival 99 vs. 44 months).
Particularly when considering allogeneic stem cell transplantation, prognostication in younger
CMML patients, defined as younger than 65 years, is crucial. A retrospective analysis of 261
such patients has identified several adverse prognostic factors that differ from those in the
general CMML population. In addition to anaemia and ASXL1 mutations, an increased
circulating blast count, SRSF2 mutations and the cytogenetic risk classification of the Mayo‐
French consortium were independently prognostic. In this study, ASXL1 and SRSF2 mutation
status did not influence response to HMAs or transplantation outcome [44].
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Although providing little prognostic information, the concept of a myelodysplastic and a
myeloproliferative variant of CMML is helpful in guiding treatment. In particular, patients
suffering mainly from uncontrolled myeloproliferation may require rapidly acting
cytoreductive treatment. On the other hand, patients with symptoms due to marrow failure
require treatment aiming at restoring adequate peripheral blood counts. No treatment so far
has been shown to prolong survival or to alter the natural history of the disease. However,
randomised studies in CMML patients have not yet been performed, with one exception [45].
Typically, CMML patients (excluding those with MPD‐CMML) were included in MDS trials,
albeit in small numbers precluding a meaningful statistical analysis. For example, in the AZA‐
001 trial that led to the registration of azacitidine in higher risk MDS only 16 of the 358 enrolled
patients had CMML [46].
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For the treatment of lower risk patients with symptomatic anaemia, erythropoiesis‐stimulating
agents (ESA) might be helpful. A 64% erythroid response rate and transfusion independence
in 33% of patients was recently reported in a retrospective analysis of 94 CMML patients. Low/
intermediate‐1 CPSS and low endogenous erythropoietin levels were predictors of response
[47]. ESA's should be used with caution in patients with myeloproliferative CMML because of
the risk of splenic enlargement or rupture.
Younger patients with high‐risk features (for example intermediate‐2 or high risk in the MMM)
should be evaluated for eligibility for allogeneic stem cell transplantation. Whether high‐risk
patients benefit from early treatment with HMAs, as in high‐risk MDS, must be tested in
prospective randomised trials.
7.2. Stem cell transplantation
Allogeneic stem cell transplant (allo‐SCT) still remains the only curative option for patients
with CMML and should be considered in younger patients with high‐risk disease. So far all
reports on allo‐SCT in CMML have been retrospective and many included patients with
CMML as well as MDS. CMML-specific patient series have only been recently reported, with
the EBMT series comprising 513 patients being by far the largest [48]. The median age was
53 years, clearly younger than the median age of CMML patients in general. The non‐relapse
mortality at 1 and 4 years was 31 and 41%, respectively. The incidence of relapse at 4 years was
32%, resulting in an estimated 4‐year relapse free survival of 27% and OS of 33%, respectively.
Of note, no influence of procedure‐related parameters such as stem cell source, type of donor
or T‐cell depletion on outcome was found. Importantly, the only significant parameter
associated with an improved outcome was the presence of a complete remission at the time of
transplantation. A similar trend was also found in a smaller study [49]. Thus, allo‐SCT can
provide long‐term remissions in about 30% of younger patients. The procedure should be
performed after achievement of the best possible remission status, either with combination
chemotherapy or with HMAs. Although the best preparatory regimen is not known, a recent
retrospective study of 83 patients from the MDACC supports the use of HMA before allo‐SCT.
The study found a significantly lower incidence of relapse at 3 years post transplant in patients
treated with HMA, compared to patients treated with other agents (22 vs. 35%, p = 0.03),
resulting in a better 3‐year progression‐free survival [50]. A selection bias might confound
these interesting results, since patients who do not progress while treated with HMA (median
of 6 cycles in the study) are likely to have a less aggressive disease.
7.3. Cytoreductive treatment
In patients with symptoms mainly caused by myeloproliferation, cytoreductive treatment is
indicated. Several studies have demonstrated the effect of the topoisomerase‐I inhibitor
topotecan in patients with CMML. As a single‐agent, complete response rates of up to 28%
have been described [51]. Similarly, clinically meaningful responses, including improvement
of life threatening pericardial and pleural effusions, as well as cytopenias were reported for
the topoisomerase‐II inhibitor etoposide [52]. However, in a randomised study of 105 patients




response rate (60 vs. 36%) and OS (20 vs. 9 months) and has thus remained the treatment of
choice for palliative cytoreduction in CMML patients [45]. The experience with intensive
chemotherapy in CMML has been disappointing [53]. AML‐like induction therapy is only
rarely used, usually as a preparatory regimen before allogeneic stem cell transplantation in
patients with an aggressive disease.
7.4. Hypomethylating agents
The introduction of the HMAs azacitidine and decitabine is likely to transform clinical
management of CMML. A growing number of studies have shown considerable single agent
activity with very low toxicity. In the largest study so far (76 patients from France, Cleveland
Clinic and Lee Moffitt Cancer Center), a response rate of 43%, with 17% complete remissions,
was found [54]. Of note, 46% had a proliferative form of CMML, as defined by a leukocyte
count of >13 × 109/L. In that study, the presence of more than 10% bone marrow blasts and
palpable splenomegaly had a negative impact on survival. A smaller Italian retrospective
study analysed the response in 31 patients with CMML (42% with CMML‐1, 58% with CMML‐
2) who were treated with azacitidine at a dose of 75 or 50 mg/m2 for 7 days. The overall response
rate was 51%, including 45% achieving complete remission [55]. A study from the Austrian
Azacitidine registry reported on the outcome of 48 patients treated with azacitidine at 11
different centres [56]. Mean age was 71 years; 40% had CMML‐1; 60% had CMML‐2; and
splenomegaly was found in 48%. Even in this unselected cohort with several high‐risk features,
there was a surprising response rate of 70%, including 22% complete responses. Matched
paired analysis suggested a better 2‐year‐survival when compared to best supportive care (62
vs. 41%, p = 0.067).
Other studies have examined the activity of the related HMA decitabine in CMML. One of the
first reports was published by the MDACC group on 19 patients with CMML, and a complete
response rate of 58% was found. The dose of decitabine was 100 mg/m2 per course, given in
three different treatment schedules [57]. In a phase 2 trial from the GFM, 39 patients with
advanced CMML were treated with decitabine at a dose of 20 mg/m2 for 5 days. The median
number of treatment cycles was 10 and the overall response rate 38%, OS at 2 years was 48%.
Interestingly, the presence of ASXL1 mutations had no significant impact on response or
survival in that study [58]. A review of CMML patients that were included in several phase 2
and one phase 3 trials of decitabine in MDS was done by Wijermans et al. [59]. Among a total
of 271 patients, 31 CMML patients were identified. The overall response rate was 25% with
14% CR, and 39% had stable disease. The treatment schedule was different than in the GFM
study, and many patients received only a few cycles of therapy (median of four cycles).
Reliable and easily available predictors of response to treatment with HMA have not yet been
identified. Although a correlation of response with TET2 mutational status would seem
plausible, this was not found in two different studies [58, 60]. Likewise, no other somatic
mutation frequent in CMML proved to be predictive of response.
A small retrospective analysis has shown activity of decatibine and azacitidine in reducing
spleen size in CMML patients. Spleen size was measured by physical examination, and
complete or partial spleen response was found in 5 of 11 patients (45%) [61].
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Although these data are promising and have led to the registration of both drugs for the
treatment of CMML, data from phase 3 trials demonstrating a survival benefit are not yet
available. Also, the optimal treatment schedule and treatment duration need to be defined.
The results of an ongoing randomised trial (DACOTA trial) comparing hydroxyurea to
decitabine in patients with advanced proliferative CMML are, therefore, eagerly awaited. This
trial is conducted in three countries (France, Italy and Germany) and will include about 160
patients. The primary endpoint is progression‐free survival.
7.5. Investigational agents
A large number of investigational agents have been tested in CMML, among them tyrosine
kinase inhibitors, farnesyltransferase inhibitors, immunomodulators and most recently JAK2
inhibitors. The experience with many of these approaches is limited to small phase 1 or phase
2 studies that have not been further developed, either because of limited activity or because
of significant toxicity.
Imatinib has shown no effect in CMML patients without a PDGFRB rearrangement. Because
CMML cells often have RAS activating mutations, drugs targeting this pathway have been
tested. In a phase 2 trial, 35 patients with CMML were treated with lonafarnib (200–300 mg
twice daily), one CR and 7 haematological improvements were reported. Major toxicities were
gastrointestinal, fatigue, fever and hypokalemia [62]. Similar results were observed for
tipifanib in a study of 10 CMML patients [63]. In several patients treated with lonafarnib, a
significant increase in the white blood cell count was noted, sometimes accompanied by
oedema and respiratory symptoms. This complication resolved quickly after discontinuation
of lonafarnib and treatment with dexamethasone [64]. Disappointingly, translational studies
have shown no correlation between responses and inhibition of farnesyl transferase.
Interesting results have been found in a study targeting angiogenesis in MDS and CMML
patients with a combination consisting of melphalan (2 mg/day) and lenalidomide (10 mg/
day). Changes in circulating endothelial cells and plasma VEGF levels served as biomarkers
of angiogenesis. The response rate was 33% in CMML patients (3/9), all of which had a
proliferative form of the disease. Interestingly, there was a correlation between response and
angiogenesis inhibition in these patients. Dose reductions were frequently necessary, but many
patients were cytopenic already at baseline [65].
Most recently, a multicentre phase 1 trial (only published in abstract form) tested the JAK2
inhibitor ruxolitinib in 19 CMML patients. All patients had CMML‐1 and those with significant
cytopenias were excluded. No dose limiting toxicity was noted. Although there were few
haematologic responses, a frequent improvement of splenomegaly and B symptoms was
found. A phase 2 trial testing ruxolitinib at a dose of 20 mg BID is planned [66].
8. Summary and outlook
CMML is a rare myeloid neoplasm with an overall poor prognosis. Important progress has




entity, separated from the myelodysplastic syndromes, is an important step towards optimis‐
ing clinical management. Second, the introduction of CPSSs will improve patient selection in
clinical trials. Phase 3 clinical trials in CMML patients will soon define the role of HMA in
treatment. The elucidation of the mutational landscape in CMML has not provided disease‐
specific mutations but highly characteristic mutational combinations, particularly of TET2 and
SRSF2. These insights into molecular pathology are very likely to provide the basis for the
development of novel therapeutic agents. Individualised therapies based on the predominant
gene mutations could be envisaged. For example, while patients with TET2 mutations are
treated with HMA, in patients with mutations affecting signalling, specific pathway inhibitors
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Abstract
Myelodysplastic syndromes (MDSs) represent clonal hematopoietic stem cell (HSC)
disorders in which genetic and/or epigenetic alteration are involved in the normal function
of hematopoietic stem and progenitor cells. This results in the development of blood
cytopenias and bone marrow dysplasia. In recent years, therapy with hypomethylating
agents (HMAs) in combination with supportive therapies is recommended as frontline
treatment for patients with high-risk MDSs according to International Prognostic Scoring
System (IPSS HR-MDS). Therapy with HMAs is essential namely for IPSS HR-MDS
patients who do not proceed to immediate allogeneic stem cell transplantation (al‐
loSCT). For IPSS LR-MDS (International Prognostic Scoring System, low-risk MDSs)
patients, however, supportive therapies and growth factors are the mainstay of treatment.
Some patients in this group are treated with immunomodulatory agents derived from
thalidomide (lenalidomide) or using immunosuppressive therapy (IST). The therapeu‐
tic decisions can change during the course of the disease based on changes in risk-
category and the functional status of patients, in response to prior therapies, changes in
patient preferences, and other factors.
Resistance to chemotherapy is a serious obstacle to the successful treatment of overall
malignancies, including AML and MDS. The failure of therapeutic treatment may be due
to the development of multidrug resistance (MDR) phenotype. MDR represents the
induction of large-scale defensive mechanisms from which the upregulation of membrane
transporters (like P-glycoprotein – P-gp) effluxing chemotherapeutic drugs from tumor
cells represents the most observed molecular causality. Other mechanisms of MDR include
drug metabolism, alterations in drug-induced apoptosis, epigenetic changes, epithelial-
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
mesenchymal transition, alteration in drug targets structures, and acceleration of DNA
repair.
The present contribution represents a state-of-the-art review of available knowledge
about this issue.
Keywords: myelodysplastic syndromes, acute myeloid leukemia, multidrug resist‐
ance, lenalidomide, 5-azacytidine, 5-aza-2-deoxyazacytidine
1. Introduction
Myelodysplastic syndromes (MDSs) represent the group of disorders associated with altered
hematopoietic stem cells (HSCs) that lead to inefficient hematopoiesis [1]. This clinically results
in dysplasia in one or more myeloid cell lineages, and variable degrees of cytopenias. The mean
age of MDS patients’ diagnosis ranges from 60 to 70 years. The incidence of MDS varied from
4.3 to 1.8 per 100,000 individuals per year in the US and Europe, respectively. Incidence slightly
favors Caucasian males. MDS can lead to acute myeloid leukemia (AML) in 10–15% of patients.
Improvements in cytogenetic analysis techniques enable predicting the risk of MDS patients
lapse into AML and the selection of optimal therapy [2]. The International Prognostic Scoring
System (IPSS) described in the 1990s [3] is still commonly used. This scoring system defines
how to measure the risk of patients’ development from MDS to AML, and recommends
dividing patients into four groups (low, intermediate 1, intermediate 2, and high risk). In lower
risk patients, a combination of supportive care (includes transfusions of blood products,
antibiotics) with substance improving erythropoiesis, immunosuppressive therapy, immuno‐
modulatory therapy, and stem cell transplantation has been used. Treatment options for
patients diagnosed as higher risk include demethylating agents, cytotoxic chemotherapy, bone
marrow HSC transplantation, and experimental treatments in clinical trials [4].
2. Treatment options
The only curative option for patients with MDS represents hematopoietic bone marrow stem
cell transplantations. However, alloSCT is not available for all patients because of the comor‐
bidities of elderly patients [1]. Therefore some patients cannot be treated with alloSCT and
other treatment options have to be used.
2.1. IPSS low-risk MDS patients’ treatment option
Supportive care is an important therapy for the management of patients with low-risk MDS,
as well as patients with poor disease prognosis which due to age or physical condition could
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not be treated with more intensive forms of therapy [5]. Several low-risk patients are dependent
on blood transfusions. However, patients treated with blood transfusions may be overloaded
with iron ions, so that iron chelation therapy is required [6]. Due to the partial dysfunction of
immunity, antibiotics are needed for treatable infections [7].
There are three commonly used therapies for low-risk MDS patients: i. erythropoiesis-
stimulating agents (ESAs); ii. immunosuppressive therapy; and iii. immunomodulatory
therapy with thalidomide derivative lenalidomide (revlimid). The treatment of patients with
ESAs leads to significant erythroid response in 20–70% of unselected patients with MDS [1].
A median response for treatment with erythropoietin and colony-stimulating factor (CSF)
applied together was 2 years and improves life quality [8]. Several immunosuppressants such
as antithymocyte globulin and cyclosporine A were studied in a randomized phase III clinical
trial. This treatment seems to be associated with hematologic responses in a subset of patients,
however, it was not found to reduce the 2-year transformation and overall survival [9].
Over recent years, attention has been paid to immunomodulatory-acting drugs (IMIDs). The
anti-MDS activity of these drugs involves antiproliferative effects, downregulation of crucial
cytokines, and costimulatory effects on T and NK cells [10]. The IMIDs are thalidomide analogs
which have greater immunological and anticancer properties, but lack the toxicity associated
with thalidomide [11]. Lenalidomide (LEN) was proven to be effective in the treatment of
patients with low-risk MDS, particularly in cases with special molecular feature, i.e., deletions
in the long arm of chromosome 5 [12, 13].
2.2. IPSS high-risk MDS patients’ treatment option
Patients with high-risk MDS have poor outcomes, high probability of AML development, and
without intensive treatment or alloSCT their median survival is limited to 1 year [3]. The
treatment of high-risk MDS patients is based on three commonly used therapies: i. alloSCT; ii.
intensive chemotherapy; and iii. drugs with epigenetic mechanism of action such as deme‐
thylation agents and histone deacetylase inhibitors (HDACi) [1]. Similarly as in low-risk
patients, the application of alloSCT is limited by the patients’ age and overall condition.
About 50% of patients with high-risk MDS achieve complete remission with standard anti‐
leukemic chemotherapy with fludarabine, idarubicin, or topotecan. This therapy could be
improved by a combination of these drugs with intermediate- or high-dose cytosine arabino‐
side [14]. The combination of such therapy with granulocyte colony-stimulating factor (G-CSF)
is well tolerated and highly effective in the remission of both high-risk MDS patients and AML
patients [15].
Inhibitors of histone deacetylase block the deacetylation of histones molecules, i.e., they protect
histones in acetylation forms. The acetylation of histones occurs in the replication- and
transcription-active euchromatin. HDACi could protect euchromatin against formation
changes to heterochromatin that is replication and transcription inactive. The effect of HDACi
could be pleiotropic, leading to the induction of differentiation, growth arrest, and finally to
the apoptosis of tumor cells. The mechanisms of HDACi’s effectiveness are under intensive
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debate, and it may be p53 dependent or independent [16]. Valproic acid, entinostat, vorinostat,
and other HDCAi are under intensive research with the aim of characterizing their effective‐
ness against MDS [16].
The cytosine analogs 4-amino-1-(β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one – azacytidine
(AzaC) and 4-amino-1-(β-D-deoxyribofuranosyl)-1,3,5-triazin-2(1H)-one – deoxyazacytidine
(decitabine, DAC), which were described as cancerostatic agents in the late 1960s and the early
1970s [17, 18], were found to effectively block DNA methylation [19]. Their effectiveness in
inducing beneficial effects in the treatment of MDS [20] and AML [21] was already proven.
The downregulation of DNA methylation induced by AzaC and DAC is related to the ability
of this substance to be artificially incorporated into DNA instead of cytosine, which has to be
methylated by DNA methyltransferase [22]. This could be considered as a major principle of
DAC action. In contrast to DAC’s effects, AzaC is more complex and also involves incorpora‐
tion into mRNA, tRNA, and rRNA, which disrupts nucleic acid and protein metabolism
leading to apoptosis in addition to the incorporation of substances into DNA [22, 23]. Consis‐
tently AzaC induced more pronounced cell damage effects than DAC [24].
3. Drug resistance of MDS and AML patients
3.1. Mechanisms of drug resistance of neoplastic cells
The multidrug resistance (MDR) of neoplastic cells represents a real obstacle in the effective
treatment of neoplastic diseases [25]. MDR could be an inherent property of tissue from which
neoplastic cells were developed – primary (intrinsic) MDR, or could be induced by prior
treatment with anticancer drugs – secondary (acquired) MDR (reviewed in [26]). In both cases
the neoplastic cells exert reduced sensitivity to more than one drug that differs in structure
and pharmacological efficiency. In many cases, cells with resistance to a large scale of diverse
drugs are present in cancer tissue. Several mechanisms are involved in the mediation of MDR,
which can be divided into seven groups (Figure 1, reviewed in [27]):
i. Potentiating drug metabolism via the induction/activation of phase I and phase II
detoxification enzymes
ii. Potentiating cell drug efflux via the induction/activation of membrane drug trans‐
porter predominantly members of the ABC family
iii. Alteration in drug target structures
iv. Acceleration of DNA-repair
v. Changes in epigenetic regulation
vi. Programmed cell death inhibition
vii. Epithelial-mesenchymal transition
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Figure 1. Mechanisms of multidrug resistance.
These mechanisms could act independently or cooperate in the development of MDR in
relation to cancer cells’ specific character. The expression of drug transporters represents the
most observed molecular causality of MDR (reviewed in [28, 29]). At least three transporters
are involved in the reduction of drug sensitivity of neoplastic cells. The best known is P-
glycoprotein (P-gp) that represents an ABCB1 member of the ABC transporter family and was
discovered as the first ABC transporter in 1976 [30]. P-gp could efflux a large scale of different
uncharged substances from cells. Drugs such as colchicine, tacrolimus, and quinidine;
chemotherapeutic agents such as etoposide, doxorubicin, and vinblastine; different lipids and
steroids; xenobiotics; DNA-intercalators such as ethidium bromide; linear or circular peptides
like valinomycin and gramicidin; bilirubin; cardiac glycosides like digoxin; different immu‐
nosuppressive agents; glucocorticoids like dexamethasone; HIV-type 1 antiretroviral therapy
agents like protease inhibitors and nonnucleoside reverse transcriptase inhibitors; and many
others are known to be P-gp substrates. When P-gp is expressed in neoplastic tissue it can
depress cell sensitivity to its substrates several hundred times [31]. Besides this generally
accepted role as a drug transporter, this protein may also play another role as an antiapoptotic
regulatory protein and this role is independent of P-gp efflux activity [29, 32]. This additional
role also enables P-gp to reduce cell sensitivity to substances that are not its substrates, such
as cisplatin several times [33, 34].
Other important transporters involved in MDR are ABCC1-3 members of the ABC transport‐
ers’ family, also known as multidrug-resistant associate proteins 1–3 (MRP1-MRP3) that in
contrast to P-gp are specific to negatively charged organic anions (reviewed in [35]). They are
also specific for drug conjugates with glucuronic acid and glutathione as a product of phase
II enzyme drug detoxification.
One more transporter ABCG2 member of the ABC transporter family is often described to be
involved in MDR [36]. This transporter also known as breast cancer-resistant protein (BCRP)
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may efflux substances such as mitoxantrone, methotrexate, topotecan, imatinib, and others.
The substrate specificity of P-gp, MRP1-3, and BCRP overlaps, and each could be responsible
for the efflux of common substrate.
The drug could be detoxified by phase I and phase II detoxification enzymes that secure
oxidative and conjugative ways of drug modification which are mediated by cytochrome P450
(CYP) monooxygenases and conjugating enzymes (glutathione S-transferases [GSTs] and
UDP-glucuronyl-transferase), respectively [37]. The CYP family, particularly the CYP3A
members of the CYP family, may be involved in the reduction of cell sensitivity to several
drugs. The transcriptional control of the CYP family is mediated by pregnane X nuclear
receptor, i.e., the same nuclear receptor involved in P-gp expression [38].
GSTs represent a group of enzymes that are often involved in the protection of cells against
toxic stress [39]. These enzymes catalyze the conjugation of several xenobiotics with reduced
glutathione [40]. The actions of GSTs are often coordinated with MRPs that transport several
conjugates of drugs and reduced glutathione [41]. While P-gp cannot transport glutathione
conjugates, coordinated coexpression of P-gp and GST was observed in vitro using AML cell
lines [42].
Alteration in drug target structures such as the mechanism of MDR represents a large group
of diverse changes in regulatory pathways, which is finally responsible for the downregulation
or upregulation of drug molecular target. An example of this behavior alteration of topoiso‐
merase II, such as the molecular causality of neoplastic cell resistance to topoisomerase
poisons, could be performed (reviewed in [28]).
The repair of DNA primarily damaged by drugs’ direct action, or secondarily by the elevation
of oxygen reactive species formation, clearly yields to the drug resistance of neoplastic cells
[27]. The therapeutic effects of DNA-damaging drugs in cancer treatment are given by the
equilibrium between drug-induced DNA damage and the effectiveness of DNA repair
mechanisms. The inhibition of repair pathways used in conjunction with DNA damaging
chemotherapy could sensitize cancer cells and therefore increase the efficacy of therapy [27].
Epithelial-mesenchymal transition is a mechanism predominantly taking part in solid tumor
metastatic processes. This mechanism could play only a minor role (if any) in drug resistance
development in MDS and AML patients.
The high expression levels of antiapoptotic proto-oncogene of the Bcl-2 family (such as BCL-2,
Bcl-XL, Mcl-1, Bcl-w, and Bfl-1) were often reported to be associated with in vitro resistance
to chemotherapeutic agents, poor clinical outcomes in cases of AML [43], and in cases of adults
with acute lymphoblastic leukemia [44]. Bcl-2 was shown to be restricted in tissues character‐
ized by apoptotic cell death [45]. Antiapoptotic proteins of the Bcl-2 family hetero-oligomerize
in vivo with a conserved homolog – proapoptotic member of the Bcl-2 family (such as Bax),
and this process is known to modulate apoptosis [46]. The translocation of the Bax (or other
proapoptotic protein) monomer from the cytosol to the mitochondria followed by the forma‐
tion of BAX homo-oligomers represents a physiological death stimulus, which may be
prevented by the presence of the Bcl-2 protein (or other antiapoptotic proteins) [47]. Therefore
for apoptosis progression, an equilibrium between anti- and proapoptotic proteins plays a
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crucial role. This is molecularly regulated by the p53 known as the central regulator of
apoptosis [48]. This is consistent with known data about the role of the mutated form of TP53
in cancer [49, 50].
Epigenetic regulations are involved in the development of MDR directly by the downregula‐
tion or upregulation of important genes responsible for cell death or survival. For example,
tumor-suppressor genes are often silenced via hypermethylation, and oncogenes are overex‐
pressed via hypomethylation [27]. Epigenetics could also play an indirect role in cell drug
sensitivity by the following mechanism: the opening of the chromatin structure, which is
prerequisite for DNA replication and transcription, and to produce uncovered DNA that is
more accessible for drug-induced DNA damage. This is consistent with more pronounced
DNA damage induced with drugs in more proliferating and/or transcriptionally active cells.
Hypermethylation of the MDR1 promoter was associated with transcriptional repression and
chromatin structural changes [51]. The demethylation of this promoter in cancer cell lines was
found to elevate the multidrug-resistant phenotype [52].
Epigenetic mechanisms can also influence DNA damage repair. For example, DNA mismatch
repair processes can be lost due to the hypermethylation of the human mutL homolog 1
(hMLH1) gene promoter, which can lead to cancer development [27].
Demethylation by DAC may have a role in increasing the efficacy of chemotherapy for patients
with tumors, as characterized by high hMLH1 promoter methylation and low hMLH1
expression [53].
3.2. Resistance to immunomodulatory drugs
Over recent years, attention has been paid to exploiting the immunomodulatory effects
primarily obtained for thalidomide [54], which has resulted in novel IMIDs. The anti-MDS
activity of these drugs (namely LEN) was proven for low-risk MDS, particularly with 5q
deletion (del[5q]) [55]. This action is attributed to several mechanisms that involve antiproli‐
ferative effects, downregulation of crucial cytokines, and costimulatory effects on T and NK
cells [10]. However, the exact mechanism of IMIDs’ action in MDS treatment is still not fully
understood. The IMIDs’ immunomodulatory compounds derived from the thalidomide
structure have greater immunological and anticancer properties, but lack the toxicity associ‐
ated with thalidomide [11]. LEN (Revlimid) was approved for use in low- and intermediate-1-
risk MDS patients who have the deletion 5q chromosome and no other chromosomal
abnormalities, are dependent on red blood cell transfusions, and for whom other treatment
options have been found to be insufficient or inadequate by EMA (European Medicines
Agency) and the FDA (Food and Drug Administration). After LEN treatment, blood transfu‐
sion-independent rates were 56–67%, and median response duration was longer than 104
weeks [1]. Additionally, a significant proportion of these responders achieved cytogenetic
responses (50–76%), indicating a direct cytotoxic effect of LEN on the neoplastic clones,
although a significant proportion of patients develop resistance to this treatment. The study
of cytogenetics and molecular predictors of responses in patients with myeloid malignancies
without del[5q] treated with LEN indicated that treatment could be effective in patients with
Different Mechanisms of Drug Resistance in Myelodysplastic Syndromes and Acute Myeloid Leukemia
http://dx.doi.org/10.5772/63483
187
normal karyotype and a gain of 8 chromosome is present [55]. The LEN response was achieved
by one quarter of MDS patients lacking the 5q abnormality. Ebert et al. [56] found that
mononuclear cells from bone marrow aspirates of patients who respond to LEN have a
decreased expression of genes, which are specific to terminal erythroid differentiation,
regardless of the presence or absence of a 5q deletion. Moreover, LEN acts directly on hema‐
topoietic progenitor cells to increase erythropoiesis relative to other lineages.
The mechanism of LEN’s therapeutic effects and the mechanisms that depress its effectiveness
in MDS treatment are not fully understood, but could be related to TP53 mutation (reviewed
in [57]).
TP53-mutated populations seem to be associated with the early stage of low-risk MDS in
patients with del[5q] [58]. However, these authors stated that TP53 mutations could not be
predicted by general clinical features but were associated with p53 overexpression. Specific
R72P polymorphism of TP53 results in two molecular forms of p53. Molecular variant p53-R72
with better mitochondrial localization activates apoptosis more efficiently (by direct induction
of cytochrome c release) than p53-P72 variant [59]. McGraw et al. [60] underscore the distri‐
bution of R72P in MDS and highlight differences between del(5q) and non-del(5q) subtypes
by gene polymorphism and the relationship to LEN response. However, to prove the potential
interaction of R72P variants with germline variants in other key regulators or effectors of the
p53 pathway that may modify MDS risk and LEN treatment response, further research will be
necessary.
Allelic deletion of the RPS14 gene is a key effector of the hypoplastic anemia in patients with
MDS and chromosome 5q deletion [61]. Disruption of ribosome integrity liberates free
ribosomal proteins to bind to and trigger the degradation of E3 ubiquitin-protein ligase MDM2
(a negative regulator of p53), with consequent p53 transactivation. Consistently, p53 is
overexpressed in erythroid precursors of primary bone marrow del(5q) MDS specimens
accompanied by reduced cellular MDM2. LEN may act in the stabilization of MDM2 that leads
to p53 degradation [61].
When LEN was used in establishing human AML cell lines SKM-1 and MOLM-13 for resist‐
ance, only SKM-1 but not MOLM-13 cells developed MDR phenotype with massive expression
of P-gp [62]. Both these cell lines were derived from AML patients, whose disease developed
from MDS. In contrast to MOLM-13 with wild type of p53 [63, 64], SKM-1 represents cells
expressing a mutated p53 form [65]. Thus cells with mutated TP53 could express P-gp under
long-term LEN treatment, which leads to typical P-gp mediated MDR.
3.3. Resistance to hypomethylating agents
In pathogenesis of MDS, both genetics and epigenetics alterations are cooperated. Disruption
of genetic pathways regulating the processes of self-renewal, differentiation, quiescence, and
stem cell-niche signaling contributes to AML transformation. The hypermethylation of
different genes was discussed to be partially responsible for the poor prognosis of MDS
patients [66]. Demethylating agents, such as AzaC and DAC, were shown to induce clinical
responses in 40–70% of MDS patients [67, 68]. Although hypomethylation is considered the
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dominant mode of therapeutic action of these drugs, it may also induce DNA damage and
consequent apoptosis [69]. Interestingly, clinically significant responses to decitabine without
significant toxicity can be seen in patients after nonsuccessful azacitidine therapy [70].
Changes in the expression profile of genes like CD9, GPNMB, FUCA1, ANGPT1, PLA2G7,
TPM1, and ARHGEF3 were observed when CD34+ cells isolated from the bone marrow of
high-risk MDS patients treated in vitro with DAC were compared with CD34+ cells isolated
from patients with untreated early stage Hodgkin's lymphoma taken as a control [66].
AzaC resistance represents a real obstacle for the effective treatment of MDS patients, which
focused the attention of scientists on alternative therapeutic strategies for nonresponsive
patients. For this reason, AzaC-resistant MDS/AML cell lines are established. AzaC-resistant
SKM-1 cells exhibited increased expression of the BCL2L10 member of the antiapoptotic Bcl-2
family that altered apoptosis progression [71]. Interestingly we described the downregulation
and changed molecular form of the Bcl-2 protein identified by polyclonal antibody (sc-492,
Santa Cruz Biotechnology, USA) in our variant of SKM-1 AzaC-resistant cells [42]. Moreover,
other AzaC-resistant AML cells derived from the MOLM-13 cell line exerted similar changes
in the Bcl-2 protein. Significant correlation of AzaC resistance with a percentage of MDS or
AML cells expressing BCL2L10 was established on a group of 77 patients [71].
AzaC resistance could include impaired mitochondrial membrane permeabilization and
caspase activation when AzaC resistant and sensitive SKM-1 myeloid were compared [72]. In
our experiments, when the same cell model was used resistance to AzaC was associated with
strong over expression of P-gp that secured additional resistance to P-gp substrates [42]. This
is a rather interesting finding because AzaC is not a P-gp substrate, and P-gp was not respon‐
sible for AzaC resistance. We obtained similar results using MOLM-13 cells. The activity of
GST was found to be elevated 8 times when AzaC resistant and sensitive SKM-1 and MOLM-13
cells were compared [42].
AzaC induced the upregulation of LC3-II and elevation of cathepsin B activity (both autophagy
markers). Increased basal autophagy was observed in SKM-1 AzaC-resistant cells, but these
cells were resistant to AzaC-mediated autophagy [72]. Autophagy depression using a LC3
silencer revealed the protective function of autophagy in AzaC-sensitive and AzaC-resistant
cells in basal condition [72]. Taking all the facts about apoptosis and autophagy progression
in AML cell models together, it could be concluded that resistance to AzaC is associated with
alterations of both processes via impaired homeostasis of its key regulators such as Bcl-2 family
proteins and LC3. However, the exact mechanism of this feature is not fully understood and
future research will be necessary.
Enzymes involved in cytidine metabolism such as cytidine deaminase (CDA) and deoxycyti‐
dine kinase (DCK) seem to be responsible for the primary (intrinsic) AzaC resistance, because
nonresponders of AzaC have a 3-fold higher CDA/CDK ratio. There were no significant
differences at relapse in DAC metabolism genes, and no CDK mutations were detected [73].
MDSs are characterized by mutations in genes encoding epigenetic modifiers and aberrant
DNA methylation. Clonal mutation of TP53 and non-receptor type 11 protein tyrosine
phosphatase were associated with shorter overall survival, but not the drug response of
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patients. Clonal tet methylcytosine dioxygenase 2 (TET2) mutations predicted a response when
subclones were treated as wild type. The highest response rate was observed in patients with
a mutation in the TET2 gene without a clonal mutation of the trancriptional regulator encoded
by ASXL1 gene. [74].
While somatic mutations did not differentiate responders from nonresponders for DAC
treatment, differentially methylated regions of DNA at baseline distinguished responders
from nonresponders. In responders, the upregulated genes included those that are associated
with the cell cycle, potentially contributing to effective DAC incorporation [75].
While DAC is generally accepted as a hypomethylating agent, it may exert a therapeutic effect
also in another way. The acceleration of reactive oxygen species induced with DAC could take
place in the overall DAC effect. However, reactive oxygen species accumulation was not
always present in the sample of AML patients after DAC treatment. Therefore, the relevance
of reactive oxygen species generation in the mechanism of DAC pharmacological effectiveness
should be studied more intensively in the future [76].
3.4. Resistance to intensive chemotherapy
MDS intermediate- or high-risk patients may be treated with an intensive chemotherapy
regimen that is similar as used for AML treatment. A combination of drugs such as cytosine
arabinoside, fludarabine, idarubicin, and topotecan, etc. could be used [14]. This chemotherapy
is oriented on destroying abnormal blood cells or preventing their growth. For patients who
are eligible, bone marrow transplantation is recommended after this therapy.
The development of MDR resistance during the application of this protocol is similar as for
other types of neoplastic diseases, and may involve each of the mechanisms described in
Chapter 3. The combination of drug-resistant mechanisms that are included in MDR pheno‐
type development during high intensive treatment depends on the specific patient molecular
feature, previous therapeutic history, and drugs applied during previous treatment.
3.5. Resistance to CD33-targeted therapy
Progressive methods of MDS treatment represent antibody targeting therapy with cytotoxic
agents linked to humanized antibodies against antigens specific to neoplastic cells. Both MDS
and AML are characterized by the presence of undifferentiated CD33-positive myeloblast in
peripheral blood and bone marrow, compared with healthy control [77]. CD33 is a 67 kDa
glycoprotein present on the surface of myeloid cells, and is a member of the sialic acid binding
immunoglobulin-like lectin family of proteins [78]. After binding to an appropriate antibody,
CD33 is rapidly internalized into leukemia cells [79, 80]. This action enables the use of a
humanized CD33 antibody, conjugated to cytotoxic agents for targeted immunotherapy [78,
79]. Gemtuzumab ozogamicin represents antibody drug (from a class of calicheamicins)
conjugates [7, 78–81]. This therapy has proven to be effective, but resistance to treatment could
be developed. Another immune-targeting preparation is AVE9633 (immunoconjugate of
humanized monoclonal CD33 antibody, linked through a disulfide bond to the maytansine
derivative DM4) that was used in the treatment of several leukemia cell lines [82]. The activity
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of P-gp was attributed as a critical factor in depressing the success of this therapy. P-gp
mediated the efflux of drug liberated from linkage with antibody due to intracellular enzymes
was attributed as being responsible for this resistance [82]. However, a significant inverse
correlation was determined for the expression of P-gp and CD33 in the AML blast obtained
from patients [81]. We described the strong downregulation of CD33 on mRNA and the protein
level in P-gp positive SKM-1 cells selected for resistance by LEN, vincristine, mitoxantrone, or
in P-gp positive MOLM-13 cells selected for resistance by vincristine or mitoxantrone [62].
Upregulation of CD33 expression level was also observed in P-gp silenced cell lines. Therefore,
the failure of CD33-targeted therapy of patients with AML blast overexpressing P-gp could be
caused by a lack of CD33 as an antibody target structure on the cell surface.
3.6. Detection of drug-resistant markers in neoplastic cells
Cellular expression of drug-resistant markers could be monitored on mRNA level (RT-PCR
methods) or protein level (Western blot and immunofluorescence flow cytometry) [83].
Proteins active in MDR development like ABC transporters, drug metabolizing enzymes,
antiapoptotic proteins, and many others could be detected by these methods. Transport
activity of drug transporters could be measured using depressed intracellular retention of their
fluorescent substrates by flow cytometry. Retentions of calcein/AM, rhodamine 123, or
doxorubicin were often used for P-gp efflux activity detection directly in cells isolated from
patients [84]. Activities of detoxification enzymes could be monitored by appropriate sub‐
strates, which enzymatic modifications induce changes in either fluorescence or light absorb‐
ance properties. Conjugation of 1-chloro-2,4-dinitrobenzene with reduced glutathione as a
result of GST activity could be taken as example [42]. Specific mutations of genes active in
MDR development (like TP53) could be detected using mutation analysis including specifically
designed PCR reaction, denaturing high-performance liquid chromatography, or DNA-
sequencing techniques. Alteration in drug-induced apoptosis could be monitored as difference
in drug-induced DNA-fragmentation by electrophoresis or using comet assay [85]. Applica‐
tion of oligonucleotide microarray for human genome represents available methods to obtain
complex information about expression profiles of MDR-associated genes in patients [86].
Moreover, when nonresponders and responders will be compared using oligonucleotide
microarrays, new information about involving different genes’ expression in MDR develop‐
ment could be obtained. Cytotoxic effects of several drugs could be monitored directly in cells
isolated from patient samples using assays based on reduction of formazan (like MTT assay)
by intracellular dehydrogenases, or liberation of fluorescent label from its esters (like fluores‐
cein diacetate) by intracellular esterases.
4. Perspectives
MDSs represent a very diverse group of hematological malignancies. Treatment of this disease
involves several drugs such as LEN, AzaC, and DAC. Unfortunately, the exact mechanism of
action is still not fully understood. Therefore, prediction of the response to this treatment is
still very complicated. For this reason, a detailed knowledge of the molecular causality of MDS
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and AML progression will be necessary. Moreover, unclear questions about the molecular
mechanisms of these drugs should be answered. Resistance to treatment use for AML and
MDS still represents serious problems with causality not fully understood. Research oriented
on these topics will bring new knowledge and new predictive molecular markers that will
enable the better selection of effective therapy for each patient.
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